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Background and objectives 
Vaccination during pregnancy can enhance transplacental transfer of protective antibody to the 
fetus and protect the infant against disease during the first few months of life. Despite the 
recommendation of maternal influenza and pertussis vaccination to protect pregnant women 
and their infants against these serious infections, uptake of the vaccines has been suboptimal 
globally. This thesis aims to determine the most effective interventions used to improve 
maternal pertussis vaccine uptake, identify psychosocial factors influencing acceptance and 
uptake of maternal pertussis and seasonal influenza vaccination and evaluate evidence for the 
safety and benefits of these two routinely recommended vaccines during pregnancy in 
improving maternal and neonatal health outcomes.  
Methods 
A systematic review was conducted to identify strategies effective in improving uptake of 
pertussis vaccine among pregnant women.  A prospective cohort study of low risk, nulliparous 
women with singleton pregnancies were recruited between 2015-2018 at two major maternity 
hospitals in Adelaide, South Australia, with the primary aim to develop screening tests to 
identify adverse pregnancy outcomes. Using this multicentre prospective cohort with 
comprehensive clinical, lifestyle, sociodemographic data, and documented maternal 
vaccination status, the thesis examined psychosocial predictors of maternal vaccination and 
evaluated the safety and impact of maternal seasonal influenza and pertussis vaccines on 
pregnancy and birth outcomes. Poisson regression models were used to identify psychosocial 
factors influencing acceptance and uptake of the two routinely recommended antenatal 





outcomes for mothers and infants, Cox proportional-hazards and log-binomial models were 
applied. 
Results 
The systematic review included six original published studies that reported on interventions to 
increase uptake of pertussis vaccine among pregnant women. Observational studies showed i) 
a midwife delivered maternal vaccination program improved uptake of pertussis vaccine during 
pregnancy from 20% to 90%; ii) implementation of an automated reminder within the 
electronic medical record improved uptake from 48% to 97%; iii) an increase in maternal 
pertussis vaccine uptake from 36% to 61% after strategies to increase provider awareness of 
recommendations were introduced.  In contrast, interventions in all three randomised controlled 
trials (RCTs) (two involved education of pregnant women, one had multi-component 
interventions) did not demonstrate improvement in the uptake of pertussis vaccination during 
pregnancy, although two of the RCT studies failed to attain their sample size estimates. Data 
from the prospective cohort showed that women’s willingness to receive the recommended 
maternal vaccines was high (90%) and independent of psychosocial factors. However, a 
difference in the actual receipt of pertussis (79%) and seasonal influenza vaccines (48%) during 
pregnancy was observed. A history of major depressive disorder was the strongest predictor of 
pertussis (adjusted prevalence ratios, aPR 1.16, 95% CI:1.06–1.26) and influenza vaccination 
uptake during pregnancy (aPR 1.32; 95% CI: 1.14–1.58). Pregnant women presenting with 
elevated depressive symptoms were also more likely to receive maternal pertussis vaccination 
(aPR 1.14, 95% CI:1.00–1.30). In contrast, women with very high-perceived stress levels (aPR 
0.87; 95% CI: 0.76–0.99) were less likely to receive maternal pertussis vaccination. Women 
with mild depressive symptoms (aPR 1.21, 95% CI: 1.00–1.44) and mild anxiety symptoms 
(aPR 1.21, 95% CI: 0.99–1.48) were more likely to receive influenza vaccine during 





of adverse pregnancy (spontaneous abortion, chorioamnionitis, gestational hypertension, pre-
eclampsia, gestational diabetes, preterm premature rupture of the membranes, spontaneous 
preterm birth) and birth outcomes (congenital anomalies, small for gestational age births, low 
birth weight, admission to the neonatal care unit, low Apgar scores and mechanical ventilation) 
among women who received seasonal influenza or pertussis vaccinations in pregnancy 
compared with unvaccinated pregnant women. This thesis also presents evidence that maternal 
influenza vaccination reduces the risk of pre-delivery hospitalisation with influenza-like illness 
during pregnancy (adjusted hazard ratios, aHR 0.61; 95% CI: 0.39–0.97). Furthermore, the 
thesis findings suggest a protective effect of maternal seasonal influenza in reducing the rates 
of low birthweight (aHR 0.46, 95% CI: 0.23–0.94) and small for gestational age births (aHR 
0.65, 95% CI: 0.40–1.04) during periods of high influenza activity.  
Conclusions 
There is limited high quality evidence for interventions to increase uptake of pertussis vaccine 
among pregnant women. Based on the existing research, incorporating midwife led maternal 
vaccination programs, increasing healthcare provider awareness of recommendations and 
implementation of a provider reminder system to target unvaccinated pregnant women are the 
most effective strategies to improve uptake of pertussis vaccine during pregnancy. The 
psychosocial predictors of maternal vaccination identified in this thesis can be used in 
designing effective interventions and maternal vaccination programs.  The thesis findings on 
the safety of maternal pertussis and influenza vaccination and additional potential benefits of 
influenza vaccine during pregnancy in improving neonatal outcomes can be used to promote 
antenatal vaccination to expecting mothers and healthcare providers. Furthermore, these 
findings may aid evidence-based decision making for policy makers in countries considering 
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Chapter 1: Introduction 
1.1 Background and Rationale for Research 
 
Pertussis, also known as whooping cough, is a highly contagious infection of the respiratory 
tract (1). It is caused by Bordetella pertussis and has re-emerged globally as a cause of 
substantial morbidity and mortality in infants, children, and adolescents, despite high 
immunisation coverage (1). In 2008, the World Health Organization (WHO) estimated around 
16 million cases of pertussis and 195,000 child deaths under five years of age annually and 
global high immunisation pertussis coverage has led to a significant reduction in child deaths 
in recent years (2-4). However, the morbidity and mortality associated with pertussis infections 
in young infants particularly within the first three months of life remains substantial (5-9). 
These first few months are the period when infants are at highest risk for complications and 
death from pertussis because they are not adequately protected against pertussis until they are 
old enough to complete the primary three doses immunisation series at six months and build 
up high levels of protection (10-13). Most young infants with pertussis are infected primarily 
at the household level (in 75–85% of the cases), with older siblings and adult close contacts 
the common reservoirs of the bacterium, with new mothers identified as one of the most 
common sources of infection to newborn infants (14, 15). A meta-analysis of nine studies from 
high-income countries identified mothers as source of disease transmission in more than 39% 
(42% in Australia) of cases in infants aged less than six months hospitalised with pertussis 
infection (15). 
Pregnant women are also at increased risk for morbidity and mortality from influenza infection 
during seasonal and pandemic influenza outbreaks (16-18). Physiological and immunological 
changes that occur during pregnancy may increase the risk of more severe complications from 





pregnant women compared to non-pregnant women (19-21). This was particularly evident 
during the H1N1 influenza pandemic outbreak of 2009–2010 in which the admission rate of 
pregnant women to an intensive care unit following infection with influenza was significantly 
higher compared to non-pregnant adults (20, 22). An increased risk of adverse outcomes such 
as stillbirth (relative risk (RR) from 2.36 to 3.62), preterm birth (RR 2.7 to 5.9) and low 
birthweight (RR 1.71) is also suggested for neonates born to women affected by influenza 
during pregnancy, evident in studies conducted during the 2009 H1N1 pandemic (23, 24). 
However, high-quality evidence from seasonal influenza time periods is lacking (23, 24). 
Vaccination against pertussis and influenza during pregnancy has emerged as an effective 
strategy to protect the mother and provide passive antibodies to the newborn, protecting them 
in early infancy to reduce the morbidity and mortality associated with these vaccine preventable 
infections (25, 26). Maternal pertussis vaccination at least seven days before delivery has been 
shown to prevent up to 91% of pertussis disease in the infants first two months of life (27, 28). 
Influenza vaccination during pregnancy might also reduce the risk of low birthweight, preterm 
birth, and stillbirth, but evidence concerning these birth outcomes is conflicting (29-35).  
Maternal influenza vaccination was first nationally recommended in the United States (USA) 
in 2004 for all pregnant women during influenza season regardless of their stage of pregnancy 
(36) and has been recommended by WHO since 2005 (37). However, most developed countries 
implemented seasonal influenza vaccination programs for pregnant women following the 2009 
H1N1 influenza pandemic outbreak (38-40). In 2011, the USA become the first country to 
recommend a pertussis-containing (diphtheria-tetanus acellular pertussis) vaccine for pregnant 
women during the third trimester of pregnancy (41) and this policy has since been adopted by 
several other industrialised countries such as the United Kingdom (UK) and Australia in 





Following the recommendation of maternal pertussis and influenza vaccination from 
immunisation advisory groups internationally and implementation of government funded 
maternal vaccination programs for pregnant women in different countries, there has been an 
increasing trend in the uptake of recommended vaccinations among pregnant women (45). 
However, influenza vaccine uptake in these countries is well below the Healthy People 2020 
target of 80% (46) ranging from about 30% to 50% (47-53). Maternal pertussis vaccine uptake 
varies between and within countries and has markedly improved, now up to 54% in the USA 
(47-51, 54-56), 70% in the UK (57), and 75-80% in Australia (52, 53), but uptake in general 
remains suboptimal. This highlights the importance of developing effective interventions to 
improve the acceptance and uptake of the recommended maternal pertussis and influenza 
vaccination to ensure optimum protection for pregnant women and their infants. 
Some recent studies have evaluated interventions used to improve maternal influenza and 
pertussis vaccination uptake in pregnant women (58-62). Most of the interventions 
predominantly focussed on educational interventions for pregnant women or healthcare 
providers to improve vaccination uptake among pregnant women (58-62). Some interventions 
were designed to enhance maternal vaccination coverage by offering free vaccines or at 
reduced cost for pregnant women (60, 63) while others included multimodal interventions such 
as implementing standing orders for maternal vaccination at antenatal care settings, increasing 
vaccine stocks or extending the number of locations to access the vaccine (59, 60). Considering 
the recommendation of maternal pertussis vaccination is relatively recent, most of these 
interventions were designed to improve the uptake of seasonal influenza vaccination among 
pregnant women. Limited data exist on strategies to enhance pertussis vaccination uptake 
among pregnant women. Given the well-documented benefits of maternal pertussis 





interventions to enhance pertussis vaccine uptake among pregnant women should be a public 
health priority.  
Previous studies examined determinants of the recommended vaccination uptake among 
pregnant women and specific aspects of vaccination such as women's perception, knowledge 
and attitudes towards vaccination in pregnancy (50, 64, 65). There is some evidence on the 
influence of these assessments on the decision to vaccinate against pertussis and influenza 
during pregnancy. Furthermore, psychological factors investigated in most studies were 
primarily specific health beliefs on maternal vaccination and vaccine preventable diseases, 
often based on the Health Belief Model (a social psychological health behavior change model 
developed to explain and predict health-related behaviors) – perceived susceptibility to 
pertussis/influenza, perceived severity to pertussis/influenza, perceived barriers to maternal 
vaccinations, perceived safety or benefits of vaccination in pregnancy (66, 67). Thus, 
psychological factors as determinants of maternal vaccination uptake are limited to beliefs, 
attitudes or perceptions that are directly related to vaccination and diseases during pregnancy. 
Considering the barriers to maternal vaccination are complex (67), it is important to determine 
the influence of psychosocial factors such as antenatal depression, stress, anxiety and maternal 
lifestyle factors on vaccination decision-making during pregnancy, which are poorly addressed 
by previous studies. Assessment of psychosocial factors might further enhance the 
understanding of why certain women receive the recommended vaccinations during pregnancy 
while others do not. Importantly, identifying psychosocial determinants of maternal 
vaccination uptake will enable comprehensive and pragmatic approach for developing effective 
interventions to improve the uptake of the recommended pertussis and influenza vaccinations 
during pregnancy. 
One of the most commonly reported reasons for pregnant women not to receive the 





(68-70). An inflammatory response from infection during pregnancy has been shown to 
increase the risk of fetal injury (71) but no evidence exists that an inflammatory response from 
a vaccine carries a similar risk. Several systematic reviews have reported no increased adverse 
pregnancy and birth outcomes following pertussis (72-75) and influenza vaccination during 
pregnancy (30-35), although the quality of evidence in the underlying studies are low. Most 
observational research into vaccine safety during pregnancy has been retrospective, due to the 
relatively cheaper cost, fewer ethical concerns, and difficulty in recruiting pregnant women to 
randomized controlled trials (RCTs). In most retrospective observational studies, authors have 
been unable to establish if a pregnancy complication preceded vaccination or account for the 
time-dependent nature of exposure to vaccination during pregnancy. A robust assessment of 
the safety of pertussis and influenza vaccination during pregnancy is critical due to population-
wide rollouts of vaccines for this group in many countries. In countries where these maternal 
vaccines are recommended, prospectively designed studies with active follow-up of pregnant 
women are likely to be the only way to accurately determine the risk or additional potential 
benefits of maternal influenza vaccination in reducing the risk of delivering low birth weight 
infants, small for gestational age birth and preterm birth, for which evidence is conflicting (29-
35). To address this, prospectively designed studies incorporating statistical approaches 
suitable for analysing time-dependent associations between maternal vaccine exposure on 
pregnancy and birth outcomes are warranted.  
1.2 Research Questions 
 
The research questions addressed in this thesis as follows: 






2. What psychosocial factors are associated with the willingness and uptake of maternal 
pertussis and influenza vaccination among pregnant women? 
3. Is there any difference in maternal and neonatal outcomes for women who receive seasonal 
influenza vaccination during pregnancy compared to unvaccinated women? 
4. Is there any difference in maternal and birth outcomes for women who received pertussis 
vaccination during pregnancy compared to unvaccinated women? 
1.3 Thesis Outline 
This thesis is organised into eight chapters. Chapter 1 contains an introduction, rationale for 
research and research questions to be addressed in this thesis. Chapter 2 will provide a 
comprehensive review of the existing literature on pertussis and influenza as well as the current 
knowledge regarding maternal pertussis and influenza vaccination during pregnancy with gaps 
in the literature. Chapter 2 will also outline the research aims and specific objectives to be 
addressed in the thesis. Chapter 3 will describe the methods used to address each of these 
objectives. Chapter 4 contains a published systematic review, which summarise and evaluate 
the available evidence on the effectiveness of interventions in improving pertussis vaccination 
uptake in pregnant women. Chapter 5 presents the results of a prospective cohort which 
determined psychosocial factors influencing acceptance and uptake of pertussis and influenza 
vaccination during pregnancy. Chapters 6 and 7 address the safety and impact of maternal 
seasonal influenza and pertussis immunisation on the health of mothers and their newborn 
infants, respectively. Finally, Chapter 8 presents summary of the overall findings and 
implications of the research findings. This thesis contains a combination of written text 
(Chapters 1-3 and Chapter 8) and peer reviewed journal articles that have been published 






Chapter 2: Literature Review 
2.1 Pertussis  
2.1.1 Bordetella Pertussis Bacterium and Pathogenesis  
Pertussis or whooping cough is a highly infectious vaccine preventable respiratory disease that 
can affect individuals of any age (76). Pertussis is the result of a human acquired infection 
caused by the gram-negative coccobacillus bacterium known as Bordetella pertussis (77).  It 
is a strictly human pathogen with no known animal or environmental reservoir (77). Bordetella 
pertussis expresses virulence factors on the external surface such as filamentous hemagglutinin 
(FHA), pertactin (PRN) and fimbriae (FIM) assisting the pathogen in the initial colonisation 
and mediating attachment to the ciliated epithelial cells in the upper respiratory tract of the 
host. Toxins such as pertussis toxin (PT) and adenylate cyclase toxin (ACT) that assist the 
bacterium in damaging the epithelial lining are produced by the bacterium (78). ACT also plays 
a role in evasion and supressing the host innate immune response during infection (78). PT 
along with other bacterial toxins secreted into the local environment result in destruction of the 
respiratory tissues, triggering coughs during the early stage of the disease (78, 79). Generally, 
these virulence factors play a major role in the clinical manifestations of the disease (78, 79). 
2.1.2 Transmission, Clinical features and Complications 
Bordetella pertussis spread to other people via tiny airborne droplets of an infected person 
generated from a cough or a sneeze (78). The average incubation period of pertussis is between 
7 to 10 days (range 6 to 21 days) preceding the onset of symptoms (77). Acute infection is 
classically separated into 3 phases: catarrhal, paroxysmal, and convalescent (78). The catarrhal 
phase (initial 7 to 14 days) is characterised by mild symptoms such as low-grade fever, sneezing 
and mild cough (80). These features are indistinguishable from other upper respiratory 





patients at this phase are considered infectious (80).  The paroxysmal stage is characterised by 
increasing severity and frequency of coughs and lasts between 1 to 6 weeks, but can be as long 
as 10 weeks. This stage is characterised by prolonged coughs followed by a long inspiratory 
gasp, which may sound like a “whoop”; hence, the name “whooping cough” is derived (80). 
Young infants particularly those less than three months of age are at highest risk of several 
complications from pertussis including apnoea, seizures, encephalopathy post-tussive emesis, 
and pneumonia and potentially death due to their immature immune and cardiorespiratory 
systems (81, 82). Adults may also experience complications including bacterial pneumonia, 
fractured ribs, otitis media and urinary incontinence (83). Convalescent is the last phase 
characterised by decreasing intensity and frequency of the cough (80). Early treatment with 
antibiotics such as macrolides can reduce the length of the infection, severity and prevent the 
spread of the disease (84). 
2.1.3 Diagnosis and Reporting 
 
The WHO definition, used for reporting purposes, is “A case diagnosed as pertussis by a 
physician, or a person with a cough lasting at least two weeks with at least one of the following 
symptoms: paroxysms (i.e. fits) of coughing, inspiratory “whooping”, post-tussive vomiting 
(i.e. vomiting immediately after coughing) without other apparent cause” (85). According to 
the National Notifiable Diseases Surveillance System (NNDSS) definition, confirmed cases 
require either laboratory definitive evidence (‘‘isolation of Bordetella pertussis or detection of 
B. pertussis by nucleic acid testing’’), or laboratory suggestive evidence (‘‘seroconversion or 
significant increase in antibody level or fourfold or greater rise in titre to B. pertussis in the 
absence of recent pertussis vaccination; or single high IgA titre to whole cells; or detection of 
B. pertussis antigen by immunofluorescence assay’’) combined with clinical evidence (‘‘a 
coughing illness lasting two more weeks; or paroxysms of coughing or inspiratory whoop or 





confirmed case (86). Culture, antigen detection (direct fluorescent antibody), and polymerase 
chain reaction (PCR) can be used in laboratory confirmation of pertussis infection, but their 
sensitivity is high only in the early phase of the disease (87). Serologic examination can be 
conducted to diagnose suspected recent pertussis infection in adolescents and adults (88).  
Pertussis is a mandatory notifiable disease in most developed countries like Australia; however, 
cases are often under-reported particularly in adolescents and adults (89, 90). Studies actively 
seeking pertussis cases found that passive surveillance statistics significantly under-report the 
true incidence, depending on the quality of the surveillance system (91, 92). In many 
developing countries, pertussis is under-reported due to lack of a well-established disease 
surveillance system and lack of diagnostic tools, which significantly delays pertussis case 




A recent model developed in 2017 with WHO data from 2014 estimated 24.1 million pertussis 
cases and 160,700 pertussis related deaths in children younger than 5 years per year worldwide 
(94). Of these, 5.1 million (21%) estimated pertussis infections and 85,900 (53%) estimated 
deaths were in infants < 1 years of age (94). The African region contributed the largest 
proportions of cases (33%, 7.8 million) and deaths (58%, 92,500) (94). Despite high vaccine 
coverage, pertussis incident rates have increased in industrialized countries with epidemics 
occurring in the USA in 2010 and 2012 (95) and in the UK in 2011–2012 (96). The incidence 
rate of pertussis in the USA between 2005 and 2010 among infants <12 months of age was 
117/100,000 person-years, with the highest rate in those aged 2 or 3 months (235/100,000 
person-years or 247/100,000 person-years, respectively (97). In 2016, a resurgence of pertussis 
was also observed in the UK, where the number of reported confirmed pertussis cases was 42% 






Pertussis is a cyclical disease usually occurring every three to four years, linked to demographic 
differences and different vaccine coverage (99). The most recent epidemic occurring in 
Australia between 2008 to 2011 (100). Following the introduction of whole-cell pertussis 
vaccine in the late 1940s, the national pertussis incidence rates in Australia declined sharply 
(101). The annual pertussis incidence rate during the 1980s ranged from 100 to 800 cases per 
100,000 population and increased to between 1,000 and 10,000 during the 1990s (101). During 
these periods, the pertussis incidence rate among adults was higher than the incidence rate 
observed among children (101, 102). 
Acellular vaccines replaced the whole-cell vaccine for booster doses in 1997 and for all doses 
in 1999, and 95% coverage with three doses of primary pertussis vaccination series was 
attained within 4 years (103). Despite high coverage of paediatric and adolescent pertussis 
vaccination since 2000 (103), the national pertussis incidence rate started to increase in 2008 
(104). All eight states and territories in Australia experienced a resurgence of pertussis during 
an epidemic in 2008-2011 making it is the second most commonly notified vaccine-preventable 
infectious disease after influenza (104, 105). The notifications rate further increased in 2011 
with 38,602 cases (104, 106). During these epidemic periods in Australia, the highest 
notification rates observed were among infants < 6 months of age (104, 105). South Australia 
had the highest state notification rate of 1,119.3 per 100,000 for this age group (100). 
2.1.5 Burden of Pertussis in young infants 
Although pertussis has been preventable by vaccination for many decades, it remains one of 
the top 10 causes of child and infant mortality (94). Young infants, particularly those too young 
to have completed the primary three dose immunisation series by six months, are vulnerable to 





<12 months continue to have the highest pertussis notification rate (Figure 1). The risk of 
pertussis-related death is inversely proportional to infant age, and deaths occur almost 
exclusively in infants aged < 6 months (5, 7, 107, 108). Overall, 48,909 infant pertussis cases 
and 255 deaths were reported in the USA from 2000 to 2015 and 39% of these cases were in 
infants aged < 2 months (109).  Between 1993 and 2004, 95% of pertussis-infected neonates 
who required mechanical ventilation and all of those who died were aged <2 months (7). 
 
Figure 2.1 Reported pertussis incidence by age group 1990-2018 in USA. 
Source: CDC: National Notifiable Disease Surveillance (NNDS) (110). 
 
Among infants <3 months of age with pertussis, as many as 5% acquire secondary bacterial 
pneumonia, and among infants <6 months of age with pertussis, up to 11.8% acquire secondary 
bacterial pneumonia, more than double the incidence in older children and adults (111). The 
burden and trends of pertussis in young infants is also similar in Australia where a recent 





were infants aged <12 months of age. Reported pertussis-related intensive care unit (ICU) 
admissions, over a 17-year period (between 1997 and 2013) in Australia were 373 (112). Of 
these cases, 53% occurred during the four years of the recent Australian epidemic 2009–2012 
and pertussis related ICU admissions were most likely to occur in infants < 6 weeks of age 
(42%, n=156) and aged 6 weeks to 4 months (43%, n=160) (Figure 2) (112). The highest 
incidence of pertussis related hospitalisations and death continued to occur in infants younger 
than six months of age (101, 102, 113). Aboriginal and Torres Strait Islander infants have the 
highest pertussis disease burden and severity (114, 115).  
 
Figure 2.2 Annual cumulative incidence of pertussis-related admissions to ICUs and 
national notification by age group (<1 year and 1 to <16 years), per 100 000 child-years, 
Australia, 1997–2013 (112). 
A study in England found that among all pertussis-related deaths, 88% of the deaths were in 





(107). As the number of reported deaths from pertussis in young infants has increased (5), the 
case fatality ratio has remained constant (116). The average case fatality rate in developed 
countries is 0.2% (117). However, an analysis of U.S. surveillance data (1990-2009) estimated 
an age-specific case fatality ratio among infants aged < 1 year to be 0.77%, 4.3 times higher 
than the overall case fatality ratio (118). Estimates of the case fatality rate for infants <3 months 
in England averaged 2.5% for 2008-2013 (27).  
2.1.6 Prevention of Pertussis through Vaccination  
 
Pertussis has a basic reproduction ratio (R0) of 12-17 (119). This means in a 100% susceptible 
population on average, each case will infect 12-17 other people during the infectious period 
(119). Overall, up to 94% of the population must have sustained immunity in order to halt 
transmission of pertussis infection (119). However, vaccination against pertussis does not 
result in lifelong immunity (119). This waning immunity makes it virtually impossible to 
achieve and sustain the required levels of population immunity to eliminate pertussis (117).  
A whole-cell pertussis vaccine using dead whole Bordetella pertussis organisms was combined 
with diphtheria and tetanus toxoids (DTwP) in the 1940s (117), and largescale vaccination 
began in the 1950s (117). Because of concerns about safety and adverse events associated with 
the whole-cell vaccine, an acellular pertussis vaccine (DTPa) was developed in the 1970s, 
which used highly purified, selected components of the Bordetella pertussis organism. The 
WHO’s Expanded Programme on Immunisation (EPI) has included pertussis vaccine (DTPa) 
since its introduction in 1974 (117). A three dose primary pertussis immunization series begins 
at age 6-8 weeks to three months, and is completed by six months, according to WHO’s 
recommendation (117). The EPI schedule used in most developing countries recommends 
pertussis containing vaccine (DTPa) at 6, 10, and 14 weeks. However, in most industrialized 





weeks of age), 4 and 6 months (117). Booster doses (dTpa) with substantially lesser amounts 
of diphtheria toxoid and pertussis antigens than paediatric vaccine (DTPa) are typically given 
at age 15-18 months and 4-5 years (120). 
In the USA in 2017, coverage of children 19-35 months for > 3 doses of DTPa was 94%, and 
for > 4 doses of DTPa was 83% (121). Similarly, pertussis vaccine coverage among infants at 
12 months is reported to be over 90% in Australia (122). According to WHO data in 2014, 86 
% of all infants worldwide-received 3 doses of pertussis vaccine (123). WHO estimates that 
global vaccination against pertussis prevents 687,000 deaths annually (123). However, 22.6 
million children under 1 year of age remain incompletely vaccinated against pertussis (124).  
A meta-analysis of vaccine effectiveness and efficacy studies showed that acellular pertussis 
vaccine effectiveness is initially as high as 91% following the primary childhood series and 
approximately declines at 9.6% annually (125). Initial absolute effectiveness of the vaccine 
after adolescent boosting is approximately 85% and declines at 11.7% annually (125). Pertussis 
immunity wanes from 4 to 12 years after the last childhood booster dose of pertussis vaccine 
(126, 127). This waning immunity leaves older children, adolescents, and adults vulnerable to 
pertussis infection, and in turn puts unprotected young infants at risk for transmission of disease 
(128). Despite successful infant pertussis immunisation programs in developed regions such as 
North America, Europe and Australia, pertussis remains an endemic disease (129). The global 
resurgence of pertussis could be attributed to several factors, including: the use of better-quality 
diagnostic methods which result in more case detection, decreasing vaccine coverage in adults, 
changes in vaccination schedules, shifting in vaccine formulations from whole cell to acellular, 
waning of immunity in adolescents or Bordetella pertussis strain variation (93, 113, 130, 131).  






Young infants typically do not have protective immunity and remain vulnerable to pertussis 
until they have received all three doses of the primary series of pertussis vaccine (1, 7, 8). 
Several vaccination strategies for protecting vulnerable young infants from pertussis have been 
evaluated in recent years, including vaccination of all people in contact with a newborn also 
known as cocooning, vaccination of pregnant women during pregnancy and immediately 
postpartum, and vaccinating newborns with a birth dose of pertussis vaccine to provide 
protection prior to the beginning of the primary series (132). The majority of infant pertussis 
cases have acquired disease from a family member or close contact (14, 15). Cocooning, which 
requires immunisation of all family members and close contacts of newborns, has been 
recommended as a way to protect newborns (133). Cocooning protects infants by preventing 
disease among their contacts, and thus prevents transmission to the infant (134). 
However, full cocoon coverage can be difficult to achieve, and a major disadvantage to 
cocooning as a protective strategy is that it leaves infants without any endogenous protective 
antibody until they begin the primary pertussis vaccine series at two months of age (135). 
Without endogenous protective antibody, infants remain solely dependent on the immunity of 
those around them for pertussis protection (133). Vaccinating mothers immediately postpartum 
(after giving birth and before hospital discharge) is another strategy intended to prevent 
pertussis transmission to young infants (136). However, a major limitation of this strategy is 
that vaccination that is administered post-delivery leaves a two-week window of risk during 
which the mother could become infected with pertussis and transmit it to the infant in the first 
weeks of life because boosted pertussis antibody levels do not peak until two weeks post 
vaccination (137-139). Recently, maternal pertussis vaccination has emerged as the most 
effective strategy in preventing morbidity and mortality associated with pertussis in young 
infants (140). Pertussis vaccination during pregnancy provides indirect protection starting at 





infant, ii) passive immunity by way of maternal pertussis antibodies passing by transplacental 
transfer to the fetus and iii) direct protection from maternal antibodies passing through the 
breast milk by breastfeeding the newborn (140). 
2.2  Influenza 
2.2.1 Influenza Virology and Pathogenesis  
Influenza is a highly contagious viral infection of the respiratory tract that cause mild to serious 
morbidity and mortality worldwide (141). Influenza virus is an enveloped, single stranded 
RNA (ribonucleic acid) genome virus with seven or eight segmented strands of RNA that each 
contain one or two genes (141).  The influenza virus belongs to the family of Orthomyxoviridae 
and infects both birds and mammals (141). There are four types of influenza viruses: A, B, C 
and D, which are classified based on antigenic variances in the internal proteins (nucleoprotein 
(NP) and matrix (M1) protein) (141-143). Influenza A, B and C cause human influenza 
infection (141-143). Influenza D viruses were recently categorised as a new genus of 
Orthomyxoviridae in 2016, which are known to infect pigs and cattle but not humans (144). 
Influenza A viruses are categorized by subtypes according to their surface antigens, 
hemagglutinin (HA) and neuraminidase (NA); whereas influenza B viruses are not categorised, 
but two distinct lineages of influenza B virus circulate annually: B/Yamagata and B/Victoria 
(143). All known subtypes of influenza A virus have been isolated from many animal species 
but wild birds serve as the natural reservoir (141). Only three of the HA subtypes (H1, H2 and 
H3) and two of the NA subtypes (N1 and N2) have circulated widely in humans this century 
(141). Influenza B viruses are usually found only in humans and have only one HA and NA 
subtype (which limits the generation of new strains by reassortment) thus are less likely to 
cause a pandemic (141). Influenza A and B can cause epidemics, and are clinically 
indistinguishable. These two types share many common properties, nonetheless all known 





believed to be a cause of the common cold and is occasionally associated with bronchitis and 
pneumonia in adults and children (145).  
HA and NA play specific roles in the initiation of influenza virus infection, as well as facilitate 
the spread of progeny virions to other host epithelial cells (146). The influenza infection starts 
when viral HA attaches to the sialic acid (SA) residues on the host cell receptor. Following 
entry into the host cell (cytoplasmic vesicles), influenza virion sheds its envelope, resulting in 
the release of the genetic material of the virus, ribonucleoprotein complex (RNP) into the host 
cell cytoplasm which leads to transcription and then translation (147, 148). Virus infected 
epithelial cells release key cytokines and activation of cytokines leads to the onset of clinical 
symptoms (147, 148). About 2 to 3 days after infection with the virus, the innate immune 
system is activated (147, 148).  
Influenza viruses go through constant genetic change, which has a significant impact on 
induced immunity and considerations for vaccine composition (149). There are two types of 
genetic changes of influenza viruses (149). The first type is minor strain change known as 
‘antigenic drift’, which takes place when point mutations and recombination events occur in 
the viral genome, causing constant emergence of new virus variants (149). Influenza A viruses 
go through antigenic drift more quickly than influenza B viruses (150). This process is 
responsible for seasonal influenza epidemics, and requires consideration of adjustment of 
influenza vaccines each season (149). The second form of major antigenic evolution of 
influenza strains is known as “antigenic shift”, which occurs among influenza A viruses. 
Antigenic shift happens less frequently than antigenic drift, and normally arises when novel 
subtypes of influenza that typically infect only birds or pigs are transmitted to humans (149). 
This process can result in new or significantly different influenza A viruses, in which there is 






2.2.2 Clinical Characteristic and Transmission  
Clinical symptoms of human influenza include headache, fever, chills, muscle aches, coughing, 
congestion and fatigue. Infectivity may start shortly (<24 h) before the onset of the clinical 
symptoms and usually persists for 3–5 days (149). Serious and fatal outcomes with primary 
viral and viral-bacterial pneumonia are common in children (151, 152). Complications occur 
particularly in older patients with chronic disease (153, 154).  
Influenza viruses are primarily spread via droplets (particles >5 microns [pm] in diameter) 
made when an infected person coughs or sneezes (149). As the influenza virus can persist 
outside of the body, it can also be transmitted by contaminated surfaces (155). Low relative 
humidity and cold temperatures favour influenza virus transmission because infected 
individuals shed more virus in colder temperatures and virus particles can remain airborne 
when relative humidity is low (156). Children are much more infectious than adults and shed 
virus prior to developing clinical symptoms and until two weeks following infection (157).  
2.2.3 Epidemiology 
Four influenza pandemics have occurred in the past century (158-160). A novel influenza A 
(H1N1) virus caused the most recent global pandemic in April 2009, which caused estimated 
confirmed deaths of 18,500 people globally (161, 162). Following the 2009 pandemic influenza 
outbreak, there were almost 44,000 confirmed A(H1N1) incidents and 2000 deaths in Australia 
(163). The WHO estimates that seasonal influenza severely affects between 3-5 million 
individuals with 260,000 to 650,000 deaths annually (164, 165). A population wide case fatality 
of seasonal influenza is highest in children, while complications including hospitalisation and 
mortality occur most frequently in elderly individuals (164, 165). Specific high‐risk groups 
prioritised by WHO for immunisation include pregnant women, the highest priority group, 
followed by individuals with a compromised immune system and individuals with 





2.2.4 Influenza Vaccination 
The best strategy for the prevention and control of influenza is vaccination and it has been 
recommended and proven to be safe for anyone six months of age and older (165). The two 
types of influenza vaccines available are i) inactivated influenza vaccines and ii) live attenuated 
influenza vaccines (165). For several decades, seasonal inactivated influenza vaccines 
(trivalent vaccines) and live attenuated influenza vaccines were designed to protect against the 
three most predominant strains in circulation: one A/H3, one A/H1 and one influenza B strain 
(165). Recently quadrivalent influenza vaccines have been developed to include a second 
influenza B strain in addition to the strains in trivalent vaccines, and are expected to provide 
wider protection against influenza B virus infections (165). The inactivated influenza vaccines 
currently in use are whole virus, split/subvirion and sub unit vaccines that only contain the two 
highly purified antigens (HA and NA), instead of the whole virus (166). The WHO makes 
recommendations for two different vaccine formulations every year; one for the Northern, and 
one for the Southern Hemisphere (167). Annual seasonal inactivated influenza vaccination of 
people at risk of severe disease is implemented in most high-income countries (166).  
The effectiveness of the vaccines that are currently available for influenza depends primarily 
on the antigenic match between the circulating viruses and the strains included in the vaccine 
(166). The efficacy of the inactivated vaccine may be influenced by a range of different factors 
including age, health status and use of concurrent medications, prior vaccination and pre-
vaccination antibody titres. In general, 70-80% of healthy individuals between 10-65 years of 
age obtain a protective immune response after vaccination (168).  
2.2.5 Influenza Infection in Pregnant Women and Infants 
Several studies have demonstrated that pregnant women are at increased risk for influenza 
associated morbidity and mortality during both influenza pandemics and seasonal epidemics 





rate, stroke volume, and oxygen consumption; diminished lung capacity; increased 
progesterone and glucocorticoids and a shift in cell-mediated immunity predispose pregnant 
women to influenza infection complications compared to non-pregnant individuals (172, 173). 
The underlying mechanism of influenza infection increasing maternal complications has been 
studied on mice and indicated that altered inflammatory responses following maternal 
influenza infection can result in increased maternal morbidity, increased risk of preterm birth, 
fetal growth impairment, and fetal mortality (174). 
 
The burden of influenza illness during pregnancy has been noted in previous pandemics (175, 
176). The severity of influenza during pregnancy was first recognized during the 1918 
pandemic of ‘Spanish Flu’ (175). A statistical study of pregnant women during the 1918 
pandemic showed that nearly 50% of the 1350 pregnant women infected with influenza were 
diagnosed with pneumonia and more than 50% of those with pneumonia died, indicating a case 
fatality rate >25% (175). The burden was also observed during the recent 2009 influenza A 
pandemic (H1N1), where the median relative risk of pregnant women to be admitted to hospital 
following influenza infection across 10 high-and middle-income countries was estimated to be 
almost seven and pregnant women were also twice as more likely to die compared with women 
of childbearing age in the general population (177). During the 2009 pandemic, the relative 
risk of pregnant women in Australia to be hospitalised, admitted to intensive care unit and to 
die as a result of influenza A pandemic (H1N1) infection complications were 5.2, 6.5 and 1.4, 
respectively (178). Several studies have also shown that pregnant women are also at a higher 
risk of seasonal influenza-related hospitalisation compared with non-pregnant women, with the 
greatest increase in risk occurring in the third trimester (171, 179-181). Pregnant women with 
chronic medical conditions are seven times more likely to require hospitalisation following 





The fetus may also suffer adverse outcomes following influenza infection during pregnancy 
(23, 24, 182-184). This was evident during the 2009 influenza A pandemic (H1N1) infection, 
where pregnant women who were hospitalised following influenza infection were at increased 
risk of still birth (23, 24), preterm birth (24, 182) and delivering a small for gestational age 
infant (185). The severity of influenza illness during pregnancy plays an important role in the 
impact on fetal health, with more severe illnesses more likely to have adverse impacts (182).  
 
Neonates are susceptible to severe influenza illness due to the immaturity of their immune 
systems and they have limited antibodies to protect against influenza infection (186). Infants 
aged <6 months are at increased risk of influenza-associated complications and have the highest 
risk for being hospitalised (187, 188) and death (186) compared with older children. Globally, 
2.9 million cases of influenza associated with Acute Lower Respiratory Infection were 
estimated among infants aged <12 months (189). During the period 2006–2015 in Australia, 
particularly in the post 2009 pandemic seasons the highest rates of hospitalisation were in 
infants under six months of age (100) (Figure 3). Furthermore, the rate of influenza-associated 
hospitalisation in Indigenous peoples were significantly higher than non-Indigenous peoples 
across all age bands in Australia but the largest disparity was seen among infants under six 






Figure 3: Rate of ICD-coded hospitalisation for influenza (any diagnosis) with 95% confidence 
intervals, Australia, 2006 to 2013, by age group and time period (100). 
In Australia, the burden of influenza continues to occur in infants < 6 months of age, ranging 
from around 150 hospitalisations per 100,000 population in years of low influenza activity to 
almost 400 admissions per 100,000 population in years of high activity (190). Among infants 
< 12 months of age hospitalised with influenza, 35% will require admission to an intensive 
care unit, and 1 in every 350 dies (191). Because of the immaturity of the newborn immune 
system, immunisation do not trigger adequate immune response and there is currently no 
licensed influenza immunisation for infants younger than 6 months (192). However, maternal 
influenza vaccination has emerged as an effective means to decrease the morbidity and 
mortality associated with influenza illness in both mothers and their newborns (26). 
2.3  Pertussis and Influenza Vaccination during Pregnancy 
 
2.3.1 Mechanism of Maternal Antibody Transfer 
 
The unique position a pregnant woman holds in the protection of the fetus or neonate from 
infection is via the pathway of vertical transmission, whereby maternally derived antibodies 
can be transmitted to the fetus through the placenta (IgG) and through breastfeeding (IgG, IgA, 
IgM) (193, 194). IgG is the only antibody class that is actively transferred from the mother to 
the fetus across the placenta, with the aid of the neonatal Fc receptor (FcRn), conferring passive 
immunity and protection against infections to the newborn during the first few months of life 
(195, 196). Although the transfer of antibodies to the fetus begins around 13 weeks, it is not 
until the 33rd week that the concentrations of maternal and fetal antibodies are equal and this 
transfer significantly increases during the third trimester (197). Compared to maternal 
concentrations, the fetal IgG concentration is higher after 40 weeks gestation (197). The 





structural and functional integrity of the placenta, total IgG concentration in maternal blood, 
vaccine type, time between vaccination and delivery, and gestational age of fetus at birth all 
may affect the ability and efficiency of maternally acquired antibodies in the fetus (99). 
Maternal vaccination boosts the concentration of vaccine-derived antibodies in maternal sera, 
and as a result, increases the transplacental transfer of maternal antibodies (198). These 
maternally derived antibodies can offer protection to the infant in the first 6 months of life (26, 
198-201).  
Maternal vaccination provides the optimal method of protection against severe vaccine 
preventable disease during early infancy (202, 203). The initial hesitancy in the design and 
study of vaccine safety in pregnant women has contributed to the delay in recommendation of 
maternal vaccination as a public health strategy in this high-risk group (204). However, 
recently the role of immunisation during pregnancy has become a primary focus as a public 
health strategy, not only for the prevention of maternal and postpartum infection but also for 
the intent to reduce neonatal and early childhood infections through maximising this unique 
relationship (204).  
2.3.2 Maternal Vaccination as a Public Health Strategy  
2.3.2.1 Maternal Pertussis Vaccination 
Pertussis vaccination during pregnancy is currently recommended for pregnant women in many 
high-income countries (205). The initial recommendation for pertussis vaccination of pregnant 
women was introduced with limited preceding safety studies, but as an alternative strategy in 
reducing pertussis-related morbidity and mortality in young infants during an epidemic 
outbreak of pertussis in the UK in 2011 (27). Pertussis vaccination during pregnancy as a public 
health strategy is based on the recognition that vaccination of infants and children, is not 
adequate for protecting against the majority of severe pertussis disease and death which 





In 2006, an animal model study conducted in piglets demonstrated that passively transferred 
maternal immunity provided protection against infection with B. pertussis in newborns of 
vaccinated sows (208). Although the porcine model used in the study is limited in analysing   
passive transfer of immunity as there is no transplacental maternal antibodies in swine, it 
identified the colostrum and milk would be the only source of antibodies (208). However, the 
authors suggested that pertussis immunisation during pregnancy could be an effective strategy 
in prevention of young infants against pertussis (208). The effectiveness of maternal pertussis 
immunisation as a public health strategy in protecting young infants was first demonstrated 
following implementation of routine antenatal pertussis vaccination of all pregnant women in 
the middle of a pertussis outbreak in England in 2011 (27).  
Following the successful implementation of the maternal pertussis immunisation program, a 
91% reduction in pertussis cases was reported in infants younger than 3 months of age born to 
women who received pertussis vaccine at least 7 days before delivery (27). Maternal pertussis 
vaccine effectiveness in preventing pertussis in young infants was also demonstrated by a case-
control study from the UK, with vaccine effectiveness of 93% (209). A study from the USA 
showed that administration of acellular maternal pertussis immunisation during the third 
trimester of pregnancy had a vaccine effectiveness of 78% against pertussis cases with cough 
in the two-month age group and a 91% effectiveness against hospitalised cases (210). 
Additionally, a retrospective cohort study demonstrated that infants with confirmed pertussis 
born to mothers who received pertussis vaccine during pregnancy, were less likely to be 
admitted to hospital than cases born to women not vaccinated during pregnancy (211). Another 
case-control study conducted in Australia also demonstrated that pertussis immunisation during 
pregnancy with a 3-component acellular vaccine (dTap) found a 94% reduction in preventing 





effectiveness at preventing mild pertussis cases that did not require admission to hospital was 
low at 39% (212).  
There has been concern that high concentration of maternally derived antibodies could interfere 
significantly with the infant’s own response to pertussis vaccine antigens and other antigens in 
the primary infant immunisation series (213-215). The studies addressing the presence of 
maternal derived antibodies interfering with the infant immune response to primary 
immunisation schedule in early life, yielded conflicting findings (213-215). However, the 
clinical significance of immunological interference or blunting effect induced by maternal 
immunisation on infant immune responses needs to be further investigated.  The primary aim 
of reduction in severe disease in infants <3 months of age supports the recommendation of 
maternal pertussis immunisation to mitigate pertussis related morbidity and mortality in young 
infants (205). The recommendation to give pertussis vaccination in each pregnancy is based on 
the assumption that maternal pertussis immunisation would be unlikely to protect infants of 
subsequent pregnancies (216, 217). 
2.3.2.2 Maternal Influenza Vaccination 
 
The recommendation for influenza vaccination of pregnant women in the USA dates back to 
the 1960s (218). However, it was only following observation of pregnant women being the 
most severely affected group during the 2009 A/H1N1 pandemic, that greater importance was 
placed on prioritising pregnant women to receive influenza vaccine at any stage of pregnancy 
by immunisation advisory groups internationally (38-40). In 2012, the WHO classified 
pregnant women as a high-risk group for influenza, recommending all pregnant women be 
vaccinated with inactivated influenza, primarily for their protection, and recommended 
countries to incorporate antenatal influenza vaccine into their existing routine immunisation 





The effectiveness of maternal influenza immunisation was conducted in animal models, which 
demonstrated that inactivated influenza immunisation during pregnancy in mice protected 
pregnant mice, fetuses and neonates from lethal challenge by influenza virus (220, 221). 
Furthermore, epidemiological studies have supported the effectiveness of seasonal influenza 
vaccination in pregnant women in protecting the women and their infants from influenza illness 
(30, 222-227). Influenza vaccination of pregnant women has been shown to have a protective 
effect on fetal outcomes including reducing the risk of low birth weight, prematurity and 
stillbirth, an effect size that might be more evident during pandemic influenza virus circulation 
than seasonal epidemics (34, 228). 
A meta-analysis (34) conducted in 2016 demonstrated that maternal inactivated influenza 
vaccination was associated with a 13% reduction in risk of delivering preterm and 26% 
decreased risk of delivering a low birth weight infant. In the meta-analysis (34), maternal 
A/H1N1 influenza vaccination against the 2009 influenza pandemic was associated with an 8% 
reduction in risk of delivering a preterm and a 12% lower risk of delivering a low birth weight 
infant. 
Data from three randomized controlled trials (RCTs) also presented conflicting evidence on 
the protective effect of maternal inactivated influenza vaccination on birth outcomes (199-201). 
A RCT conducted in Nepal reported a 42-gram higher birth weight in infants born to mothers 
who received maternal inactivated influenza vaccination and a 15% lower reduced rate of 
delivering a low birth weight infant (200). However, this effect was neither observed in the 
RCT conducted in South Africa (201) nor in the RCT conducted in Mali (199). Additionally, 
a secondary analysis of an earlier RCT conducted in Bangladesh (26) demonstrated a 200-gram 
higher mean birthweight in infants born during periods of high influenza activity to vaccinated 





The two RCTs in South Africa (201) and Nepal (200) found maternal influenza vaccination 
was neither associated nor protective against preterm birth. However, a secondary analysis of 
the RCT in Nepal (200) and the RCT in Bangladesh (29) showed a reduction of small for 
gestational age infants among a subset of infants born during high influenza circulation to 
vaccinated women. The mixed findings on the potential protective effect of maternal influenza 
vaccination on birth outcomes from these RCTs raise concern about the validity of 
observational studies reporting protective effect of maternal influenza vaccination on birth 
outcomes. For instance, some observational studies have reported protective effects on preterm 
birth as high as 40% to 70% (229-232). Similarly, a meta-analysis examining the association 
between maternal influenza vaccination and stillbirth which included seven epidemiological 
studies, reported a 27% reduced risk of stillbirth and 31% reduction for those women who 
received the pandemic influenza A/H1N1 vaccine in 2009 (228). However, there was no 
difference in stillbirth rates observed in the RCT conducted in Nepal (200) or South Africa 
(201). Although RCTs usually do not have sufficient study periods or population sizes to 
identify stillbirth, the rates of stillbirth in these settings were 20 per 1000 births with a 
combined cohort size of more than 5,500 women (200, 201). 
The initial RCT from Bangladesh (26) reported a 36% reduction in acute febrile respiratory 
illness for pregnant women who received maternal inactivated influenza vaccination; findings 
which were replicated in the subsequent trial in Nepal with a 19% reduction (200).  However, 
the RCTs in South Africa and Mali did not observe efficacy against all-cause influenza-like-
illness, but, reported a 50% and 70% significant efficacy against influenza-confirmed (PCR 
detected) illness in the women respectively (199, 201). Furthermore, all four RCTs (26, 199-
201) reported on the efficacy of maternal influenza vaccination in protecting the infants in their 
first few months of life from influenza. A meta-analysis of these four RCTs yielded an overall 





following maternal inactivated influenza vaccination (233). The meta-analysis (233) also 
pooled estimates of influenza-associated hospitalisation in infants following maternal influenza 
vaccination from four observational studies and found a 72% protective effect in reducing 
influenza related hospitalisations in infants. However, the four RCTs (26, 199-201) were not 
designed to evaluate effectiveness of maternal influenza vaccination in reducing influenza 
related hospitalisation in mothers and infants or examining safety outcomes. Further studies 
are needed to corroborate the protective effect of maternal influenza vaccination in reducing 
the risk of influenza related hospitalisation in pregnant women and their infants.  
A post-hoc analysis from the RCT in South Africa demonstrated a 43% lower rate of all-cause 
pneumonia hospitalisation in infants born to women who received influenza vaccination during 
pregnancy (234). These data were subsequently corroborated in the Nepal study with a 31% 
lower rate of severe pneumonia (200), although this was not replicated in the RCT in Mali 
(200). A pooled analysis across the three studies yielded an overall vaccine efficacy of 20% 
against all-cause severe pneumonia in infants under six months of age (235). This evidence 
suggests that maternal influenza vaccination can potentially offer other benefits to both mother 
and infant. Therefore, monitoring and determining uptake, and evaluating the benefits of 
maternal influenza vaccination is important.  
2.3.3 Uptake of Pertussis and Influenza Vaccination during Pregnancy 
 
Maternal pertussis vaccination was first introduced in the United States in 2011(236) and in 
the UK in 2012 (237). The Australian Immunisation Handbook was also updated in March 
2015 to recommend pertussis vaccination for pregnant women between 28-32 weeks’ gestation 
in the third trimester of every pregnancy (44). Jurisdictional funded pertussis vaccination 
programs for pregnant women were introduced between August 2014 and June 2015 in all 





women via general practitioners, hospital antenatal clinics, immunisation clinics, community 
health clinic, and obstetricians (238) with a large state-wide promotional campaign targeting 
healthcare providers and pregnant women (238). Recently in July 2018, the National 
Immunisation Program (NIP) incorporated pertussis vaccination for all pregnant women during 
each pregnancy (44).  
Since the introduction of maternal pertussis vaccination programs in 2015 in Australia (239), 
there are no published data on national maternal pertussis vaccine coverage. However, several 
studies have indicated that it has been suboptimal but improved to 80% in 2019 (52, 63). 
Similarly, high uptake of pertussis vaccination during pregnancy, up to 70% was achieved in 
the UK after the antenatal pertussis vaccination program was implemented in response to an 
increase in neonatal pertussis deaths (57). Similar improved vaccine rates have not been 
observed in the USA, but rates recently have been estimated to be 54% (56). Although uptake 
of pertussis vaccination among pregnant women varies and differs between and within 
countries, there is still room for improvement of vaccination rates to protect young infants from 
pertussis related morbidity and mortality.  
Since 2010 influenza vaccine has been supplied free-of charge for all pregnant women in 
Australia through the NIP (240). Maternal influenza vaccine uptake in Australia has been low, 
with estimates ranging from about 10% to 30% (240-246). Although these estimates are usually 
derived from relatively small sample studies, recent population-based cohort estimates in 
Australia indicated improved uptake of influenza vaccination up to 35% to 40% in pregnancy 
(52, 53). Similarly, the uptake of maternal influenza vaccination in other countries has 
improved significantly during the last several years, following the 2009 influenza pandemic 
season (247). In the USA during the 2001-2002 epidemic season only 11% of pregnant women 
had been vaccinated against influenza (247). This was unchanged in 2009 with only 13%, 





influenza (247). By 2010 and 2011 the uptake had improved to 40% and 50% respectively 
(247). Currently, maternal influenza vaccination uptake in the USA has now increased to 
approximately 50% (248). The uptake of influenza vaccine among pregnant women in most 
countries is still well below the benchmarks set by Healthy People 2020, which specifies a goal 
of 80% influenza vaccination for pregnant women (46). 
Previous studies have also indicated that uptake of the recommended maternal vaccinations 
among ethnic minorities, women of culturally and linguistically diverse background (249-251) 
and Indigenous women (252-254) are suboptimal. Such disparity in maternal vaccination 
uptake among pregnant women presents a significant risk to the health of these vulnerable 
women and their newborn infants. Furthermore, most countries including Australia currently 
lack a coordinated approach to maternal immunisation, with coverage not systematically 
monitored. It is important to monitor and evaluate the impact of maternal immunisation 
programs for pregnant women and determine strategies to maximise uptake of the vaccine and 
design tailored interventions to enhance vaccination coverage for groups with low vaccination 
rates. 
2.3.4 Determinants of Maternal Pertussis and Influenza Vaccination Uptake 
 
There are a number of predictors as well as barriers to achieving high uptake of maternal 
pertussis and influenza vaccination coverage among pregnant women (66, 67, 255-257). 
Several systematic reviews have indicated that healthcare provider recommendation is a key 
driving factor or a major predictor in the decision-making process for pregnant mothers to 
receive pertussis and influenza vaccines during pregnancy (50, 66, 67, 255-257). Some of the 
reasons suggested by healthcare providers for not recommending maternal vaccination to their 





vaccinating pregnant women against pertussis and influenza and the perception that pregnant 
women would not want to receive the recommend maternal vaccinations (50, 258).  
Furthermore, previous studies have suggested that not all women who receive a healthcare 
provider recommendation are vaccinated, but women who do not receive a recommendation 
for vaccination are unlikely to be vaccinated (66, 67, 255, 256). Healthcare providers should 
discuss influenza and pertussis vaccinations with women during pregnancy. Many studies have 
shown that healthcare provider recommendation is the most important factor to improve 
maternal vaccine uptake among pregnant women (66, 67, 255, 256, 259). Both healthcare 
providers and pregnant women should continue to be educated on the importance and safety of 
the recommended vaccination during pregnancy. In addition to healthcare provider 
recommendation, other sociodemographic factors previously identified to be associated with 
uptake across five literature reviews included: maternal age, educational attainment, 
employment status, socioeconomic status, parity, marital status, ethnic background or race (66, 
67, 255-257).  
Importantly, the decision to receive the recommended vaccination during pregnancy is, 
ultimately, an individual decision. Most studies examining individual level determinants of 
acceptance and uptake of pertussis and influenza during pregnancy focus on women's beliefs, 
perception, knowledge, and attitudes towards vaccination in pregnancy (50, 64-66, 70, 242, 
255, 260-263). The psychological factors investigated in most studies are directly related to 
health beliefs on maternal vaccination and vaccine preventable diseases and are often based on 
the Health Belief Model – perceived susceptibility pertussis/influenza, perceived severity to 
pertussis/influenza, perceived barriers to maternal vaccinations, perceived safety or benefits of 
vaccination in pregnancy (both for themselves and for their unborn infant) (67). The Health 
Belief Model is a valuable theoretical or conceptual framework in providing an understanding 





Belief Model is derived from psychological and behavioral theories, it is not a suitable 
framework to examine psychosocial factors associated with disparities in the vaccination 
uptake among pregnant women. 
Considering the barriers to vaccination in pregnancy are complex (67), it is important to 
determine the influence of other psychosocial factors such as antenatal depression, stress, 
anxiety and maternal lifestyle factors on vaccination decision-making during pregnancy, which 
are poorly addressed by previous studies. Pregnant women are seen as responsible for the health 
of their fetus through regulation of their own behaviours and are pressured to act in a way 
which meets society’s expectations of a good “reproductive citizen” (265). Hence, pregnant 
women are urged to take part in a healthy maternal lifestyle i.e. avoid smoking and 
consumption of alcohol, increase intake of multivitamins and folate supplements, avoid 
becoming stressed, and maintain good health and optimum body weight through diet and 
exercise (265).  
Previous studies revealed that psychosocial factors such as depression, stress, risky maternal 
healthy behaviours i.e. smoking or binge drinking are associated with suboptimal adherence to 
standard antenatal care recommendations such as exclusive breastfeeding duration to six 
months postpartum (266, 267). Thus, it is important to examine whether non-adherence to 
antenatal vaccination recommendation such as vaccine refusal or hesitancy during pregnancy 
is associated with the negative effects of anxiety, depression, or stress during pregnancy. 
Understanding and identifying psychosocial factors in relation to maternal vaccination decision 
making will enable comprehensive and pragmatic approaches for developing effective 
interventions to improve the uptake of vaccination during pregnancy. 






The barriers to vaccination in pregnancy are more complicated than the barriers identified for 
low uptake in childhood immunisation programs (268). Pregnant women have to weigh the 
benefits and risks not only for themselves, but also for their unborn child. Importantly, new 
mothers have often advised they are dependent on healthcare provider recommendation for 
pregnancy related interventions, including vaccination (261).  
 
Some recent studies have evaluated strategies to improve immunisation uptake with pertussis 
and seasonal influenza vaccination in pregnant women (58-62). Most of the interventions 
predominantly focussed on educational interventions for pregnant women or healthcare 
providers to improve pertussis vaccination uptake among pregnant women (58-62). Some 
interventions were designed to enhance pertussis vaccination coverage by offering vaccines 
free or at reduced cost for pregnant women (60, 63) while others included bundled antenatal 
vaccine promotion package such as implementing vaccine standing orders for pregnant women, 
increasing vaccine stocks or extending number of locations for women to access the vaccine 
(59, 60).  
A systematic review published in 2016 summarised and evaluated strategies used to improve 
influenza vaccination in pregnancy and suggested the use of vaccination reminders in 
healthcare systems and educational intervention for pregnant women such as providing an 
information pamphlet in the antenatal clinic to increase influenza vaccine during pregnancy 
(51). Most publications describing interventions to improve maternal vaccination relate to 
influenza vaccine, given the recommendation for pertussis is more recent. There are no 
systematic or literature reviews published that solely focus on evaluating strategies to improve 
pertussis vaccination uptake in pregnancy. Considering limited data exist on rigorously 





determining effective interventions to improve pertussis vaccine uptake should be a public 
health priority.  
2.4  Safety of pertussis and influenza vaccination during pregnancy 
 
2.4.1 Safety of maternal pertussis vaccination 
 
Concerns about vaccine safety during pregnancy has been consistently identified as one of the 
most significant reasons for women not accepting or receiving vaccination during pregnancy 
(68-70). Efforts to inform expectant mothers and healthcare providers about vaccine safety are 
essential to continue the momentum of maternal vaccination uptake. Following the introduction 
of antenatal pertussis vaccination programs in developed countries, several systematic reviews 
have supported the safety of pertussis or pertussis containing vaccines during pregnancy (72-
75).   
Several studies reported vaccine reactogenicity among pregnant women following pertussis 
vaccination with the most frequently reported reactions being injection site reactions (214, 269-
272). Although injection site reactions such as pain/tenderness, induration/swelling, itching, 
and erythema/redness were reported after receipt of maternal pertussis vaccination in most 
clinical studies, pregnancy was not considered to have increased the rates of these events (214, 
269-272). However, moderate to severe injection site pain was more frequent in pregnant than 
non-pregnant women in two studies (269, 271). Injection site reactions assessed over a week 
were more common after pertussis vaccination than placebo in one small clinical study (214) 
but occurred at similar rates over 48 hours in another slightly larger study (273). Furthermore, 
the rate of fever ranged from 0% to 5.1% in pertussis vaccinated pregnant women but these 
were usually mild and self-limiting fever and generally well tolerated (214, 231, 269-275). 





by repeat exposure to containing tetanus toxoid in pertussis vaccines (269, 276) or by 
concomitant vaccination with influenza vaccines (231, 272). 
Review of passive adverse events following immunization (AEFI) reporting system data have 
shown there is no concerning maternal or fetal outcomes following pertussis vaccination during 
pregnancy (275, 277). Both RCTs and observational cohort studies also corroborated the safety 
of maternal pertussis vaccination, finding no increase in pregnancy or birth complications (274, 
278), preterm birth (277, 279), small for gestational birth (277, 279), low birthweight (214, 
278, 280), congenital anomalies (280), spontaneous abortion, (280) or stillbirth (278). Three 
retrospective cohort studies (281-283) reported a small but significant increase in 
chorioamnionitis for women who had received pertussis vaccination during pregnancy. 
However, this finding was not replicated in other studies (284-286). A review of the Vaccine 
Adverse Event Reporting System (VAERS) for all reports of chorioamnionitis showed that the 
condition is rarely reported following vaccination during pregnancy and 58% of women who 
report chorioamnionitis had at least one risk factor predisposing them to the condition (286). 
However, further studies are needed to investigate if there is any biological plausibility of 
maternal pertussis vaccine causing chorioamnionitis, since this condition is associated with 
severe short-term and long-term birth complications (287). 
2.4.2 Safety of maternal influenza vaccination 
 
Although the initial recommendation for maternal influenza vaccination was based on limited 
safety, several systematic reviews of RCTs, observational studies, retrospective data linkages, 
case control studies, and post-licensure vaccine safety studies have reported the safety of 
influenza vaccination during pregnancy (30-35). Safety data across post-licensure settings have 
demonstrated the safety of maternal inactivated influenza vaccines on pregnancy and birth 





1-6% of pregnant women report a fever following seasonal influenza vaccination during 
pregnancy (272, 290, 291). However, similar rates of local reactions are reported following 
influenza vaccination by non-pregnant women of the same age, suggesting pregnancy does not 
elevate the risk of these adverse events (292).  
Several studies have shown that influenza vaccination during pregnancy is not associated with 
increased risk for adverse pregnancy outcomes such as spontaneous abortion (293), gestational 
diabetes, pre-eclampsia, emergency caesarean delivery (288, 294) or chorioamnionitis (295). 
Furthermore, many studies corroborated that maternal influenza vaccination is not associated 
with harmful effects on birth outcomes, including preterm birth (229, 288, 296), small for 
gestational age births (230, 296-298), congenital anomalies and malformations (230, 288) and 
stillbirth (228, 299). Several studies have also shown no adverse effects following first 
trimester administration of influenza vaccine (230, 297, 300). However, a significant increased 
risk of spontaneous abortion was reported in a case-control study among women who received 
inactivated influenza vaccination within 28 days before their diagnosis of spontaneous abortion 
(301). The association was only stronger among women who had also received a A(H1N1) - 
containing vaccine in the previous influenza season (301). The authors (301) reported the 
findings could be biased because women who sought care for symptoms foreshadowing 
spontaneous abortion diagnosis may have had greater opportunity for vaccination in the 28-
day exposure window. Compared to the control arm, cases were significantly older, more likely 
to have a history of two or more previous spontaneous abortions and to have smoked during 
pregnancy which are known risk factors for spontaneous abortion (302). Another case-control 
study with a larger sample size found no association between maternal influenza vaccination 
and spontaneous abortion (303). However, further prospectively designed studies are needed 





Following mass vaccination of pregnant women against 2009 influenza A/H1N1, several 
studies and surveillance initiatives were rapidly initiated (304-308). Among 2.4 million 
pregnant women in the US vaccinated against 2009 influenza A/H1N1 between 2009 and 2010, 
there were 294 adverse events submitted to VARES (308). Medical review of these reported 
events demonstrated that pandemic influenza A/H1N1 vaccine during pregnancy is not 
associated with adverse pregnancy and birth outcomes (308). Similar to seasonal influenza 
vaccine, no increased risk of adverse obstetric or birth outcomes were detected following either 
adjuvanted or non-adjuvanted maternal pandemic influenza vaccination in prospective or 
retrospective cohort studies (306, 309-312). Overall, numerous systematic reviews and meta-
analysis have demonstrated that influenza vaccination at any time during pregnancy is safe for 
the mother, fetus and newborn (30-35, 228). However, the quality of evidence in the underlying 
observational studies included in these reviews is low.  
 
2.5  Methodological Issues in Maternal Vaccination Studies 
 
Currently, the effect of maternal pertussis and influenza vaccination on pregnancy and birth 
outcomes is primarily studied through non-experimental observational studies. This is because 
RCTs are considered unethical in countries where maternal pertussis and influenza vaccination 
is recommended and funded for pregnant women. Implementation of further RCTs in many 
countries including low-and middle-income countries where maternal pertussis or influenza 
vaccination is not the “standard of care” is challenging. This is due to ethical considerations, 
limited availability of baseline epidemiologic data on influenza and pertussis disease burden, 
higher baseline rates of obstetric complications and adverse birth outcomes, lack of local 
influenza activity surveillance, challenges in recruitment and retention of pregnant women and 





gestational age) (313).” Given the paucity of RCTs available, observational studies on safety 
and protective effects of maternal influenza and pertussis vaccination are integral in providing 
evidence, although they pose some methodological issues. Retrospective observational 
research has been the mainstay of evidence available for women vaccinated during pregnancy, 
due to the comparative cost, ethical considerations, and underrepresentation of pregnant 
women in RCTs. Retrospective observational studies evaluating the effect of maternal pertussis 
and influenza vaccination are complex due to the multi-factorial risks and causes of pregnancy 
and birth complications (30-35, 72-75).  
Systematic reviews of maternal influenza and pertussis vaccine have highlighted that 
confounding is a threat to the validity of all observational studies and particularly to 
retrospective observational studies in examining the effect of vaccination during pregnancy 
(30-35, 72-75). Many of the large retrospective cohorts examining maternal vaccine safety 
studies fail to capture important variables that may increase the risk of poor pregnancy or birth 
outcomes (30-35, 72-75). This is partly due to the use of data gleaned from medical databases 
or secondary data extracted from computerised medical information that is already coded from 
a national or state data registry (30-35, 72-75) in many retrospective cohort studies. Several 
important potential confounders (e.g. gravidity, smoking status, drug use, binge drinking, 
psychosocial factors) in assessing safety of vaccination during pregnancy are often not 
collected through medical databases (30-35, 72-75). Therefore, the risk of residual confounding 
is inherent in the nature of retrospective observational cohort studies into maternal vaccine 
safety. Furthermore, many observational studies that rely on data extracted from administrative 
databases do not capture maternal vaccination administered in non-traditional settings (i.e. 
pharmacist or community health clinics or workplace-administered vaccination). Thus, uptake 
of maternal vaccinations is likely to be underestimated in such studies. Moreover, most 





Classification of Diseases (ICD) codes or documentation of influenza or pertussis illness, 
pregnancy or birth complications from regional or national databases (30, 314). This method 
of data collection can be susceptible to missing and misclassification of data (30, 314).  
Nevertheless, retrospective cohort studies involving large numbers of women are preferable to 
RCTs in evaluating the impact of maternal vaccination on rare pregnancy and birth outcomes 
i.e. stillbirth or congenital anomalies. This is because RCTs are not usually statistically 
powered to evaluate rare pregnancy or birth outcomes. Moreover, placebo-controlled RCTs are 
highly controlled experiments and they do not replicate the “real-world” circumstances in 
monitoring health outcomes of pregnant women (315). Therefore, observational cohorts with 
large representative samples of pregnant women are necessary for complementary 
investigation of less common adverse pregnancy outcomes, in addition to assessing safety and 
protective effects of maternal influenza and pertussis vaccination under real-world settings 
(315). 
In observational studies, women with the most favourable risk profile may be more likely to 
receive the recommended vaccine (315). It would be expected that the women receiving 
vaccine would be more highly educated, less likely to smoke, have a more optimal pre-
pregnancy weight and diet during pregnancy, and be more likely to adhere to prenatal care 
guidelines (315). Conversely, women with increased risk of obstetric complications or other 
risk factors for adverse outcomes are more likely to receive influenza vaccination during 
pregnancy (316), hence increasing the potential for confounding by indication. Therefore, in 
studies evaluating effect of maternal vaccination on pregnancy and birth outcomes, 
prospectively designed observational studies are more advantageous over retrospective studies 





The interpretation of maternal influenza vaccine studies has assumed that the same study design 
and analytic methods used to examine adverse outcomes from vaccination can be directly 
applied to assessment of potential benefit (i.e., risk ratios greater than 1.0 relating vaccination 
to adverse pregnancy outcome would suggest harm; risk ratios less than 1.0 would therefore 
indicate benefit) (315). Although this approach is reasonable, the underlying scenarios for harm 
and benefit following influenza vaccination are not symmetric (315). This is because a 
protective effect of maternal influenza vaccination in reducing risk of adverse pregnancy or 
birth outcomes is potentially mediated by the effectiveness of the maternal influenza vaccine 
in preventing influenza infection. On this premise, women who received influenza vaccination 
during pregnancy would be protected from maternal influenza infection, consequently averting 
potential influenza illness and any adverse effects on their pregnancy that would result from 
infection. 
Since the protective effect of maternal influenza vaccination derives from the sustained 
reduction in risk of acquiring disease during the influenza season, and vaccination status 
outside that window would be less pertinent. However, influenza viruses can circulate year-
round particularly in tropical regions (317). Assuming the influenza vaccine is usually 
administered in the pre-influenza season, the period of pregnancy at reduced risk for influenza 
will depend on the calendar timing of the influenza season in relation to the stage of pregnancy 
(315). Therefore, it is important to consider the duration of pregnancy length and exposure to 
a period of widespread influenza circulation in evaluating the protective effect of maternal 
influenza vaccination on pregnancy and birth outcomes.  
Pregnancies must be followed longitudinally since the effect of maternal influenza illness or 
vaccination on pregnancy or birth outcomes will vary depending on the gestational age at the 
time of exposure, which introduces the potential for immortal time bias (318, 319). A given 





vaccination is considered “immortal” because any adverse event that takes place before a 
pregnant woman had the opportunity to receive vaccine would result in the event being 
assigned to the unvaccinated group (319). This bias may lead to inaccurate estimates of the 
magnitude of effect of maternal immunisation on time-varying outcomes (318-320).  
Methodologically, using a time-invariant analysis or simply dichotomising a given pregnancy 
as vaccinated if vaccine was received at some time during the pregnancy or unvaccinated 
otherwise is insufficient (315). There needs to be a weekly consideration of the pregnancy with 
regard to vaccination status, the time at risk period prior to adverse pregnancy or birth 
outcomes, and calendar time of influenza activity and circulating influenza viruses (for 
maternal influenza vaccination studies). Therefore, it is important to incorporate appropriate 
time varying analytic methods and confirm receipt of vaccine and date of receipt to calculate 
the ‘time at risk’ period prior to adverse pregnancy or birth outcomes. 
Another methodological challenge with observational studies is that pregnancies are not 
followed from the time of conception (i.e. first day of the last menstrual period). This causes 
downward bias in estimation of early pregnancy outcomes such as spontaneous abortion. Such 
data are said to be left truncated (320). Additionally, including follow-up time during which 
pregnancies are no longer at risk of some adverse outcomes (e.g. gestation after 37 weeks 
considered for preterm birth outcomes) can lead to overestimation of any true benefits of 
maternal vaccination. It is important for observational studies analysing the effect of maternal 
influenza or pertussis vaccination on birth outcomes to incorporate analytical techniques 
suitable for time dependent outcomes to minimise these potential biases. 
In summary, collecting maternal vaccination status, potential confounding variables, and 
pregnancy and birth data from medical histories and databases may result in non-differential 
misclassification bias. This may attenuate the effect of influenza or pertussis vaccine estimates 





true benefits of maternal vaccination on pregnancy or birth outcomes. In planning retrospective 
observational studies concerned with evaluating influenza or pertussis vaccine effects on 
pregnancy or birth outcomes, researchers may consider validating maternal vaccination status 
and pregnancy or birth outcome data using medical case note review. Importantly, prospective 
observational studies with active follow-up of pregnant women incorporating methodological 
approaches suitable for analysing time-dependent associations between maternal vaccine 
exposure on pregnancy and birth outcomes are warranted.   
2.6  Aims and Specific Objectives 
 
Aim 1.  To systematically collect and summarise the available evidence on the effectiveness 
of interventions used to improve pertussis vaccination uptake in pregnant women (Chapter 4) 
(evaluations of interventions to improve uptake of maternal influenza vaccine has been 
previously examined and hence not the focus of this thesis). 
Objective 1.1 – To identify and describe interventions to increase uptake of pertussis 
vaccination during pregnancy.  
Objective 1.2 – To determine the effectiveness of any identified interventions or strategies to 
increase uptake of maternal pertussis vaccination. 
Objective 1.3 – To identify the most effective interventions used to improve maternal pertussis 
vaccination and make recommendations based on the available evidence.  
Aim 2. To identify psychosocial factors associated with the willingness and uptake of pertussis 
and influenza vaccination during pregnancy (Chapter 5). 
Objective 2.1 – To assess the impact of antenatal depression, anxiety and stress on the 






Objective 2.2 – To identify sociodemographic and maternal health behaviours associated with 
the willingness and uptake of the pertussis and influenza vaccination during pregnancy 
Aim 3. To investigate the safety and protective effect of seasonal influenza vaccine during 
pregnancy (Chapter 6). 
Objective 3.1 – Measure the rate of adverse pregnancy and birth outcomes among women who 
received seasonal influenza vaccine during pregnancy compared to unvaccinated women.  
Objective 3.2 – Measure the rate of pre-delivery hospitalisations with respiratory illness among 
women who received seasonal influenza vaccine during pregnancy compared to unvaccinated 
women.  
Objective 3.2 – To evaluate the protective effects of maternal influenza vaccination in 
improving birth outcomes. 
Aim 4. To investigate the safety of pertussis containing (dTpa) vaccine on pregnancy and birth 
outcomes (Chapter 7). 
Objective 4.1 – Measure the rate of adverse pregnancy and birth outcomes among mothers who 
received pertussis vaccine during pregnancy compared to unvaccinated women.  
Chapter 3: Methods  
 
For each of the studies, detailed methods are provided in Chapters 4, 5, 6 and 7. This chapter 
provides an overview of the methods employed for each study. A systematic review was used 
for the study in Chapter 4. Quantitative analyses were employed for studies in Chapters 5, 6 
and 7, all based on data that were drawn from a prospective cohort study. First, a description 
of the cohort from which data were drawn for these studies in this thesis is given below. 






3.1.1 Screening Tests to predict poor Outcomes of Pregnancy (STOP) cohort  
 
The Screening Tests to predict poor Outcomes of Pregnancy (STOP) study is a prospective, 
multicentre cohort study of healthy nulliparous women with singleton pregnancy across two 
major maternity hospitals in Adelaide, South Australia (Lyell McEwin Hospital, Elizabeth 
Vale; and Women’s and Children’s Hospital, North Adelaide) from 2015-2018. This is a 
prospective cohort study of 1364 women. The overarching aim of the STOP study is to 
developing screening tests to predict the risk of adverse pregnancy outcomes including 
preeclampsia, gestational diabetes mellitus, small for gestational age birth and spontaneous 
preterm birth. Women were excluded from participation if they had ≥ 3 miscarriages or ≥ 3 
terminations of pregnancy, major fetal anomalies, pre-existing hypertension on medication, 
Type I or Type II diabetes mellitus, renal disease, systemic lupus erythematosus, anti-
phospholipid syndrome, known major uterine anomaly or previous cervical cone biopsy. 
At time of recruitment participants interviewed were between 9+0 and 16+0 weeks’ gestation 
(superscripts denote number of days in addition to weeks of gestation). Extensive baseline 
information regarding demographics (including maternal age, ethnicity, level of education, 
household income, socioeconomic index, employment status), family medical and obstetric 
history, complications during the current pregnancy, BMI, pre-existing conditions, maternal 
vaccination status and lifestyle questionnaire (including smoking status, intake of alcohol and 
recreational drugs, micronutrient supplement use, physical exercise) were collected. 
Participating women also completed the Perceived Stress Scale (PSS-10), (321) to assess 
perceived stress levels in the past month, the short form of the Spielberger State–Trait Anxiety 
Inventory (STAI), (322) assessing current anxiety symptoms, and the Edinburgh Postnatal 





The women were monitored throughout pregnancy, and pregnancy and birth complications 
were diagnosed using current international guidelines. All women participating in the study 
were invited to attend a follow-up visit between 31+5 and 37+2 weeks’ gestation. During this 
follow-up, participants had an interview regarding current pregnancy issues, medication use, 
and maternal vaccination status. Following delivery, a research midwife verified final maternal 
vaccination status by reviewing the South Australian Pregnancy Record (SAPR) (the primary 
hand-held antenatal medical record in South Australia) and interviewing women. Clinical 
measurements, pregnancy outcomes, neonatal outcomes data were collected and managed 
using REDCap (Research Electronic Data Capture) (324, 325). REDCap is a secure, web-based 
software platform designed to support data capture for research studies, providing 1) an 
intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and 
export procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages; and 4) procedures for data integration and interoperability with external 
sources (324, 325). 
3.2  Study Designs and Methods used in the Thesis  
3.2.1 Aim 1 - Interventions to improve uptake of maternal pertussis vaccination 
 
A systematic review was used to identify strategies or interventions that were effective in 
improving uptake of pertussis vaccine among pregnant women. The details of the methodology 
of the systematic review, which followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) reporting guidelines (326) were pre-specified in a 
published protocol in the international prospective register of systematic reviews (PROSPERO, 
ID CRD42017058178), presented in Appendix A. The methods are also summarised in the 
systematic review publication, presented in Chapter 4. 






Data from the STOP cohort were drawn to identify psychosocial predictors of pertussis and 
influenza vaccine uptake among pregnant women. A Poisson regression model was the most 
appropriate model to determine psychosocial factors influencing acceptance and uptake of 
pertussis and influenza vaccines during pregnancy. This is because when the incidence of an 
outcome of interest is common in the population of interest (i.e. > 10%), the estimated odds 
ratio (OR) derived from the logistic regression is a poor approximation of the prevalence ratio 
(PR) (327).  In this situation, the OR tends to overestimate the strength of the association when 
the outcome is common (i.e. vaccine uptake, as in this study) (328). As vaccination uptakes 
increase, ORs become increasingly less reliable estimates of the PR. In this situation, use of 
ORs are potentially misleading for readers or policy makers, who may inappropriately interpret 
ORs and PRs as being interchangeable. Additionally, in this study fitting the Poisson regression 
model allowed the incorporation of the natural logarithm of the total time of each woman’s 
pregnancy in gestational weeks as an offset term in the model, thereby accounting for the 
relative opportunity each woman had to receive influenza vaccination during pregnancy. 
3.2.3 Aim 3 - Safety and benefits of seasonal influenza vaccination during pregnancy 
 
Data from the STOP cohort were used to evaluate the safety and impact of maternal seasonal 
influenza vaccination on pregnancy and birth outcomes. Time-dependent analyses were 
conducted. Cox proportional-hazards models with gestational age in weeks as the underlying 
time scale were used to derive hazard ratios (HRs) that compared the hazard rates for time-
sensitive outcomes such as spontaneous abortion (Objective 3.1), hospital admissions during 
pregnancy with influenza-like illness (Objective 3.2) and preterm birth (Objective 3.3) between 
vaccinated and unvaccinated women. Maternal influenza vaccination status was coded as a 
time-dependent exposure variable. In this approach, each woman may contribute unvaccinated 
and vaccinated time in any risk set. Vaccinated women contributed unvaccinated exposure time 





occurring prior to vaccination was designated as occurring in unvaccinated time period. Log-
binomial models were also used in this study to estimate risk ratios (RR) and adjusted risk 
ratios (aRR) comparing risk of late onset or early postpartum adverse pregnancy outcomes or 
time-independent perinatal outcomes. Finally, a linear regression model was applied to 
compare the difference in mean gestational age at delivery and mean birthweight by maternal 
vaccination status. Details of these analyses and the findings are described in Chapter 6.  
3.2.4 Aim 4 - Safety of pertussis vaccination during pregnancy 
 
Data were drawn from the prospective STOP cohort to evaluate the safety of pertussis vaccine 
during pregnancy. The methodological approach that was applied to address Aim 3 was also 
used to address Aim 4. Cox proportional-hazards models and log-binomial models were fit to 
quantify the associations between maternal pertussis vaccination status and pregnancy and birth 
outcomes. The analyses and findings are explained in more detail in Chapter 7. 
3.3  Ethics 
 
Written informed consent was obtained from all women. Personal identifying information in 
the STOP study database was eliminated to ensure that confidentiality of all patients’ records 
was maintained. The STOP study protocol was approved by the Women’s and Children’s 
Health Network Human Research Ethics Committee Adelaide, Australia 
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Maternal pertussis vaccination has been introduced in several countries to prevent pertussis
morbidity and mortality in infants too young to be vaccinated. Our review aimed to systemati-
cally collect and summarize the available evidence on the effectiveness of interventions
used to improve pertussis vaccination uptake in pregnant women.
Methods
We conducted a systematic search of MEDLINE/PubMed, PMC and CINAHL. Before and
after studies and those with a concurrent control group were considered for inclusion. Stan-
dardized effect sizes were described as the ratio of the odds to be vaccinated in the interven-
tion group compared with the standard care group and absolute benefit increase (ABI) were
calculated.
Results
Six studies were included in the review, of which three were randomized controlled trials
(RCTs). Strategies to improve uptake were focused on healthcare providers, pregnant
women, or enhancing vaccine access. Healthcare provider interventions included provider
reminder, education, feedback and standing orders. Interventions directed at pregnant
women focused solely on education. Observational studies showed: (1) the provision of
maternal pertussis vaccination by midwives at the place of antenatal care has improved
uptake of pertussis vaccine during pregnancy from 20% to 90%; (2) introduction of an auto-
mated reminder within the electronic medical record was associated with an improvement in
the pertussis immunization rate from 48% to 97%; (3) an increase in prenatal pertussis vac-
cine uptake from 36% to 61% after strategies to increase provider awareness of recommen-
dations were introduced. In contrast to these findings, interventions in all three RCTs (2
involved education of pregnant women, 1 had multi-component interventions) did not dem-
onstrate improved vaccination uptake.
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Conclusions
Based on the existing research, we recommend incorporating midwife delivered maternal
immunization programs at antenatal clinics, use of a provider reminder system to target
unvaccinated pregnant women and include maternal pertussis immunization as part of stan-
dard antenatal care.
Introduction
There has been a global resurgence in pertussis in recent years, particularly in the US, the UK
and Australia, with the highest rates of hospitalization and death in young infants, mainly
those less than 2 months of age, prior to the recommended age for vaccination [1–6]. Infection
of young infants occurs primarily at the household level with new mothers identified as the
most common sources [7, 8]. Maternal pertussis immunization protects infants through
passive and active transfer of maternal antibodies that protect the infant until the primary
immunization series commences in infants at 6–8 weeks of age [9–11]. The highest level of
protection is not achieved in infants until they have received 3 doses at 6 months of age [12].
Pertussis vaccination in pregnancy at least 7 days before delivery can prevent up to 91% of per-
tussis disease in infants age <3 months [11]. In 2011, the US became the first country to rec-
ommend that health care personnel administer pertussis vaccine to pregnant women [13] and
many countries have recently adopted this policy in an attempt to reduce the burden of pertus-
sis in young infants [14]. Despite the recommendation of maternal pertussis vaccination from
immunization advisory groups internationally [13–15], uptake remains suboptimal [16–19].
The barriers to vaccination in pregnancy are more complicated than the barriers identified for
low uptake in childhood immunization programs [20].
Some recent studies have evaluated the effectiveness of strategies in improving maternal
immunization uptake, which predominantly focussed on educational interventions for preg-
nant women or healthcare providers while others included a multi-component intervention
package [21–25]. A systematic review has been recently published to identify effective strate-
gies in improving the uptake of vaccination in pregnancy in high-income countries [26].
However, the review [26] was aimed to make recommendations to an English setting and the
majority of the published articles (18/22) identified in the review evaluated the effectiveness of
strategies in improving seasonal influenza vaccination uptake in pregnancy. Limited data exist
on rigorously evaluated interventions to improve pertussis immunization uptake among preg-
nant women. Given the well-documented benefits of maternal pertussis immunization in pro-
tecting very young infants, determining effective strategies to improve pertussis vaccine
uptake during pregnancy should be a public health priority. This is the first review aimed to
systematically collect and summarize the available evidence on the effectiveness of interven-
tions in improving pertussis vaccination uptake in pregnant women. The protocol for this
review is published in PROSPERO International prospective register of systematic reviews—
CRD42017058178.
Materials and methods
This systematic review was conducted in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement (see S1 Table) [27].
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does not alter our adherence to PLOS ONE policies
on sharing data and materials.
Search strategy
The search strategy included the following electronic databases:—PubMed, PMC, Medline,
Cochrane Library, CINAHL and ClinicalTrials.gov. Other sources include conference pro-
ceedings—World Society for Paediatric Infectious Diseases (WSPID) and European Society
for Paediatric Infectious Diseases (ESPID). Specific search terms suitable to the individual
databases were developed. These search terms included combinations of Medical Subject
Headings (Messi)/Emtree and text words contained in the title and abstract (see S2 Table).
Eligibility criteria
Our systematic review includes all original studies that reported on interventions to improve
pertussis uptake during pregnancy. Some countries recommending pertussis vaccination dur-
ing pregnancy are using combined tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) or with inactivated polio vaccine (Tdap-IPV) in their programs. Hence, stud-
ies comparing pertussis vaccination uptake in pregnancy combined with or without other anti-
gens either pre-post introduction of intervention or a concurrent control group during the
same observation period were considered. The primary outcome measured was pertussis vac-
cination uptake during pregnancy, with confirmation in electronic medical records or self-
reported data (Table 1).
Study selection
Two independent reviewers (HM and MM) completed initial screening based on titles and
abstracts of potentially relevant studies. If the articles reported interventions to improve per-
tussis vaccination uptake during pregnancy, the reviewers performed a more detailed subse-
quent assessment by looking at the full text. The reference lists considered for inclusion were
searched for additional studies that might have been missed in the database search. Disagree-
ments about the inclusion or exclusion of studies were resolved through consensus discussions
among reviewers.
Data analysis
The primary measures extracted were percentage changes in uptake of pertussis vaccination
during pregnancy from standard care group to intervention group. Standardized effect sizes
were described as the ratio of the odds to be vaccinated in the intervention group compared
with the standard care group and absolute benefit increase (ABI) with 95% confidence
Table 1. The inclusion and exclusion criteria used during the screening process.
Criteria Included
Study design • Studies comparing pertussis vaccine uptake among pregnant women who were exposed to an
intervention vs. standard care
• Observational studies
• Randomised controlled trials
• Interventions that include pertussis as a compound of the immunization i.e. Tdap or Tdap-IPV
Population Pregnant women
Outcomes Pertussis vaccination uptake during pregnancy
(Standard care vs. intervention group)
Publication
date
Up to January 2019
Language Studies published in English
https://doi.org/10.1371/journal.pone.0214538.t001
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intervals (CI), were calculated. In studies with concurrent comparison groups, the overall
change in pertussis vaccination uptake was calculated by using the difference in vaccine uptake
change observed in the intervention and comparison groups. In studies without a concurrent
comparison group, the absolute percentage change was calculated from measurements of per-
tussis vaccination uptake during pregnancy in pre- and post-intervention. Additionally, a list
of all confounders adjusted for in the data analysis was reported. To strengthen the generalisa-
bility of our review results, we used the intervention classification guidelines adopted from the
Task Force on Community Preventive Services [28].
1. Provider-focused interventions
2. Pregnant woman-focused interventions
3. Interventions to enhance maternal pertussis vaccination access
Our review did not conduct meta-analysis because of the broad heterogeneity in study
design and types of interventions used to improve pertussis vaccination uptake during
pregnancy.
Data quality assessment
Two independent reviewers (HM and MM) assessed the quality of the included studies. The
Cochrane Collaboration method was used for the risk of bias assessment of randomized con-
trolled trials (RCTs) [29]. The risk of bias was assessed in six domains: sequence generation,
allocation concealment, blinding, incomplete outcome data, selective outcome reporting and
‘other issues’. A ‘risk of bias summary’ displaying the quality assessment of all included RCT
studies was generated. For each outcome, the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) criteria were also used to evaluate the quality of the
RCT studies [30]. The GRADE criteria were used along with the Cochrane Collaboration tool
because these criteria, take into account assessment of three additional domains: consistency,
directness, and precision of the results in addition to the risk of bias. Randomized trials began
as high-quality evidence but were rated down if trials demonstrated limitations (see S3 Table).
The Joanna Briggs Institute (JBI) critical appraisal tools were used to assess the quality of
experimental studies without random allocation (observational studies) (see S4 Table) [31].
Results
Search results
The initial search generated 3542 published studies. After removing duplicates, screening titles
and abstracts of the remaining 1935 studies, 16 studies were identified for full text review (Fig
1). Of these, we excluded 10 papers because they did not include an intervention component
(n = 4), eligible population (n = 3), outcome of interest (n = 1) or did not have a standard care
group for comparison (n = 2) (see S5 Table). Six studies that met the selection criteria were
included. No additional studies were obtained from the reference lists of the included studies.
Study characteristics
The six included studies were published between 2015 and 2017. Five studies were conducted
in the United States (US) [23–25, 32, 33] and one study was conducted in Australia [34]. The
sample sizes varied from 106 to 10,600 participants. Pregnant women were recruited from
public maternity hospitals, tertiary hospitals, antenatal clinics, university hospitals and a multi-
specialty medical organization.
Interventions to improve uptake of pertussis vaccination in pregnancy
PLOS ONE | https://doi.org/10.1371/journal.pone.0214538 March 28, 2019 4 / 14
The studies investigated a variety of interventions; two studies used provider-based inter-
ventions only [25, 32], two studies used pregnant woman-focused interventions only [24, 33]
and two studies incorporated provider-focused interventions, pregnant woman-focused inter-
ventions, as well as interventions to enhance maternal pertussis vaccination access (Table 2)
[23, 34]. Standard care varied and included pre-intervention routine prenatal care [23, 24, 32,
34], routinely offered pertussis vaccination only during the postpartum period [25] and stan-
dard Vaccine Information Statements (VISs) produced by the Centers for Disease Control and
Prevention (CDC) [33].
Critical appraisal
Randomized controlled trials. The evidence quality of the two RCTs were rated “moder-
ate” [23, 32] and “low” [24]. In two studies, the proportion of missing outcomes likely resulted
in bias of the effect estimates [23, 24]. Self-report was the primary method used to judge if a
pertussis vaccine was administered in two of the RCTs [23, 24]. In Chamberlain et al. [23]
there was a higher proportion of self-reported vaccination in the intervention group compared
to the standard care group, which may have introduced bias. Kris et al. [24] assessed the
Fig 1. Flow diagram of the process and results of study selection.
https://doi.org/10.1371/journal.pone.0214538.g001
Table 2. Strategies used to improve pertussis vaccination uptake among pregnant women.
Included
studies
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https://doi.org/10.1371/journal.pone.0214538.t002
Interventions to improve uptake of pertussis vaccination in pregnancy
PLOS ONE | https://doi.org/10.1371/journal.pone.0214538 March 28, 2019 5 / 14
outcome via self-report during a follow-up survey which could introduce recall bias (Supple-
mentary File).
Two of the RCT studies [23, 24] did not have a sufficient number of participants in both
arms to achieve 80% power to detect effects caused by the interventions while only one of
the RCT studies met the required sample size [33]. One RCT targeted minority women who
were African American women [24]. One of the RCT [33] studies was conducted in only one
public hospital and the majority of participants were from low socioeconomic backgrounds
and had poor health literacy. Hence, these findings may not be representative of other preg-
nant women in different US regions [33]. The risk of bias of all RCTs is summarized in Fig 2.
Observational studies. For all observational studies, interventions were introduced with
the aim to improve the uptake of pertussis vaccines among pregnant women. These were
assessed using electronic medical records [25, 32] or self-reported data [34]. Two studies [25,
34] included pregnant women who were recruited prior to the recommendation as the stan-
dard care groups and the intervention groups included women recruited after the change in
the pertussis vaccination recommendations. Hence, observed improvement in vaccination
rates could also be attributed to the change in national recommendations in these studies [25,
34]. These observational studies are likely to result in chronology bias and an overestimation
of the effect of an intervention. Adjustment for confounding was performed in two of the
observational studies (Table 3) [23, 34]. However, not all of the observational studies have con-
sidered potential confounders influencing vaccination uptake during pregnancy in their
adjusted analysis such as maternal age, parity, primary language, ethnicity, socioeconomic fac-
tors, educational level and marital status.
Effect of various interventions in increasing pertussis vaccine uptake
Provider-focused interventions. Two retrospective cohort studies [25, 32] implemented
intervention solely on provider-focused interventions while one RCT study used multi inter-
vention components that targeted both HCPs and pregnant women [23]. One of the retrospec-
tive studies involved delivering an electronic reminder “best practice alert” within the medical
record system by alerting HCPs to offer maternal pertussis vaccination to their pregnant
patients [25]. Post-implementation of best practice alert, uptake of pertussis vaccine during
pregnancy was significantly improved to 97% compared with 48% of postpartum pertussis vac-
cination uptake prior to the program. The computed absolute benefit increase (ABI) of the
intervention was 49% (95% CI 48% to 50%) (Table 3). Healy et al. [32] evaluated an American
College of Obstetricians and Gynaecologists (ACOG) tool kit that aimed to improve HCPs’
awareness of the recommendation to vaccinate pregnant women with pertussis vaccines. The
uptake of pertussis vaccine among pregnant women was significantly improved after the
Fig 2. Risk of bias in included RCT studies.
https://doi.org/10.1371/journal.pone.0214538.g002
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Table 3. Absolute benefit increase and 95% confidence intervals of each intervention.
Author Study design, period and methods Participants and setting Uptake of maternal





A. Pregnant women focused intervention programs
Payakachat
[33]
RCT: Academic medical centre
Arkansas, USA
Standard care 0.03 (-0.07, 0.15) None
May–August 2014 65/144 (45%)
Standard care:
Vaccine information statement (sVIS) Intervention
66/135 (49%)
Intervention:
Plain language version (mVIS)
Kriss [24] RCT: Pregnant African American
women in 4 antenatal clinics in
metropolitan Atlanta, USA
Standard care Intervention 1 None
January 30-April 3, 2013. 2/34 (6%)during
pregnancy
0.00 (-0.13,0.15)
Follow up: after delivery 4/34 (12%)
postpartum
Intervention 2
Standard care: Intervention 1
(Video)
0.00 (-0.13, 0.16)






1. Messaging video Intervention 2
(iBook)
0.10 (-0.07,0.29)






B. Healthcare provider focused intervention programs
Morgan [25] Retrospective study Pregnant women from Parkland
Hospital, USA
Standard care 0.49 (0.48,0.50) None
Standard care: Routinely offered Tdap during the





Intervention A best-practice alert, June 2013 to
July 2014
Healey [32] Retrospective study Women delivering at Texas
Children’s Hospital, USA
Standard care 0.25 (0.11,0.37) None
Standard care: Routine antenatal care. Historical
control April to Sept 2013
(36%)a
Intervention:
Intervention: ACOG “toolkit” Physicians
information through email and regular meetings.
Sep 2013 to Jun 2014
(61%)a
N = 6577
C. Interventions with bundled components
Mohammed
[34]
Observational prospective study Pregnant women attending a
territory obstetric hospital in
Adelaide, Australia
Standard care 0.70 (0.50, 0.82) Age, parity, country of birth,
provider recommendation5/25 (20%)
November 2014 and July 2016
Standard care: Routine antenatal care Intervention
140/155 (90%)
Intervention: A midwife delivered immunization
program
(Continued)
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release of the ACOG tool kit in the tertiary care centre. The ABI generated from this study was
25% (95% CI 11% to 37%) (Table 3).
Pregnant woman-focused interventions. Two RCT studies [24, 33] evaluated the sole
effect of pregnant women-focused interventions alone while three studies also incorporated
other intervention components [23, 25, 34]. Kris et al. [24] assessed the effect of two Elabora-
tion Likelihood Model (ELM) based vaccine educational interventions—an affective messag-
ing video and a cognitive messaging iBook intervention among pregnant African American
women [24]. Only 6% and 7% received the pertussis vaccination during pregnancy in the
iBook and video groups, respectively. Sample sizes were too small to obtain meaningful esti-
mates in the improvement of pertussis vaccination during pregnancy. However, of the two
interventions, the iBook was significantly associated with uptake of the postpartum pertussis
vaccination compared with women in the control group (Table 3). Payakchat et al. [33] con-
ducted a prospective study among pregnant women who were randomized to receive either
the standard CDC pertussis vaccine information statement (sVIS) or a modified version
(mVIS). There was no significant differences in the pertussis vaccination uptake during preg-
nancy between the sVIS and mVIS groups. The computed ABI for the study was 3% (95% CI
-7% to 15%) (Table 3).
Interventions to enhance access to pertussis vaccination. Our review found no studies
that implemented interventions solely focused on enhancing access to the pertussis immuniza-
tion during pregnancy. However, two of the reviewed studies included strategies to enhance
vaccine access along with two of the classified intervention types: pregnant woman-focused
and provider-focused strategies [23, 34]. One of the studies was a cluster-randomized trial [23]
while the other was a prospective observational study [34].
Bundled interventions. The reviewed studies included only two intervention components
as part of bundled interventions [23, 34]. Chamberlain et al. [23] introduced multi-component
antenatal vaccine promotion package among 11 obstetric practices in Georgia. Each interven-
tion obstetric practice was instructed to hand out iPads pre-loaded with lessons demonstrating
the importance of maternal immunization to obstetric patients in examination rooms. Cham-
berlin et al. [23] also evaluated the use of identification of a vaccine champion and assessed
whether stocking of influenza and pertussis vaccines in obstetric practices could improve vac-
cine uptake during pregnancy. Women who received pertussis vaccination during pregnancy
were significantly more likely to have been enrolled from a practice stocking pertussis vaccines
Table 3. (Continued)
Author Study design, period and methods Participants and setting Uptake of maternal







A cluster RCT Pregnant women from obstetric
practices in Georgia, USA
Standard care 0.04 (-0.02,0.12) Adjusted for clustered study design
and intention to receive the vaccine
before delivery
December 2012–April 2013 13/151 (9%)
Standard care Routine antenatal care
Intervention
Intervention Vaccine Champions, provider-to-
patient talking points, educational brochures,
posters, lapel buttons & iPads loaded with
tutorials
19/140 (14%)
a The authors did not state the number of vaccinated women pre-and post-intervention
https://doi.org/10.1371/journal.pone.0214538.t003
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than women who did not receive a pertussis vaccine during pregnancy (78% vs 51%; p< 0.01).
Overall, antenatal pertussis vaccination uptake was higher in the bundled intervention group
than the control group, although improvements were not significant (RR 1.58, 95% CI 0.81,
3.07) [23].
Mohammed et al. [34] aimed to estimate maternal vaccine uptake pre-post introduction of
a midwife delivered maternal immunization program at a territory obstetric hospital, South
Australia. The midwife vaccine delivery program in South Australia equipped midwives with
knowledge and skills to engage with pregnant women on the topic of maternal immunization
and administer pertussis immunizations to pregnant women [35]. The adjusted odds of
women receiving pertussis vaccination during pregnancy were significantly higher after the
implementation of the midwife delivered program compared with women who delivered
babies prior to the program (AOR 21.1, 95% CI 6.14–72.9; p<0.001) [33]. The calculated ABI
for this study was 70% (95% CI 50% to 82%).
Discussion
Given the well-documented benefits of maternal pertussis immunization in protecting young
infants, our review findings are relevant to HCPs and public health policy makers, to guide the
establishment of effective maternal pertussis immunization programs. Our review identified
six studies evaluating the effectiveness of interventions that promote pertussis vaccination in
pregnant women. These studies primarily focused on interventions targeting either HCPs or
pregnant women. Our review included three RCTs and three observational studies. RCTs are
the most rigorous scientific method for appraising the effectiveness of health care interven-
tions [36]. The interventions in all the three RCTs included in this review did not demonstrate
a significant improvement in the uptake of pertussis vaccination during pregnancy, although
two studies failed to attain their sample size estimates.
The three observational studies in our review have reported statistically significant absolute
increases in the vaccination rate of at least 25% [25, 32, 34]. Mohammed et al. [34] demon-
strated provision of pertussis vaccination by midwives at the place of antenatal service was
strongly associated with increased pertussis vaccination uptake during pregnancy. The pro-
gram enables registered midwives to administer vaccination during pregnancy using a stand-
ing medication order, without seeking permission from a referring medical doctor [34].
Previous studies suggested that administering maternal immunizations through standard ante-
natal care by midwives could improve vaccination uptake among pregnant women [37, 38].
However, the relatively small sample size of the reviewed study could be a limitation to the
study findings [34].
Previous studies have shown the implementation of a “best practice alert” with in the elec-
tronic medical record is associated with improved uptake of influenza vaccines in several
high-risk groups [39–41] which supports our reviewed observational study findings in
pregnant women [25]. Installing an automated reminder within electronic medical records
in an antenatal care setting may encourage health care provider–patient discussions on the
safety, efficacy, and necessity of pertussis vaccination during pregnancy. The use of the best-
practice alert would also enable prenatal care providers to administer the vaccine at a
moment when the pregnant women can act immediately with a minimum of additional
time, effort or cost.
The finding of one of the reviewed observational studies [32] is also consistent with earlier
research that multiple educational interventions to improve provider awareness has improved
vaccine uptake among pregnant women in antenatal care settings [38, 39, 42]. Several studies
have also reported that recommendation from maternity care providers is the most important
Interventions to improve uptake of pertussis vaccination in pregnancy
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factor in improving vaccination uptake during pregnancy [43–49]. Many of the barriers cited
for pregnant women often apply to HCPs as well, including lack of knowledge about the bene-
fits of maternal vaccinations [50–54]. Pregnant women’s misperceptions about the risk of the
disease, effectiveness and safety of vaccination during pregnancy are the main barriers to the
delivery of vaccinations during pregnancy [55–58]. Hence, overcoming pregnant women and
HCP barriers play a major role in improving pertussis vaccination uptake among pregnant
women.
Two of the studies assessing the sole effect of pregnant woman-focused interventions were
RCTs and found no significant effect of pregnant woman-focused educational interventions
[24, 33]. Although, these studies have shown a positive effect of educational interventions on
improving pertussis vaccination uptake among pregnant women, they did not significantly
improve uptake of pertussis vaccination during pregnancy. It could be argued that interven-
tions solely focussed on educating pregnant women on the benefits of vaccines might not be
an effective strategy. Moniz et al. [59] argued that the content of the message in educational
interventions might influence its effectiveness and further studies assessing messaging would
be of value. There is a need for high-quality patient education highlighting the role of maternal
pertussis vaccination in preventing severe pertussis infection in very young infants. Educa-
tional materials on maternal pertussis immunization should also be easily readable and accessi-
ble to women from culturally and linguistically diverse backgrounds. There is also a need for
studies in other countries and low resource settings as it is likely that interventions will need to
be cognisant of cultural considerations. In addition, understanding the psychological and
social factors influencing women’s decisions to accept vaccines during pregnancy could help
in designing strong maternal immunization programs.
Limitations
Although our review tried to standardize intervention into distinct classifications to enhance
their comparability, some studies included interventions of more than one classification,
which complicated comparability between interventions. Some of the studies were not ade-
quately powered and were susceptible to bias and thus may only provide indirect evidence of
effectiveness. Vaccination behaviour influences the self-report and explains a tendency to
overestimate vaccination coverage in self-reporting compared to the electronic medical record
[60]. Hence, the reviewed studies with self-reported vaccination are likely biased toward over-
estimating the intervention’s effect. Moreover, none of the reviewed studies takes into account
the impact of contemporaneous vaccination for influenza as a predictor of pertussis vaccina-
tion uptake. In other words, participants could be more likely to be vaccinated for pertussis
during the time of year when HCPs were also recommending vaccination for influenza partic-
ularly during the flu season. Furthermore, recommended national changes in timing of mater-
nal pertussis vaccination from postpartum to antepartum may have introduced bias in
comparison of vaccination coverage between standard care and intervention groups in some
of the observational studies. In addition, most of the reviewed studies were done in the US and
the difference in access to the antenatal health care system among countries limits the gener-
alizability of the results internationally.
Overall, the certainty of the findings in this review are low. To improve the certainty of evi-
dence more RCTs are required. In situations where only observational designs are feasible,
consideration of how best to limit potential bias is paramount. Before and after studies should
use at least three data points before and after the implementation of the intervention, and
adjust for secular trend in the analysis [61].
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Conclusions
The best available evidence suggests that to improve maternal pertussis vaccination to protect
young infants, HCPs should inform all pregnant women about the importance of pertussis
vaccination during pregnancy, incorporate midwife delivered maternal immunization pro-
gram at antenatal clinics, use provider reminder systems to target unimmunized pregnant
women, and include maternal pertussis immunization as part of standard antenatal care.
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a b s t r a c t
Objective: To identify the psychosocial factors influencing women’s uptake and willingness to receive
pertussis and influenza vaccine during pregnancy.
Methods: The study population comprised 1364 healthy nulliparous pregnant women who participated
in a prospective cohort study at two obstetric hospitals in South Australia between 2015 and 2017.
Information on women’s vaccination status, sociodemographic, lifestyle and psychological state were col-
lected at 9–16 weeks’ gestation and medical case notes were checked post-delivery to verify the reported
vaccination status. Poisson regression models were used to estimate the crude and adjusted prevalence
ratios (aPRs) to identify psychosocial factors influencing uptake of vaccination during pregnancy.
Results: Willingness to receive the recommended maternal vaccines was high (90%). Overall, 79% and 48%
received maternal pertussis and influenza vaccines respectively. There was no evidence to support the
influence of psychosocial factors on women’s willingness to receive immunization during pregnancy.
High levels of anxiety (aPR 0.98, 95% CI: 0.87–1.09) was not associated with uptake of maternal pertussis
vaccine. However, elevated depressive symptoms (aPR 1.14, 95% CI: 1.00–1.30) and very high-perceived
stress during pregnancy were significantly associated with receipt of pertussis vaccination (aPR 0.87; 95%
CI 0.76–0.99). Women with mild depressive symptoms (aPR 1.21, 95% CI 1.00–1.44) and mild anxiety
symptoms (aPR 1.21, 95% CI: 0.99–1.48) were more likely to receive influenza vaccine during pregnancy.
A history of major depressive disorder was independently associated with receipt of pertussis (aPR 1.16,
95% CI 1.06–1.26) and influenza vaccination during pregnancy (aPR 1.32; 95% CI 1.14–1.58).
Conclusion: Regardless of psychosocial factors, most women reported a positive willingness to receive the
recommended vaccinations during pregnancy. However, psychosocial factors influenced the uptake of
pertussis and influenza vaccines during pregnancy. Psychosocial factors should be taken into considera-
tion in designing interventions and implementation of maternal pertussis and influenza immunization
programs.
 2020 Elsevier Ltd. All rights reserved.
1. Introduction
Pregnant women are at increased risk of morbidity and death
from influenza infection particularly during seasonal and pan-
demic influenza outbreaks [1–3]. Newborn infants born to mothers
with influenza during pregnancy are also at increased risk of
adverse birth outcomes such as preterm birth and low birthweight
[4]. Similarly, Bordetella pertussis infections pose the highest risk
for pertussis-related complications and death in infants too young
to be fully protected by routine childhood immunization schedules
[5,6]. Vaccination of pregnant women against influenza and per-
tussis has now been shown to be effective in not only protecting
the mother but also the newborn via transfer of transplacental
antibodies [7,8]. Maternal pertussis vaccination can provide more
than 90% protection against pertussis disease in infants under
3 months of age [9,10]. Maternal influenza vaccination has been
https://doi.org/10.1016/j.vaccine.2020.02.020
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shown to decrease the risk of influenza and its complications
among pregnant women and prevent up to 91% of influenza related
hospital admissions in infants under 6 months of age [11,12]. Sub-
stantial evidence supports the safety of influenza and pertussis
vaccination in pregnancy, with no serious adverse pregnancy or
neonatal outcomes related to maternal vaccination [13,14].
Despite the recommendation of maternal pertussis and influenza
vaccination from immunization advisory groups internationally,
uptake of the vaccines has been low [15–17].
Pregnant women’s low perceptions of disease severity and con-
cerns about the safety of maternal vaccination are barriers to the
delivery of vaccinations during pregnancy [18,19]. Previous litera-
ture investigated determinants of pertussis and influenza vaccina-
tion uptake during pregnancy and specific aspects of vaccination
such as women’s perception, knowledge and attitudes towards vac-
cination in pregnancy [20–22]. There is some evidence on the influ-
ence of these assessments on the decision to vaccinate against
influenza and pertussis during pregnancy. However, the association
between maternal vaccination uptake and antenatal depression,
anxiety, stress, and maternal lifestyle factors are poorly addressed
by previous studies. Research about prenatal psychosocial factors
might further enhance the understanding of why certain women
receive the recommended vaccinations during pregnancy while
others do not. This is the first study aimed to investigate the influ-
ence of psychosocial factors on uptake and willingness to receive
pertussis and influenza vaccines during pregnancy.
2. Material and methods
2.1. Sample and study design
The current study draws on data collected as part of a prospec-
tive cohort study (STOP), which aims to develop screening tests to
identify adverse pregnancy outcomes. Healthy nulliparous women
were recruited in pregnancy at two major public maternity hospi-
tals in metropolitan Adelaide (Lyell McEwin Hospital, in the North-
ern suburbs of Adelaide, in a low socio-economic area and at the
Women’s and Children’s Hospital, the primary tertiary maternity
hospital for complex care with approximately 5000 births per year)
between March 2015 and December 2017. Women with a single-
ton pregnancy attending their first antenatal clinic between 9 + 0
and 16 + 0 weeks’ gestation were eligible to participate. Women
were excluded if they were considered to be at high risk of
preeclampsia, small for gestational age (SGA) birth, spontaneous
preterm birth or had previously experienced three or more miscar-
riages. Participants were followed prospectively, with pregnancy
outcome data collected by research midwives.
Pregnancies ending before 28 weeks’ gestation were excluded in
our final analyses of psychosocial factors influencing maternal per-
tussis vaccination because pertussis vaccine was recommended to
be administered between 28 and 32weeks of pregnancy at the time
of the study.Womenwho only received seasonal influenza vaccina-
tion within 6 months prior to their conception were excluded from
our final analyses of psychosocial factors influencingmaternal influ-
enza vaccination because they had a shorterwindow of opportunity
to receive a seasonal influenza vaccine during their pregnancy.
Assigning thesewomen to the ‘‘unvaccinatedduringpregnancy” ref-
erence group would likely bias the results as vaccination receipt in
the preceding influenza season has been associated with positive
perceptions regarding maternal vaccination [18,21].
2.2. Main outcome measures
The primary outcome was the proportion of women immunized
against pertussis and influenza during pregnancy. The secondary
outcome was women’s willingness to receive the recommended
vaccines during pregnancy. Women’s willingness to receive the
prenatal vaccines and vaccination status were collected by a
research midwife during the first study visit at 9–16 weeks’ gesta-
tion. Pregnant women were asked to confirm if they had been vac-
cinated against pertussis and influenza during pregnancy at the
32–36 weeks’ gestation. If the vaccines were administered, the
date or gestational week of administration were recorded. Follow-
ing delivery, the vaccination status of the women was checked
against their medical case notes to verify the reported vaccination
status. A woman was considered vaccinated if there was written
documentation of receipt of vaccines in the patient’s hand held
antenatal care record or medical notes. A woman was considered
to have been unvaccinated if she could not recall receipt of vacci-
nation and/or there was no documentation.
2.3. Psychosocial factors
Participating women completed sociodemographic and lifestyle
questionnaires at their first STOP visit, which included information
on education, occupation, employment, ethnicity, exercise, smok-
ing status, intake of alcohol and recreational drugs, psychological
history and current psychological state. During the interview,
women completed the Perceived Stress Scale (PSS-10) [23], to
assess perceived stress levels in the past month, the short form
of the Spielberger State–Trait Anxiety Inventory (STAI) [24], assess-
ing current anxiety symptoms, and the Edinburgh Postnatal
Depression Scale (EPDS) [25], assessing depressive symptoms dur-
ing pregnancy.
Scores for psychological measurements were calculated after
reverse keying positive items and summation of scores. For all psy-
chological measures, higher scores represent lower mental well-
being. For the purposes of the present study, we categorized the
psychological measures for improved interpretation of the results.
The depression scale was converted using three clinical cut-off val-
ues to indicate unlikely to have antenatal depression (EPDS score
0–9), increased risk of depression in the next 6–12 months (EPDS
score 10–12) and very likely depressed (EPDS score > 13) [25]. As
there are no standardized cut-off values for the Perceived Stress
Scale (PSS-10) and the State-Trait Anxiety Inventory (STAI), they
were converted into five categories to indicate low (<25th per-
centile), mild (25th to <50th percentile), moderate (50th to <75th
percentile), high (75th to <90th percentile) and very high (>90th
percentile) scores. Participant’s psychosocial risk status was also
determined using the Antenatal Risk Questionnaire (ANRQ) [26].
Our study used a recommended clinically useful cut-off score of
23 or more on ANRQ [26] or the presence of any of the weighted
critical factors i.e. a history of depression or psychiatric diagnosis
to identify women at high mental health risk group. This enabled
a comparison of the influence of different levels of prenatal stress,
anxiety, depression and prenatal mental health on a woman’s deci-
sion to vaccinate against pertussis and influenza during her
pregnancy.
2.4. Statistical analyses
Differences in baseline characteristics between vaccinated and
unvaccinated women were examined using the Chi-square test
for categorical variables and Mann-Whitney U test for continuous
variables. Poisson regression models were used to estimate both
the crude and mutually adjusted prevalence ratios (aPRs) and their
corresponding 95% confidence intervals to determine psychosocial
factors associated with uptake of maternal pertussis and influenza
vaccination during pregnancy. We chose a Poisson model with
robust errors as the appropriate analysis model, because it is usu-
ally preferable to model and estimate prevalence ratios instead of
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odds ratios in cohort studies when the prevalence of the outcome
are not rare (i.e. vaccination uptake is common among pregnant
women) and due to convergence issues with log binomial models
[27].
In the mutually adjusted models, we included all covariates (i.e.
maternal age, educational level, employment status, country of
birth, marital status, Indigenous status and season of delivery) that
were known potential confounders associated with vaccination
uptake in pregnancy based on published literature [18,21,28].
Potential psychosocial and periconceptional lifestyle predictors of
vaccination uptake in pregnancy (i.e. prenatal stress, anxiety and
depression, history of depression, smoking and illicit drug use,
multivitamin use and physical exercise) previously shown to be
associated with adherence to other prenatal care recommenda-
tions [29–31] were also included in the final adjusted models.
Although the influenza vaccine can be given at any time during
pregnancy, women who had miscarriages or terminations before
20 weeks’ gestation would have a shorter window of opportunity
to receive influenza vaccine during pregnancy compared with
women who had successful full-term pregnancies. To account for
the relative opportunity each woman had to receive influenza vac-
cination during pregnancy, the natural logarithm of the total time
of a pregnancy in gestational weeks up to miscarriage, termination,
stillbirth, or delivery was included in the final adjusted model as an
offset term. All statistical analyses were performed using Stata ver-
sion 15 (Stata Corp, College Station, Texas, USA).
3. Results
During the study period between 2015 and 2018, 1364 nulli-
parous pregnant women with singleton pregnancies were
recruited to the STOP study. Of the final 1364 women, 12 women
who withdrew access to their medical records, 3 women with no
medical case notes and 3 women who were lost to follow up were
excluded from our final analyses. After excluding 83 women who
had only received influenza vaccination within 6 months before
they become pregnant, information from the remaining 1263 par-
ticipating women with examined vaccination status against their
medical case notes were included in our analyses of psychosocial
factors influencing influenza vaccination uptake during pregnancy
(Fig. 1). The overall percentage of women vaccinated against influ-
enza during pregnancy was 47.9% (95% CI: 45.2–50.7%; n = 605).
After excluding 50 pregnancies that ended earlier than 28 weeks’
gestation, 1296 pregnancies were included in our analyses of psy-
chosocial factors influencing uptake of pertussis vaccination during
pregnancy (Fig. 1). Of these 1296 women, 1024 (79.0%; 95% CI:
76.8–81.2%) received pertussis vaccination during pregnancy.
Overall, 44% (n = 556) of the women received both recommended
maternal vaccines.
The mean age of the women at recruitment was 26.0 ± 5.0 years
(range: 15–45 years old). The mean gestational age at delivery was
39.2 ± 1.9 weeks. Baseline characteristics are presented in Table 1.
During the first study visit at 9–16 weeks’ gestation, 90% of the
women (n = 1227) reported willingness to receive the recom-
mended vaccines during pregnancy. Willingness to get vaccinated
during pregnancy at the first study visit was lower among unem-
ployed women (aPR, 0.91; 95% CI 0.86–0.97) and women with
diploma/certificate (compared with university graduates) (aPR,
0.94; 95% CI 0.89–0.99) (Table 2). Women who had been vacci-
nated against influenza (PR, 2.51; 95% CI 1.72–3.67) and pertussis
(PR, 1.15; 95% CI 1.01–1.31) during pregnancy were significantly
more likely to have reported willingness to accept the recom-
mended vaccines in pregnancy at baseline compared to those
who had not been vaccinated.
Maternal influenza vaccination uptake was higher for pregnan-
cies ending in winter or spring (Fig. 2). Uptake of influenza vaccine
during pregnancy significantly increased from 40.2% in the 2015–
16 influenza season to 51.7% in the 2017–2018 influenza season
(P < 0.01). Receipt of maternal influenza vaccine was lowest for
women whose estimated birth season was in autumn (26.6%)
(Fig. 2) and women who conceived during winter (24.2%). The pro-
portion of women vaccinated against pertussis was relatively
stable over time. However, the highest uptake of pertussis and
influenza vaccines was recorded when the women’s estimated
month of birth is in August (late winter) (Fig. 2). The uptake of per-
tussis vaccine during pregnancy increased from 76.8% in 2015 to
80.5% in 2016, decreasing slightly to 78.4% in 2017.
3.1. Antenatal depression
Of the 1364 women, 112 (8.2%) screened positive on the EPDS
(scored  13). Most of the women (1133, 83%) had scores sugges-
tive of low depressive symptoms (0–9) while some women (106,
7.8%) had scores indicating mild depressive symptoms (10–12)
(Table 1). Women with a prior history of major depression were
almost 8 times more likely to screen positive for antenatal depres-
sion symptoms (EPDS scores 13) (PR 7.90; 95% CI 5.11–12.20)
and 3 times more likely to have mild maternal depressive symp-
toms (PR 3.30; 95% CI 2.19–4.97) compared to those who had no
history of depression. Of the women who screened positive on
the EPDS, 89% of them reported in the highest quintile of perceived
stress. Women who screened positive were more likely to be single
(PR 3.87; 95% CI 2.20–6.80), obese (PR 1.47; 95 CI 1.17–1.84),
younger (PR 3.26; 95% CI 1.83–5.81), less educated (PR 2.50; 95%
CI 1.33–4.70), unemployed (PR 2.40; 95% CI 1.66–3.47), from the
lowest socioeconomic status group (PR 1.87; 95% CI 1.09–3.27)
and illicit drug users (PR 2.36; 95% CI 1.41–3.93).
Women who screened positive for antenatal depression were
significantly more likely to receive pertussis vaccination during
pregnancy compared with women who had a score of low mater-
nal depressive symptoms (aPR 1.14; 95% CI 1.00–1.30) (Table 3).
However, there was no evidence to support an association between
high depressive symptoms scores in early pregnancy and receipt of
maternal influenza vaccine (aPR 0.99; 95% CI 0.77–1.28). Pregnant
Fig. 1. Flowchart of recruited participants.
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women who had scores of mild depressive symptoms in early
pregnancy were significantly more likely to receive influenza vac-
cination during pregnancy (aPR 1.21; 95% CI 1.00–1.44) (Table 4).
Pregnant women with a history of major depressive disorder were
significantly more likely to receive both maternal pertussis (aPR
1.16; 95% CI 1.06–1.26) and influenza vaccination (aPR 1.32; 95%
CI 1.14–1.58) (Tables 3 and 4).
3.2. Antenatal psychosocial risk status
Of the 1364 women, 578 (42.3%) were classified as being at
moderate to high risk for poor perinatal mental health outcomes.
Women identified as ‘high risk’ were significantly more likely to
be unemployed (PR 1.38; 95% CI 1.21–1.58), single (compared with
married women) (PR 1.94; 95% CI 1.61–2.34) asthmatic patients
(PR 1.36; 95% CI 1.18–1.57) and in the low household income
group (PR 1.58; 95% CI 1.33–1.89). Given that the ANRQ includes
current mood as a risk, women at high-risk were significantly more
likely to screen positive on the EPDS (scored 13 points or higher)
(PR 2.71; 95% CI 2.35–3.13) and significantly more likely to report
in the highest quintile of the anxiety score (>90th percentile) (PR
2.03; 95% CI 1.70–2.44). However, there was no evidence to sup-
port correlation between pertussis and influenza uptake during
pregnancy and antenatal psychosocial risk status (Tables 3 and 4).
3.3. Perceived stress
The median score of the pregnant women on perceived stress
scale was 13 (IQR: 8–17). The likelihood of receiving the pertussis
vaccine for women with very high-perceived stress levels was sig-
nificantly lower compared to women with low perceived stress
(aPR 0.87; 95% CI 0.76–0.99) at the first visit. However, there was
little evidence of an association between influenza vaccination
uptake during pregnancy and perceived stress score at the first
study visit (Table 4).
3.4. Anxiety
The median score of the women on State-Trait Anxiety Inven-
tory (STAI-6) was 9 (IQR: 7–12). The skewness statistic for STAI
scores was 0.84 indicating a positively skewed distribution. Rela-
tively few women presented with moderate anxiety scores.
Women with moderate levels of state or trait anxiety were more
likely to receive pertussis (aPR 1.08; 95% CI 0.98–1.18) and influ-
enza vaccine (aPR 1.21; 95% CI 0.99–1.48) during pregnancy com-
pared with those women who scored low levels of state or trait
anxiety. The lowest proportion of pertussis and influenza vaccine
uptake was among women who scored in the highest quintile of
anxiety (>90th percentile). However, there was no evidence to sup-
port an association between elevated anxiety scores measured at
9–16 weeks’ gestation and low pertussis and influenza vaccination
uptake during pregnancy (Tables 3 and 4).
3.5. Sociodemographic factors
The adjusted model (Table 3) suggests social factors such as
being younger than 25 years of age, born outside of Australia, being
in a defacto relationship (compared with married women) and
being unemployed were associated with low pertussis vaccination
uptake during pregnancy. For influenza uptake, women aged 20–
24 (compared with women aged >30) and being unemployed were
significantly associated with low influenza vaccination uptake dur-
ing pregnancy after adjusting with all variables in the model
(Table 4). Pertussis and influenza vaccine uptake during pregnancy
was lowest among women with secondary school qualification or
lower level but these associations were not significant in the final
adjusted model (Tables 3 and 4).
3.6. Maternal health behaviors
Pregnant women who did not use multivitamin and mineral
supplements pre-conception or during pregnancy were signifi-
cantly less likely to have received both pertussis (aPR 0.88; 95%
CI 0.81–0.96) and influenza vaccination during pregnancy (aPR
0.77; 95% CI 0.64–0.93). Women who were physically inactive
were less likely to receive maternal pertussis vaccine (aPR 0.95;
95% CI 0.87–1.03) compared to women who actively engaged in
regular moderate-intensity exercises. Smoking or illicit drug use
Table 1
Maternal characteristics of enrolled pregnant women, 2015 to 2018.
Variable Level Raw data
N = 1364
%




Born in Australia Yes 1116 81.8
No 248 18.2



















Missing values 4 0.3






Missing values 15 1.1
Employment Status Full/part-time work 1115 81.7
Unemployed 242 17.7
Missing values 7 0.6
The Antenatal Risk
Questionnaire (ANRQ)
Low (0–22) 773 56.6
High (23) 578 42.3
Missing values 13 0.9
Likelihood of depression











Missing values 13 0.9
Smoking status at 9–16 weeks’
gestation
Non-smoker 1078 79.0
Quit during pregnancy 148 10.8
Current smoker 130 9.5
Missing values 8 0.5











a Use of Binge alcohol  6 drinks per session, Marijuana, Cocaine/crack, Cigars,
Amphetamines, Substance P/crystal meth, XTC, Opiates, Hallucinogens, Herbal
highs, E-cigarettes, Shisha (or hookah).
H. Mohammed et al. / Vaccine 38 (2020) 3358–3368 3361
Table 2
Factors associated with willingness to receive vaccination during pregnancy.
Variable Willing to get vaccinated Prevalence ratio (PR) (95% CI) P-value Adjusted PRc (95%CI) P-value
n/Na (%)
1227/1342b (91.4)
Perceived stress score (PSS)
Low 258/281 (91.8) Reference
Mild 252/275 (91.6) 0.99 (0.94,1.04) 0.939 1.00 (0.95,1.05) 0.905
Moderate 224/246 (91.0) 0.99 (0.94,1.04) 0.757 0.98 (0.93,1.04) 0.645
High 253/278 (91.0) 0.99 (0.94,1.04) 0.733 0.97 (0.92,1.04) 0.510
Very High 235/257 (91.4) 0.99 (0.94,1.04) 0.875 0.97 (0.90,1.04) 0.943
Anxiety score (STAI)
Low 323/349 (92.5) Reference
Mild 289/327 (88.3) 0.95 (0.90,1.00) 0.067 0.96 (0.91,1.01) 0.151
Moderate 114/124 (91.9) 0.99 (0.93,1.05) 0.828 1.00 (0.94,1.07) 0.858
High 285/304 (93.7) 1.01 (0.97,1.05) 0.544 1.01 (0.96,1.06) 0.472
Very High 191/211 (90.5) 0.97 (0.92,1.03) 0.411 0.98 (0.92,1.04) 0.592
Depression score (EPDS)
Unlikely to have depression (0-9) 1020/1116 (91.4) Reference
Increased risk of depression (10-12) 100/105 (95.2) 1.04 (0.99,1.09) 0.082 1.02 (0.97,1.08) 0.292
Very likely depressed (13) 95/109 (87.1) 0.95 (0.88,1.02) 0.210 0.93 (0.86,1.01) 0.127
Previous history of depression
No history of depression 883/974 (90.6) Reference
History of depression 167/179 (93.3) 1.02 (0.98,1.07) 0.203 1.01 (0.96,1.06) 0.636
History of major/clinical depression 177/189 (93.6) 1.03 (0.98,1.07) 0.132 1.10 (0.96,1.06) 0.571
ANRQ
Low (0–22) 684/762 (89.7) Reference
High (23) 531/568 (93.4) 1.04 (1.00,1.07) 0.014 1.03 (0.99,1.10) 0.106
Moderate exercise early pregnancy
4 per week 145/156 (92.9) Reference
1–3 per week 596/641 (92.9) 1.00 (0.95,1.04) 0.989 1.00 (0.95,1.04) 0.992
Never 478/537 (89.0) 0.95 (0.90,1.00) 0.106 0.96 (0.91,1.02) 0.252
Smoking status at 9–16 weeks’
Non-Smoker 976/1065 (91.6) Reference
Quit during pregnancy 135/145 (93.1) 1.01 (0.96,1.06) 0.518 1.01 (0.96,1.06) 0.687
Current smoker 115/130 (88.4) 0.96 (0.90,1.02) 0.284 0.96 (0.90,1.04) 0.389
Illicit drug use during 1st trimester/pre-pregnancy
No 1155/1266 (91.2) Reference
Yes 72/76(94.7) 1.03 (0.98,1.09) 0.185 1.03 (0.97,1.10) 0.250
Multivitamin use
Pre-conception and 1st trimester 283/303 (93.4) Reference
1st trimester 651/718 (90.6) 0.97 (0.93,1.00) 0.126 0.97 (0.93,1.01) 0.173
None 285/313 (91.0) 0.97 (0.93,1.02) 0.277 0.98 (0.93,1.03) 0.491
Maternal age group
>30 295/325 (90.7) Reference
25–29 437/475 (92.0) 1.01 (0.97,1.05) 0.545 1.01 (0.96,1.06) 0.528
20–24 371/407 (91.1) 1.00 (0.95,1.05) 0.857 1.00 (0.95,1.06) 0.755
15–19 124/135 (91.8) 1.01 (0.95,1.07) 0.704 1.03 (0.97,1.11) 0.277
Born in Australia
Yes 994/1074 (92.5) Reference
No 209/243 (86.0) 0.92 (0.88,0.97) 0.006 0.94 (0.88,1.00) 0.084
Indigenous status
Not Indigenous 1203/1317 (91.3) Reference
Indigenous 24/25 (96.0) 1.05 (0.96,1.14) 0.233 1.03 (0.95,1.12) 0.365
Marital status
Married 492/515 (89.7) Reference
Cohabiting/living with a partner 629/679 (92.6) 1.02 (1.00,1.05) 0.082 1.03 (0.99,1.08) 0.113
Single/separated/widowed 136/148 (91.8) 1.02 (0.96,1.08) 0.401 1.04 (0.97,1.11) 0.249
Education level
Bachelor’s or higher degree 254/276 (92.0) Reference
Diploma/certificate 434/477 (90.9) 0.98 (0.94,1.03) 0.618 0.94 (0.90,0.99) 0.048
Secondary school qualification 538/588 (91.5) 0.99 (0.95,1.04) 0.789 0.96 (0.91,1.02) 0.263
Employment Status
Full/part-time work 1015/1097 (92.5) Reference
Unemployed 207/240 (86.2) 0.93 (0.88,0.98) 0.001 0.91 (0.86,0.97) 0.004
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during pregnancy were also associated with lower uptake of both
vaccines during pregnancy but these associations were not signif-
icant in the final adjusted model (Tables 3 and 4).
4. Discussion
The study found that 79% of women received a pertussis vaccine
during pregnancy which is higher coverage than other high-
income countries with a national maternal pertussis immunization
programs such as the United States of America (54% in 2018) [32]
and the United Kingdom (68% in 2018) [33]. Following the intro-
duction of government funded antenatal pertussis immunization
programs in all Australian states over the previous few years,
uptake of maternal pertussis immunization has increased in Aus-
tralia [34,35]. The uptake of influenza vaccine among pregnant
women in our cohort was 48%, still well below the benchmarks
set by Healthy People 2020, which specifies a goal of 80% influenza
vaccination for pregnant women [36]. The lower uptake of influ-
enza vaccine during pregnancy compared to pertussis vaccine in
our study could be because most women perceive influenza as a
disease affecting the mother, rather than a threat to their infant,
as for pertussis. Evidence indicates that women are more con-
cerned about potential risks to their infant’s health than their
own [37].
Our findings suggest that women whose pregnancies started in
winter with estimated birth season in autumn had the lowest
influenza vaccine uptake during pregnancy. This may have serious
adverse consequences particularly for pregnant women at high risk
of developing complications from influenza when the influenza
season is unpredictable. In Australia, the influenza season is gener-
ally from May to October, peaking in the winter month of August.
However, during the 2018–2019 influenza season, most Australian
states experienced a high increase in influenza-like illness notifica-
tions from March 2019, while South Australia had already experi-
enced a peak in influenza notifications in Autumn (early April)
[38]. Hence, it is possible for a pregnant woman to be severely
affected by influenza infections at any time of the year and immu-
nization providers need to offer influenza vaccination at any stage
of pregnancy, year round.
The study investigated psychosocial factors that influence
uptake of pertussis and influenza vaccination uptake during preg-
nancy. We hypothesized that non-adherence to maternal healthy
behaviors such as vaccine refusal or hesitancy during pregnancy
might be associated with the negative effects of anxiety, depres-
sion, or stress during pregnancy. Interestingly, our results indicate
that women’s willingness to receive the recommended prenatal
vaccines was high and independent of psychosocial factors but
we observed a difference in the actual vaccination uptake during
pregnancy. Although, willingness to receive the recommended
Table 2 (continued)
Variable Willing to get vaccinated Prevalence ratio (PR) (95% CI) P-value Adjusted PRc (95%CI) P-value
n/Na (%)
1227/1342b (91.4)
Estimated season of delivery
Summer 313/351 (89.1) Reference
Autumn 330//360 (91.6) 1.02 (0.97,1.07) 0.260 1.01 (0.96,1.06) 0.555
Winter 315/334 (94.3) 1.05 (1.01,1.10) 0.015 1.04 (0.99,1.09) 0.054
Spring 269/297 (90.5) 1.01 (0.96,1.06) 0.566 1.01 (0.96,1.07) 0.559
Bold values denote statistical significance at the p < 0.05 level.
a Weighted n in cohort.
b Missing data (n = 22, participants were excluded from the analysis because they did not provide answer).
c Mutually adjusted.












Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Estimated Month of Delivery
Willing to receive prenatal vaccines Received maternal pertussis vaccine
Received maternal influenza vaccine Received both recommended maternal vaccines
Fig. 2. Willingness to receive maternal vaccinations and pertussis and influenza vaccination uptake in pregnant women at two obstetric hospitals in South Australia, by
expected birth month. Note: The monthly denominator reported was the number of pregnant women with an estimated date of delivery (EDD) in that month. The monthly
numerator was the number of women identified in the denominator defined above who received the recommended vaccines during their pregnancy or were willing to
receive the prenatal vaccines.
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Table 3
Factors associated with the uptake of pertussis vaccination during pregnancy.
Variable Vaccinated Prevalence ratio (PR) (95% CI) P- value Adjusted aPRb (95%CI) P-value
n/N (%)a
1024/1296 (79.0)
Perceived stress score (PSS)
Low 217/267 (81.2) Reference
Mild 212/263 (80.6) 0.99 (0.91,1.07) 0.846 0.98 (0.91,1.07) 0.800
Moderate 200/244 (81.9) 1.00 (0.92,1.09) 0.840 0.98 (0.90,1.07) 0.703
High 209/269 (77.7) 0.95 (0.87,1.04) 0.306 0.94 (0.85,1.04) 0.272
Very High 181/245 (73.8) 0.90 (0.82,0.99) 0.047 0.87 (0.76,0.99) 0.039
Anxiety score (STAI)
Low 275/339 (81.1) Reference
Mild 252/325 (77.5) 0.95 (0.88,1.03) 0.291 1.00 (0.92,1.08) 0.979
Moderate 92/109 (84.4) 1.04 (0.94,1.14) 0.587 1.08 (0.98,1.18) 0.085
High 232/293 (79.1) 0.97 (0.90,1.05) 0.976 1.02 (0.94,1.11) 0.538
Very High 151/199 (75.8) 0.93 (0.85,1.02) 0.162 0.98 (0.87,1.09) 0.748
Depression score (EPDS)
Unlikely to have depression (0-9) 8541078 (79.2) Reference
Increased risk of depression (10-12) 74/99 (74.7) 0.94 (0.83,1.06) 0.337 0.97 (0.86,1.10) 0.738
Very likely depressed (13) 87/107 (81.3) 1.02 (0.93,1.12) 0.595 1.14 (1.00,1.30) 0.035
Previous history of depression
No history of depression 737/949 (77.6) Reference
History of depression 131/170 (77.0) 0.99 (0.90,1.08) 0.864 1.06 (0.96,1.18) 0.210
History of major/clinical depression 156/177 (88.1) 1.13 (1.06,1.20) 0.001 1.16 (1.06,1.26) 0.001
ANRQ
Low (0–22) 581/739 (78.6) Reference
High (23) 433/544 (79.6) 1.01 (0.95,1.07) 0.670 0.98 (0.91,1.07) 0.781
Moderate exercise early pregnancy
4 per week 127/149 (85.2) Reference
1–3 per week 495/620 (79.8) 0.93 (0.86,1.01) 0.099 0.94 (0.87,1.02) 0.181
Never 395/517 (76.4) 0.89 (0.82,0.97) 0.009 0.95 (0.87,1.03) 0.252
Smoking status at 9–16 weeks’
Non-Smoker 819/1025 (79.9) Reference
Quit during pregnancy 113/141 (80.1) 1.00 (0.91,1.09) 0.947 1.04 (0.95,1.14) 0.322
Current smoker 87/123 (70.7) 0.88 (0.78,0.99) 0.043 0.96 (0.90,1.03) 0.588
Illicit drug use during 1st trimester/pre-pregnancy
No 973/1219 (79.8) Reference
Yes 51/77 (66.2) 0.82 (0.70,0.97) 0.024 0.91 (0.77,1.06) 0.254
Multivitamin use
Pre-conception and 1st trimester 249/289 (86.1) Reference
1st trimester 549/689 (79.6) 0.92 (0.87,0.98) 0.010 0.96 (0.91,1.02) 0.301
None 220/311 (70.7) 0.82 (0.75,0.89) 0.001 0.88 (0.81,0.96) 0.007
Maternal age group
>30 258/310 (83.2) Reference
25–29 391/464 (84.2) 1.01 (0.95,1.07) 0.702 0.99 (0.93,1.06) 0.958
20–24 289/390 (74.1) 0.89 (0.82,0.96) 0.003 0.90 (0.83,0.98) 0.020
15–19 86/132 (65.1) 0.78 (0.68,0.89) 0.001 0.86 (0.74,0.99) 0.040
Born in Australia
Yes 8521065 (80.0) Reference
No 172/231 (74.4) 0.93 (0.85,1.00) 0.084 0.91 (0.84,1.00) 0.066
Indigenous status
Not Indigenous 1009/1272 (79.3) Reference
Indigenous 15/24 (62.5) 0.78 (0.57,1.07) 0.133 0.87 (0.65,1.16) 0.360
Marital status
Married 425/507 (83.8) Reference
Cohabiting/living with a partner 490/641 (76.4) 0.91 (0.86 ,0.96) 0.002 0.93 (0.87.0.99) 0.037
Single/separated/widowed 109/148 (73.6) 0.87 (0.79 ,0.97) 0.014 0.96 (0.86,1.08) 0.582
Education level
Bachelor’s or higher degree 218/265 (82.6) Reference
Diploma/certificate 366/461 (79.3) 0.96 (0.89,1.03) 0.338 1.04 (0.95,1.13) 0.342
Secondary school qualification 438/566 (77.3) 0.94 (0.87,1.01) 0.094 0.98 (0.90,1.06) 0.658
Employment Status
Full/part-time work 864/1059 (81.5) Reference
Unemployed 157//231 (67.9) 0.83 (0.75,0.91) 0.001 0.90 (0.81,0.99) 0.050
Estimated season of delivery
Summer 257/339 (75.8) Reference
Autumn 273/346 (78.9) 1.04 (0.95,1.12) 0.355 1.07 (0.99,1.16) 0.084
Winter 259/322 (80.4) 1.08 (0.97,1.15) 0.151 1.06 (0.97,1.15) 0.143
Spring 234 288 (81.2) 1.07 (0.98,1.16) 0.097 1.09 (1.00,1.18) 0.042
Bold values denote statistical significance at the p < 0.05 level.
a Weighted n in cohort.
b Mutually adjusted.
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Table 4
Factors associated with the uptake of influenza vaccination during pregnancy.
Variable Vaccinated Prevalence ratio (PR) (95% CI) P-value Adjusted PRb (95%CI) P-value
n/N (%)a
605/1263 (47.9)
Perceived stress score (PSS)
Low 121/261 (46.3) Reference
Mild 126/259 (48.6) 1.04 (0.87,1.25) 0.602 1.02 (0.85,1.22) 0.818
Moderate 110/229 (48.0) 1.03 (0.85,1.24) 0.711 0.96 (0.79,1.16) 0.684
High 137/269 (50.9) 1.09 (0.92,1.30) 0.294 1.07 (0.87,1.24) 0.503
Very High 109/238 (45.8) 0.98 (0.81,1.19) 0.900 1.07 (0.88,1.33) 0.549
Anxiety score (STAI)
Low 153/328 (46.6) Reference
Mild 147/308 (47.7) 1.02 (0.86,1.20) 0.785 1.03 (0.87,1.21) 0.681
Moderate 61/112 (54.4) 1.16 (0.95,1.43) 0.139 1.21 (0.99,1.48) 0.061
High 143/287 (49.8) 1.06 (0.90,1.25) 0.431 1.05 (0.89,1.25) 0.508
Very High 86/199 (43.2) 0.92 (0.76,1.12) 0.477 0.85 (0.68,1.07) 0.186
Depression score (EPDS)
Unlikely to have depression (0-9) 501/1056 (47.4) Reference
Increased risk of depression (10-12) 55/93 (59.1) 1.24 (1.09,1.49) 0.017 1.21 (1.00,1.44) 0.040
Very likely depressed (13) 45/104 (43.2) 0.91 (0.72,1.14) 0.431 0.99 (0.77,1.28) 0.985
Previous history of depression
No history of depression 429/923 (46.4) Reference
History of depression 76/166 (45.7) 0.98 (0.82,1.17) 0.869 1.11 (0.90,1.35) 0.309
History of major/clinical depression 100/174 (57.4) 1.23 (1.06,1.43) 0.004 1.32 (1.14,1.58) 0.002
ANRQ
Low (0–22) 338/717 (47.1) Reference
High (23) 262/535 (48.9) 1.03 (0.92,1.16) 0.520 0.99 (0.85,1.16) 0.958
Moderate exercise early pregnancy
4 per week 81/150 (54.0) Reference
1–3 per week 283/586 (48.2) 0.89 (0.75,1.05) 0.198 0.89 (0.76,1.05) 0.191
Never 238/518 (45.9) 0.85 (0.71,1.01) 0.070 0.90 (0.76,1.07) 0.276
Smoking status at 9–16 weeks’
Non-Smoker 493/994 (49.6) Reference
Quit during pregnancy 67/140 (47.8) 0.96 (0.80,1.15) 0.704 1.07 (0.90,1.28) 0.414
Current smoker 43/121 (35.5) 0.71 (0.55,0.91) 0.008 0.92 (0.72,1.16) 0.500
Illicit drug use during 1st trimester/pre-pregnancy
No 576/1188(48.4) Reference
Yes 29/75 (38.6) 0.79 (0.59,1.06) 0.128 0.94 (0.70,1.26) 0.705
Multivitamin use
Pre-conception and 1st trimester 157/275 (57.0) Reference
1st trimester 326/676 (48.2) 0.81 (0.72,0.91) 0.001 0.95 (0.83,1.09) 0.490
None 118/305 (38.6) 0.67 (0.57,0.79) 0.001 0.77 (0.64,0.93) 0.008
Maternal age group
>30 164/297 (55.2)) Reference
25–29 234/449 (52.1) 0.94 (0.82,1.08) 0.403 0.95 (0.83,1.09) 0.538
20–24 157/390 (40.2) 0.72 (0.62,0.85) 0.001 0.81 (0.69,0.97) 0.022
15–19 50/127 (39.3) 0.71 (0.56,0.90) 0.006 0.90 (0.68,1.18) 0.456
Born in Australia
Yes 491/1032 (47.5) Reference
No 114/231 (49.3) 1.03 (0.89,1.19) 0.622 0.96 (0.81,1.14) 0.676
Indigenous status
Not Indigenous 598/1240 (48.2) Reference
Indigenous 7/23 (30.4) 0.63 (0.33,1.17) 0.146 0.95 (0.52,1.75) 0.888
Marital status
Married 270/490 (55.1) Reference
Cohabiting/living with a partner 277/630 (43.9) 0.79 (0.70,0.89) 0.001 0.87 (0.76,0.99) 0.046
Single/separated/widowed 58/143 (40.5) 0.73 (0.59,0.61) 0.005 0.86 (0.68,1.09) 0.222
Education level
Bachelor’s or higher degree 143/248 (57.6) Reference
Diploma/certificate 214/450 (47.5) 0.82 (0.71,0.95) 0.009 0.87 (0.73,1.02) 0.103
Secondary school qualification 247/561 (44.0) 0.76 (0.66,0.87) 0.001 0.92 (0.77,1.09) 0.355
Employment Status
Full/part-time work 524/1034 (50.6) Reference
Unemployed 78/223 (34.9) 0.69 (0.57,0.83) 0.001 0.78 (0.64,0.95) 0.014
Estimated season of delivery
Summer 173/338 (51.1) Reference
Autumn 82/308 (26.2) 0.52 (0.42,0.64) 0.001 0.55 (0.44,0.67) 0.001
Winter 184/322 (57.1) 1.11 (0.96,1.28) 0.125 1.09 (0.95,1.25) 0.200
Spring 166/294 (56.4) 1.10 (0.95,1.27) 0.184 1.10 (0.95,1.28) 0.185
Bold values denote statistical significance at the p < 0.05 level.
a Weighted n in cohort.
b Mutually adjusted.
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vaccines in pregnancy was a significant predictor of the actual
receipt of both maternal vaccines, only just over half of the women
who were interested in receiving the vaccines had actually been
vaccinated against influenza during their pregnancy.
Previous studies suggest that most pregnant women are willing
to be vaccinated following recommendation from their health care
provider [39,40]. However, women’s willingness to receive the rec-
ommended vaccinations in pregnancy does not necessarily lead to
actual vaccination. Expectant mothers’ decision-making to receive
vaccination in pregnancy is complex and involves emotional, ante-
natal health system/institutional, and socio-cultural factors as
much as cognitive factors [41]. Incorporation of an automated
reminder within electronic medical records in an antenatal care
setting so as to aid healthcare providers in identifying women
needing immunization was found to be an effective intervention
in improving maternal vaccinations uptake by following up
women and verifying their actual behavior after their verbal
response [42]. This strategy would enable providers to administer
the vaccine at a moment when the pregnant women can act imme-
diately with a minimum of additional time, effort or cost [42].
Hence, addressing system-level barriers and understanding psy-
chosocial factors influencing women’s uptake of pertussis and
influenza vaccination during pregnancy could assist in improving
maternal immunization programs.
Contrary to what we expected, a history of clinical depression
was the strongest independent predictor of both influenza and per-
tussis vaccination uptake during pregnancy. Moreover, screening
positive for antenatal depression in our findings was associated
with uptake of pertussis vaccine uptake in pregnancy. Women
with a past history of a severe mental health condition require
comprehensive mental health assessment before conception or in
the prenatal period and additional support [43]. The South Aus-
tralian Perinatal Practice Guideline [43] endorsed the use of the
EPDS as part of a universally-delivered psychosocial assessment
for women receiving maternity care in the public health care sys-
tem. A score of 13 or more merits possible referral for specialized
assessment or at least re-application of the EPDS within two to four
weeks for women experiencing mild maternal depressive symp-
toms [43].
Women with a history of clinical depression or experiencing
severe symptoms of antenatal depression are more likely to have
more encounters with health services including being referred to
perinatal mental health services that include specialized psychi-
atric and mental health midwife services [44]. Additionally,
women with a history of severe depression in our study were
receiving antidepressant medication and may already be under
the care of a psychiatrist and/or a general practitioner (GP) as deci-
sions about continuing use of antidepressant during pregnancy
need to be discussed [45]. Current antenatal mild depressive symp-
toms was also a predictor of influenza vaccination during preg-
nancy due to the possibility that women with an EPDS score
between 10 and 12 are referred to their GP for mental health
reassessment within two to four weeks [43]. It is plausible that fre-
quent antenatal midwife services or GP visits for women with
mental health issues may have provided more opportunities for
maternal vaccination. Previous studies have shown that GP led
care was associated with high uptake of influenza vaccination dur-
ing pregnancy [35,46].
The present study suggests women with a very high level of
perceived stress score were less likely to be vaccinated against per-
tussis. There is evidence that high-perceived stress in pregnant
women is associated with engaging in unhealthy behaviors during
pregnancy and infrequent antenatal visits [29,47]. This may
explain why elevated perceived stress in early pregnancy is associ-
ated with low receipt of pertussis vaccine during pregnancy. The
current study also demonstrated that the lowest influenza and per-
tussis vaccine uptake was among women who reported a very high
anxiety score in early pregnancy. It is possible that women with
high anxiety symptoms are more likely to be concerned about
the safety of vaccination during pregnancy with safety concerns
known to be one of the barriers to vaccination during pregnancy
[18]. Moderate anxiety score was a predictor of pertussis and influ-
enza vaccination uptake during pregnancy. However, this should
be interpreted with caution as the anxiety scores in our study were
positively skewed and relatively few women presented with mod-
erate anxiety scores.
In the current study, women who used multivitamin/supple-
ments routinely in the preconception period were more likely to
receive both pertussis and influenza vaccination during pregnancy.
Previous research has shown that women with planned pregnan-
cies are more likely to use multivitamin/supplements before
becoming pregnant [30]. Our findings also suggest that women
who engaged in moderate exercise were more likely to receive per-
tussis vaccination during pregnancy. These results are consistent
with previous studies that demonstrated women who engage in
periconceptional health-promoting behaviors or who plan their
pregnancies are more likely to follow other recommended health
behaviors during pregnancy and personally feel more responsible
for the health of their unborn baby [31,48].
Consistent with previous findings, our study has indicated
maternal sociodemographic characteristics such as lower educa-
tional attainment or unemployment are associated with low
uptake of influenza vaccination during pregnancy [18,21,28]. Our
results are also consistent with previous studies that demonstrated
an association between younger maternal age and low uptake of
pertussis and influenza vaccination during pregnancy [35,21].
Improving access to maternal vaccines for first-time young moth-
ers needs consideration. Uptake of maternal pertussis vaccine
was also lower among women born overseas. Educational materi-
als on the importance of maternal vaccination should be easily
readable and accessible to culturally and linguistically diverse
women in several languages. Receipt of the recommended vaccines
by Indigenous Australian women was lower than non-Indigenous
women; the uptake difference was not statistically significant but
more research is needed to understand and reduce this disparity.
This study has some limitations. The participants in the cohort
were healthy nulliparous women and 95% of them were recruited
through the Lyell McEwin Hospital, one of the most socio-
economically disadvantaged urban areas in Australia. Hence, the
estimated vaccine uptake and prenatal psychosocial factors may
differ for women receiving antenatal care through private obstetric
care providers and multiparous women in Australia. Although vac-
cination status was checked against patients’ medical records, pro-
viders without access to medical records could have administered
vaccinations not captured in patients’ medical records (i.e. phar-
macist or workplace-administered vaccination). Thus, uptake of
the vaccines during pregnancy may have been underestimated.
5. Conclusion
Regardless of prenatal psychosocial factors, our findings suggest
that most expectant mothers are willing to vaccinate against per-
tussis and influenza vaccination during pregnancy. However, we
found that psychosocial factors influenced the uptake of pertussis
and influenza vaccines during pregnancy. This highlights that
addressing health care provider–patient barriers and provider cog-
nizance of psychosocial factors is important in improving vaccina-
tion uptake during pregnancy. Interventions that improve
maternal vaccination uptake in women with psychological stres-
sors should be designed and implemented in maternal immuniza-
tion programs. Mental health midwives or nurses are well
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positioned to recommend vaccines to pregnant women while
undertaking psychosocial assessment in conjunction with screen-
ing for antenatal depression and anxiety.
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A B S T R A C T
Background: Our study aimed to assess the safety and protective effect of maternal influenza vaccination on
pregnancy and birth outcomes.
Methods: The study population comprised 1253 healthy nulliparous pregnant women in South Australia
between 2015 and 2018. Participants were followed prospectively, with vaccination status (confirmed by
medical records), pregnancy, and birth outcome data collected by midwives. Adjusted relative risks (aRRs)
and adjusted hazard ratios (aHRs) were estimated accounting for time-varying vaccine exposure and tempo-
ral nature of each outcome.
Findings: Maternal influenza vaccination (48%, 603 of 1253) reduced the risk for pre-delivery hospitalisation
with influenza like illness (aHR 061; 95% CI 039, 097). Maternal influenza vaccination was not associated
with spontaneous abortion (aHR 042, 95% CI 012, 145), chorioamnionitis (aRR 078, 95% CI, 032, 188),
gestational hypertension (aHR 078, 95% CI 047, 129), pre-eclampsia (aHR 0.84, 95% CI 054, 127), gesta-
tional diabetes (aHR 116, 95% CI 082, 166) nor preterm birth (aHR 094, 95% CI 059, 149). No associa-
tions between antenatal influenza vaccination and congenital anomalies, admission to the neonatal care
unit, low Apgar scores, and mechanical ventilation were observed. Results were not materially changed after
adjustment for pertussis vaccination. We observed a protective effect of maternal influenza vaccination on
low birth weight (aHR 046, 95% CI 023, 094) and a marginal protective effect on small for gestational age
births (aHR 065, 95% CI 040, 104) during periods of high influenza activity.
Interpretation: These results support the safety of maternal influenza vaccination and suggest a protective
effect in reducing the rates of low birthweight and small for gestational age births.
Funding: There was no funding for this study.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
1. Introduction
Pregnant women are vulnerable to serious complications from
influenza including preterm labour, pneumonia, hospitalisation and
death, particularly during seasonal and pandemic influenza out-
breaks [1,2]. Newborns whose mothers had influenza during preg-
nancy are also at increased risk of adverse outcomes such as preterm
birth and low birthweight [3,4]. Maternal influenza vaccination pro-
tects mothers against influenza infection and their offspring by trans-
placental antibody transfer from mother to foetus conferring passive
immunity until the first influenza vaccination from age six months
[5,6]. Influenza vaccination during pregnancy might also reduce the
risk of low birthweight, preterm birth, and stillbirth but evidence
concerning these birth outcomes is conflicting [713]. Despite rec-
ommendations for maternal influenza vaccination, uptake during
pregnancy remains suboptimal globally [14].
A major challenge for achieving high uptake of influenza vaccina-
tion during pregnancy relates to relatively limited published evi-
dence of vaccine safety for pregnant women and their foetus [812].
* Corresponding author at: Vaccinology and Immunology Research Trials Unit,
Women’s and Children’s Hospital, 72 King William Road, North Adelaide 5006, South
Australia, Australia.
E-mail address: helen.marshall@adelaide.edu.au (H.S. Marshall).
https://doi.org/10.1016/j.eclinm.2020.100522
2589-5370/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
EClinicalMedicine 26 (2020) 100522
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: https://www.journals.elsevier.com/eclinicalmedicine
A review of factors influencing acceptance of antenatal vaccination
indicated that access issues and safety concerns are major barriers to
uptake [15]. An inflammatory response from infection during preg-
nancy has been shown to increase the risk of foetal injury [16] but no
evidence exists that an inflammatory response from a vaccine carries
a similar risk. A robust assessment of the safety of influenza vaccina-
tion during pregnancy is critical due to population-wide rollouts of
vaccines for this group. A number of systematic reviews have
reported pregnancy and birth safety outcomes following influenza
vaccination in pregnancy [813].
Most observational research into vaccine safety and efficacy
during pregnancy has been retrospective, due to the relatively
cheaper cost, fewer ethical concerns, and difficulty in recruiting
pregnant women to randomized controlled trials (RCTs). Whilst
providing timely reporting, this approach has limitations. In most
retrospective studies, authors have been unable to establish if a
pregnancy complication preceded vaccination nor account for the
time-dependant nature of exposure to vaccination during preg-
nancy. In countries where maternal influenza vaccination is rec-
ommended, prospectively designed studies are likely to be the
only way to accurately determine the true risk or potential bene-
fits of maternal vaccination beyond prevention of influenza for
pregnant women and their infants. Our study aimed to prospec-
tively assess maternal and birth outcomes following inactivated
influenza vaccination during pregnancy, while also taking into
account the most comprehensive set of potential confounding
variables considered to date.
2. Methods
2.1. Study design and participants
The current study draws on data collected as part of a prospective
cohort study (STOP), which aims to develop screening tests to iden-
tify adverse pregnancy outcomes. Healthy nulliparous women were
recruited in pregnancy at two major maternity hospitals, the Lyell
McEwin Hospital, the tertiary hospital serving the low socio-eco-
nomic community in Adelaide’s Northern suburbs and the Women’s
and Children’s Hospital, the primary tertiary maternity hospital for
complex care, accounting for around 50% of the 16,000 annual births
in metropolitan Adelaide, South Australia. Between March 2015 and
December 2017, nulliparous women with a singleton pregnancy
attending their first antenatal clinic between 9 + 0 and 16+0 weeks’
gestation were enroled. Women were excluded if they were consid-
ered already at high risk of pregnancy complications at screening (i.e.
experienced three or more previous miscarriages or with pre-existing
hypertension or diabetes). Participants were followed prospectively,
with vaccination, pregnancy, and birth outcome data collected by
research midwives. Written informed consent was obtained from all
participants included in the STOP study. The original STOP study pro-
tocol was approved by the Human Research Ethics Committee of the
Women’s and Children’s Hospital Adelaide Australia (HREC/14/
WCHN/90), registered at Australian New Zealand Clinical Trials Regis-
try, ACTRN12614000985684.
2.2. Exposure
The exposure of interest was trivalent inactivated influenza vacci-
nation during pregnancy, defined as a vaccine received between the
first day (date) of the last menstrual period and the end of pregnancy.
A research midwife interviewed and collected maternal vaccination
status of the women during their first study visit at 916 weeks’ ges-
tation and during their second study visit interview at 3236 weeks’
gestation. Vaccination date and gestation of administration were
recorded. Following delivery, a research midwife interviewed the
Research in context panel
Evidence before this study
We searched PubMed for English language studies published
until March 31, 2020, with no start date restriction, with the
terms “influenza”, “influenza vaccine”, “maternal influenza vac-
cination”, maternal influenza immunisation”, “humans” and
“pregnancy”. The World Health Organization (WHO) considers
pregnant women as a priority group for seasonal inactivated
influenza vaccination due to their vulnerability to influenza
infection and its resulting morbidities. Previous studies have
shown that inactivated influenza vaccine during pregnancy is
safe and provides passive antibodies to the infant, as well as
clinical protection for both mother and infant < 6 months of
age against influenza infections and influenza-related hospital-
isations. Despite the recommendation of maternal influenza
vaccination from immunisation advisory groups internationally
including WHO, it has not been implemented in most low-
resource countries, and even in high income countries where it
is incorporated into standard antenatal care, vaccination uptake
is often suboptimal. While the body of literature regarding the
safety of influenza vaccination during pregnancy is mounting,
there are relatively few prospectively designed or clinical trials
that include pregnant women. In high income countries where
maternal influenza vaccination is recommended, prospectively
designed studies with advanced statistical approaches are likely
to be the only way to comprehensively assess the safety of
influenza immunisation during pregnancy and its important
potential protective effects in reducing low birth weight, small
for gestational age birth and preterm birth, for which evidence
is conflicting.
Added value of this study
This prospective cohort of healthy pregnant women, with con-
firmed vaccination status and accurate pregnancy and infant
outcome data used robust nuanced time-to-event analyses. The
study showed that influenza vaccination during pregnancy is not
associated with adverse pregnancy, foetal or birth outcomes.
This study also presents evidence that inactivated influenza vac-
cination decreases the risk of pre-delivery hospitalisation with
maternal influenza-like illness by 39% and reduces the risk of
low birthweight and small for gestational age births during peri-
ods of high influenza activity.
Implications of all the available evidence
These findings provide further reassurance to women and
health care providers about the safety of inactivated influenza
vaccination during pregnancy. Importantly, our results provide
evidence in support of maternal influenza vaccination reducing
low birth weight and small for gestational age births during
periods of widespread influenza activity. These findings need to
be replicated in other countries as it is plausible that the impact
of maternal influenza vaccine on these birth outcomes may
vary with the underlying local influenza epidemiology and
demographic characteristics. Our findings could be pivotal for
countries weighing the additional benefits of implementing
maternal influenza immunisation programs. This may be par-
ticularly important for low income countries where the rates of
low birthweight and small for gestational age births are very
high, and known to be strong risk factors for neonatal and early
childhood morbidity and in which health systems have poor
capacity to mitigate short and long-term effects.
2 H. Mohammed et al. / EClinicalMedicine 26 (2020) 100522
participants and verified final vaccination status by reviewing medi-
cal case notes and Pregnancy-Hand-Held-Record to confirm the
reported vaccination status. Pregnancy-Hand-Held-Records are the
main medical record of pregnancy care in South Australia and are
reviewed and updated at antenatal appointments.
2.3. Outcomes
Pregnancy outcomes assessed were pre-delivery admission due to
influenza-like illness, spontaneous abortion after inclusion in the
STOP study, gestational diabetes, gestational hypertension, pre-
eclampsia, severe pre-eclampsia, chorioamnionitis, premature rup-
ture of membranes, spontaneous preterm birth, preterm birth and
stillbirth. Birth outcomes included congenital anomalies, small for
gestational age (SGA), low birthweight (< 2500 g) (LBW), low birth-
weight at term ( 37 weeks’ gestation), Apgar scores at 1 and 5 min,
neonatal care unit admissions, respiratory distress and mechanical
ventilation.
Pregnancy and birth complications were diagnosed using the
Brighton Collaboration consensus list of terms, and international
guidelines. Gestational hypertension was defined as (peripheral)
hypertension [systolic BP (SBP)  140 mmHg or diastolic BP (DBP) 
90 mmHg] after 20 weeks of gestation in previously normotensive
women. Pre-eclampsia was defined as gestational hypertension with
proteinuria (24 h urinary protein  300 mg or spot urine protein: cre-
atinine ratio  30 mg/mmol creatinine or urine dipstick protein  2+)
or any multi-organ complication of pre-eclampsia. Severe pre-
eclampsia was defined as pre-eclampsia with one or more of the fol-
lowing clinical features: BP of  160/110 mmHg or hypertension
requiring intravenous therapy with an antihypertensive agent or
magnesium sulphate after 20 weeks of gestation. Preterm birth was
defined as any birth before 37 and after 20 completed weeks of gesta-
tion. SGA was defined as neonates with a birthweight below the
<10th percentile customized for maternal factors such as maternal
height, booking weight, ethnicity and gestational age at delivery. The
estimated date of delivery was calculated from a certain last men-
strual period (LMP) date and was only adjusted if either (1) a scan
performed at < 16 weeks of gestation found a difference of 7 days
between the scan gestation and that calculated by the LMP or (2) on
20-week scan a difference of  10 days was found between the scan
gestation and that calculated from the LMP. If the LMP date was
uncertain, then scan dates were used to calculate the estimated date
of delivery.
2.4. Covariates
During the first study visit at 916 weeks’ gestation, informa-
tion was obtained regarding baseline socio-demographic, lifestyle
and clinical characteristics such as age, ethnicity, level of educa-
tion, household income, employment, exercise, smoking, supple-
ment use, intake of alcohol and recreational drugs, medical and
obstetric history, and complications during the current pregnancy.
Participating women also completed the Perceived Stress Scale
(PSS-10), to assess perceived stress levels in the past month, the
short form of the Spielberger StateTrait Anxiety Inventory
(STAI), assessing current anxiety symptoms, and the Edinburgh
Postnatal Depression Scale (EPDS), assessing depressive symp-
toms during pregnancy.
2.5. Statistical methods
Demographic, lifestyle and clinical characteristics of participants
were summarized descriptively, by influenza vaccination exposure
during pregnancy. Continuous variables were summarized as mean
with standard deviation (SD) or median with interquartile range
(IQR), as appropriate, while counts and percentages were used to
summarize categorical variables. To investigate if there was an
association between influenza vaccination status and each of the
outcome variables, we initially conducted independent samples t-
tests or Mann-Whitney U tests, as appropriate, for continuous
variables and chi-square tests of association for binary and cate-
gorical variables.
The timing for vaccination exposures and time at risk windows
were calculated for each time sensitive pregnancy and birth outcome
accounting for the temporal nature of each outcome of interest. For
example, women were at risk for preterm birth from 20 weeks until
36+6 weeks of gestation. Cox proportional-hazards models with gesta-
tional age in weeks as the underlying time metric were used to derive
hazard ratios (HRs) that compared the hazard rates for time-sensitive
outcomes such as spontaneous abortion or preterm birth between vac-
cinated and unvaccinated women. Vaccination status was treated as a
time-varying exposure in these models, in that each vaccinated wom-
an’s pregnancy was decomposed into an unvaccinated exposure
period and a vaccinated exposure period. In sensitivity analyses, we
estimated HRs and adjusted HRs of time-dependant pregnancy or birth
outcomes by trimester of influenza vaccination during pregnancy. To
assess the impact of the intensity of influenza activity on the associa-
tion between maternal influenza vaccination and key birth outcomes,
we also stratified analyses by the level of influenza activity at time of
delivery using the South Australian Influenza Surveillance Report [17]
based on the percentage of laboratory confirmed influenza during the
study period 20152018. We identified high activity periods as having
rates of laboratory confirmed influenza of at least 10% for at least 3 of
4 consecutive weeks. Low influenza activity period was defined as the
first week during which the positive rate was lower than 10% and
remained at that level for at least four consecutive weeks. On this basis,
“high influenza activity” periods were identified for 01 June 31 Octo-
ber 2015, 01 July  31 December 2016, 01 June  30 November 2017
and 31 August  31 October 2018. The delivery months of the vacci-
nated women were classified into “high” and “low” influenza activity
to compare key birth outcomes of infants born to vaccinated mothers
during high/low influenza activity with births occurring at any time to
unvaccinated women.
We used log-binomial models to estimate risk ratios (RR) and
adjusted risk ratios (aRR) comparing risk of late onset or early post-
partum adverse pregnancy outcomes and adverse birth outcomes
including congenital anomalies, low Apgar score, admission to neo-
natal unit, respiratory distress syndrome and mechanical ventilation
in infants of vaccinated and unvaccinated mothers. Finally, we used a
multivariable linear regression model to predict the difference in
mean gestational age at delivery and mean birthweight by vaccina-
tion status. For all multivariable (i.e. adjusted) models, annual house-
hold income, level of education, ethnicity, maternal health risk
factors (age, gravidity, alcohol intake, recreational drug use, smoking,
pre-pregnancy body mass index (BMI)), use of micronutrient supple-
ments, asthma and current psychological states were amongst the
variables selected as potential confounders based on evidence in the
literature [811] guided by directed acyclic graphs. Additional sensi-
tivity analyses were conducted in all multivariable models to evalu-
ate whether the effects of maternal influenza vaccination on
pregnancy and birth outcomes were maintained after adjustment for
pertussis vaccination in third trimester. As pertussis vaccination was
also recommended in pregnancy from 28 to 32 weeks’ gestation in
Australia, in our linear regression analyses, we restricted the cohort
to women whose pregnancies reached at least 32 weeks’ gestation to
allow for all women to have had the opportunity to receive the per-
tussis vaccine. Missing covariate values are reported in the baseline
table where relevant. The amount of missing data is minimal ranging
between 01% (estimated season of delivery data) to 23% (STAI
data), and therefore all available data were used in the analyses of all
pre-specified outcomes. For all analyses, a p value< 005 was consid-
ered statistically significant. Data were recorded in a REDCap [18, 19]
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online database and all statistical analyses were conducted using
Stata version 15 (Stata Corp, College Station, Texas, USA).
Role of Funding Source: Not applicable
3. Results
Of 1364 pregnant women enroled, 12 withdrew access to their
medical records, three had no medical case notes and three were lost
to follow up or delivered elsewhere (n = 10); all 28 were excluded
from our final analyses. So as not to confound any observed associa-
tions, we excluded 83 women who had influenza vaccination prior to
pregnancy. Our final cohort consisted of 1253 women (Fig. 1). Key
variables of interest did not differ between women included and
excluded from our study (supplementary material p 1). At recruit-
ment, mean maternal age of nulliparous women was 259 years (SD
50) (range: 1545 years) and median gestational age was 114
weeks (IQR 91128) with 822% (1031 of 1253) presenting for
their first antenatal care visit in the first trimester of pregnancy.
The overall uptake of influenza vaccination was 481% (603 of
1253); of the vaccinated women, 240% (n = 145) were vaccinated in
first trimester, 202% (n = 122) in second trimester, and 557%
(n = 336) in third trimester. Both influenza and pertussis vaccinations
occurred in 555 of 1253 (442%) pregnancies. Unvaccinated women
were more likely to be younger, Aboriginal and/or Torres Strait
Islander, in lowest household income group, smoke cigarettes, use
illicit drugs, physically inactive, have lower educational attainment
and less likely to take micronutrient supplements pre-conception or
during pregnancy, and give birth during Autumn compared with vac-
cinated pregnant women (Table 1).
3.1. Pregnancy outcomes
Of the 1253 women, 34 (27) had spontaneous abortions < 20
weeks’ gestation, seven had terminations (05%), six had stillbirths
(04%), and 1201 (958%) delivered a live infant (five missing values).
The mean gestational age at delivery was 392 weeks (SD 20 weeks).
Overall, 95 of 1253 (75%) women were admitted to hospital due to
influenza like illness during pregnancy; mostly in the third (93 of 95)
trimesters of pregnancy. The time-dependant Cox proportional haz-
ards regression model shows that women vaccinated at any time
during pregnancy had a significant lower risk of pre-delivery hospi-
talisation with influenza like illness compared to unvaccinated
women (aHR 061; 95% CI 039, 097) (Table 2). After accounting for
the assumption that immunologic protection after influenza vaccina-
tion requires 2 weeks for full effect, the estimated aHR remained
unchanged (supplementary material p 2). The observed protective
effect of maternal influenza vaccination in reducing hospitalisation
due to influenza like illness was stronger for those vaccinated in sec-
ond trimester (aHR 009; 95% CI 001, 071) and those who delivered
during periods of high influenza activity (aHR 051; 95% CI 027,
095) (Table 3).
There was no association with spontaneous abortion for women
who were vaccinated for influenza prior to 20 weeks’ gestation (aHR
042, 95% CI 012, 145) (Table 2). Our Cox model shows that influ-
enza vaccination during pregnancy was not associated with maternal
hypertensive disorders including gestational hypertension (aHR
078, 95% CI 047, 129), pre-eclampsia (aHR 084, 95% CI 054,
127) or severe pre-eclampsia (aHR 065, 95% CI 026, 164)
(Table 2). Additional adjustment for maternal pertussis vaccination
as a time-varying covariate yielded similar results for hypertensive
disorders (supplementary material p 2). In the log-binomial models,
there was no association between risk of chorioamnionitis and influ-
enza vaccination during pregnancy (aRR 078, 95% CI, 032, 188)
(Table 4).
After adjusting for covariates, women vaccinated for influenza
during pregnancy had on average 18 days longer gestation at deliv-
ery than unvaccinated women (Table 2). Restricting the analysis to
pregnancies reaching at least 32 weeks’ gestation followed by
Enrolled to study at 9–16 weeks’ 
gestation (n=1373)
Eligible women (n=1364)




High risk pregnancy (n=1)
Excluded influenza vaccine uptake - in 





Did not receive influenza 
vaccine during pregnancy
(n=650, 51·9%)
Final eligible women with vaccination status 
during pregnancy (n=1253)
Missing data on influenza vaccination 
status or pregnancy outcome (n=28)
Withdrawn access to medical record (n=12)
No medical record (n=3)
Lost to follow up (n=3)
Delivered elsewhere/incomplete data on 
pregnancy and birth outcomes (n=10)
Fig. 1. Participants flow diagram.
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adjustment for maternal pertussis vaccination showed that any dif-
ferences in gestational age at birth between unvaccinated and vacci-
nated mothers were negligible (supplementary material p 2). Overall,
73% (89 of 1207) of pregnancies resulted in preterm birth. There
was no difference in stillbirth between vaccinated (n = 3) and unvac-
cinated women (n = 3). Our time-dependant analysis showed no
association between influenza vaccination through to 37 weeks’ ges-
tation and preterm birth (aHR 094, 95% CI 059, 149), preterm pre-
mature rupture of the membranes (aHR 085, 95% CI 044, 163),
and spontaneous preterm birth (aHR 074, 95% CI 041, 133)
(Table 2). Maternal influenza vaccination showed a modest reduction
in the hazard of spontaneous preterm birth during periods of lower
influenza virus circulation but the confidence intervals were wide
and included one (aHR 052, 95% CI 024, 113) (supplementary
material p 3).
3.2. Birth outcomes
Maternal influenza vaccination was protective against delivering
LBW term infants in our Cox proportional hazard regression analyses
Table 1
Maternal characteristics of vaccinated and unvaccinated pregnant women who delivered at two obstetric hospitals in South Australia, 2015 to
2018 (N = 1253).
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Illicit drug use during 1st trimester/pre-pregnancy 29 (48) 46 (70)
Multivitamin and mineral supplements use












Moderate exercise during 1st trimester/pre-pregnancy












Gravidity >1 165 (273) 185 (284)














Psychological measures at 916 weeks’ gestation
Edinburgh Perinatal Depression Scale (EPDS) scores, mean (SD)
State and trait anxiety (STAI) scores, mean (SD)


















Gestational week of vaccine administration, mean (SD) 230 § 105 NA
Received pertussis vaccination during pregnancy 555 (920) 398 (612)
















Data are mean (SD) or n (%). SD= standard deviations. AUD=Australian dollars. BMI=body-mass-index.
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(aHR 038, 95% CI 016, 089) (Table 2). This effect persisted follow-
ing additional adjustment for maternal pertussis vaccination (aHR
038, 95% CI 015, 094) (supplementary material p 2). An even
greater protective effect of influenza vaccination against delivering a
LBW infant at term (aHR 020, 95% CI 004, 087) and LBW in either
preterm or term infants (aHR 046, 95% CI 023, 094) was observed
during periods of high influenza activity (Table 3). There was no evi-
dence of increased risk of LBW associated with receipt of inactivated
influenza vaccine during any trimester of pregnancy (Table 3). First
trimester influenza vaccination had no effect on risk of congenital
anomalies (aRR 033, 95% CI 004, 273) (Table 4). Overall, 510
(422%) of 1207 infants were born during high influenza activity
across three Australian influenza seasons 20152018. The infants
born to vaccinated mothers were estimated to be 59 g heavier than
infants born to unvaccinated mothers (588 g, 95% CI 42 g,
1217 g) but the confidence intervals were wide and included zero
(Table 2). This association was attenuated (183 g, 95% CI  422 g,
790 g) after adjustment for maternal pertussis vaccination (supple-
mentary material p 2).
Our study found no increased risk for SGA delivery after influenza
vaccination during pregnancy (aHR 084, 95% CI 058, 120) (Table 2).
Maternal influenza vaccination was associated with a marginal
reduction in risk of SGA births during periods of high influenza activ-
ity (aHR 065, 95% CI 040, 104). Influenza vaccination in third tri-
mester was associated with a 39% reduction in risk of SGA birth
regardless of the level of influenza activity (aHR 061, 95% CI 038,
098) (Table 3). However, these protective effects on SGA were
slightly attenuated after adjustment for pertussis vaccination (sup-
plementary material p 3). There was no association between mater-
nal influenza vaccination and adverse infant outcomes including low
Apgar scores at 1 and 5 min, admission to the neonatal care unit,
mechanical ventilation, and respiratory distress syndrome (Table 4).
4. Discussion
In robust nuanced analyses that account for timing of maternal
influenza vaccination and the time risk of adverse pregnancy out-
comes, we show maternal influenza vaccination is safe in a prospec-
tive cohort of healthy pregnant women, with confirmed vaccination
history and accurate, pregnancy and infant outcome data. There was
no evidence of associations between influenza vaccination adminis-
tered at any time in pregnancy and adverse pregnancy or foetal out-
comes including spontaneous abortion, congenital anomalies,
shortened gestation, gestational diabetes, chorioamnionitis or gesta-
tional hypertensive disorders, consistent with the literature [812].
In addition to reassuring safety of maternal influenza vaccination,
our study found influenza vaccination during pregnancy reduced a
pregnant woman's risk of pre-delivery hospitalisation with influenza
like illness by around 39%. This protective effect was most pro-
nounced for those women who delivered during periods of high
influenza activity, consistent with previous studies [20, 21]. Across
the three influenza seasons 20152018 in South Australia, influenza
A (H3N2) was the dominant circulating virus followed by influenza B
[17].
In contrast to our findings, a recent Bayesian meta-analysis of 28
cohort studies showed maternal influenza vaccination protects
against preterm birth [13]. However, the pooled summary estimates
[13] did not find any association when the preterm birth analysis
included 2 randomized placebo-controlled studies (RCTs) and 2 case-
control studies. The two RCTs [22, 23] investigating maternal influ-
enza vaccine efficacy and safety in South Africa and Nepal, respec-
tively, found that vaccination was not associated with preterm birth.
However, the RCT in Nepal showed a reduction of LBW [23] and
another RCT [7] conducted in Bangladesh demonstrated a reduction
of SGA amongst a subset of infants born during peak influenza
Table 2
Crude and adjusted hazard ratios for time-based pregnancy and birth outcomes by maternal influenza vaccination status at two obstetric hospitals in South Australia 20152018.
Variables Total Unvaccinated N (%) Vaccinated N (%) Crude HR* (95% CI) p-value Adjusted y aHR (95% CI) p-value
Pre-delivery hospitalisation due
to influenza like illness z
95/1253 (75) 60/650 (92) 35/603 (58) 058 (037, 091) 0018 061 (039, 097) 0038
Spontaneous abortion x 34/1253 (27) 31/650 (47) 3/603 (05) 066 (020, 219) 0507 042 (012, 145) 0171
Gestational hypertension || 81/1205 (67) 41/606 (67) 40/599 (66) 080 (049, 131) 0391 078 (047, 129) 0343
Pre-eclampsia || 111/1205 (92) 58/606 (95) 53/599 (88) 085 (058, 126) 0445 084 (054, 127) 0417
Severe pre-eclampsia || 28/1204 (23) 14/606 (23) 14 /598 (23) 086 (037, 196) 0725 065 (026, 164) 0368
Gestational diabetes { 190/1207 (157) 85/608 (139) 105/599 (175) 133 (095, 184) 0088 116 (082, 166) 0383
Preterm premature rupture of
the membranes **
47/1207 (38) 27/608 (44) 20/599 (33) 082 (043, 156) 0561 085 (044, 163) 0634
Preterm birth ** 89/1207 (73) 49/608 (80) 40/599 (66) 094 (060, 147) 0802 094 (059, 149) 0817
Spontaneous preterm birth ** 59/1207 (48) 36/608(59) 23/599 (38) 071 (040, 126) 0253 074 (041, 133) 0323
LBW (<2500 g) yy 80/1205 (66) 49/606 (80) 31/599 (51) 070 (042, 114) 0158 071 (043, 119) 0202
LBW at term (<2500 g)yy, zz 29/1116 (26) 20/557 (35) 9 /559 (16) 043 (018, 099) 0048 038 (016, 089) 0027







Mean birth weight yy, g (95% CI) 33349 § 557 33018 § 610 33684 § 498 637 (009, 1270) 0050 588 (- 42, 1217) 0067
Mean gestational age at delivery,
weeks (95% CI)
392 § 20 391 § 23 394 § 16 026 (004, 049) 0019 027 (004, 049) 0019
CI=confidence interval. HR=hazard ratios. LBW=low birthweight. SGA=small for gestational age.
* HR results compared outcome variable in vaccinated group to reference (unvaccinated).
y Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, smoking, pre-pregnancy body mass
index (continuous), use of multivitamin supplements, Edinburgh Postnatal. Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), phys-
ical activity, infertility treatment, asthma and estimated season of delivery.
z Women admitted to hospital with influenza/ respiratory tract infection were censored at their admission date.
x The time metric for spontaneous abortion analysis was the first week of gestation up to the event (week of last available pregnancy data or week 20 of gestation; whichever
occurred first).
|| For hypertensive disorders analysis, women who were vaccinated at or after the gestational age at diagnosis ( 20 weeks' gestation) and pregnancies ending prior to 20 weeks
of gestation were censored.
{ Women who were vaccinated at or after the gestational age at diagnosis of gestational diabetes mellitus (median gestational age at screening was 278 (IQR, 26529) weeks)
were censored.
** Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of preterm birth.
yy Additionally adjusted for infant's sex.
zz Low birthweight at term (<2500 g and  37 completed weeks’ gestation at birth).
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circulation to influenza-vaccinated women. We also found that vacci-
nated mothers were less likely to deliver LBW and SGA infants during
periods of high influenza activity. Decreased risk for LBW and SGA
during peak influenza season amongst vaccinated mothers could be
attributed to decreased risk of influenza infection during pregnancy
following maternal influenza vaccination. Differing from our study
Table 3
Crude and adjusted hazard ratios for pre-delivery hospitalisation due to influenza like illness and key adverse birth outcomes stratified by trimester of influenza vaccination
and influenza activity.
Variables Unvaccinated N (%) Vaccinated N (%) Crude HR* (95% CI) p-value Adjustedy aHR (95% CI) p-value






































































































































































CI=confidence interval. HR=hazard ratios. LBW=low birthweight. SGA=small for gestational age.
* HR results compared outcome variable in vaccinated group to reference (unvaccinated).
y Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, smoking, pre-pregnancy body
mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale
(PSS-10), physical activity, infertility treatment, asthma and estimated season of delivery.
z Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of having a preterm birth.
x Additionally adjusted for infant's sex.
|| Low birthweight at term (<2500 g and  37 completed weeks’ gestation at birth).
{ Analysis by trimester of influenza vaccination was not performed because a small number of mothers who delivered LBW at term babies received the vaccine prior to
their third trimester (n = 1 during 1st trimester, n = 1 during 2nd trimester).
Table 4
Pregnancy and birth outcomes following influenza vaccination in pregnancy at two obstetric hospitals in South Australia 20152018.
Pregnancy outcomes Total Unvaccinated N (%) Vaccinated N (%) Risk Ratios RR (95% CI) p-value Adjusted* aRR (95% CI) p-value
Chorioamnionitis and/or funisitis 25/1207 (20) 15/608 (24) 10/599 (16) 065 (028, 149) 0316 078 (032, 188) 0581
Postpartum haemorrhage 113/1205 (93) 62/606 (102) 51/599 (85) 079 (055, 114) 0215 072 (049, 106) 0099
Caesarean delivery (Vs Vaginal)y 349/1205 (289) 176/606 (290) 173/599 (288) 101 (093, 108) 0758 091 (075, 109) 0326
Birth outcomes
Congenital anomaliesz 23/1207 (19) 21/1066 (18) 2/141 (14) 031 (004, 233) 0256 033 (004, 273) 0311
Low Apgar at 1 min (<7) 151/1201 (125) 72/603 (119) 79/598 (132) 113 (083, 153) 0433 111 (081, 152) 0490
Low Apgar at 5-min (<7) 31/1203 (25) 16/604 (26) 15/599 (25) 093 (044, 197) 0874 084 (039, 181) 0670
Admitted to Neonatal unitx 282/1207 (233) 140/608 (230) 142/599 (237) 098 (080, 122) 0780 104 (084, 128) 0693
Respiratory distress syndrome 14/1207 (11) 10/608 (16) 4/599 (06) 040 (012, 126) 0120 046 (014, 152) 0208
Mechanical ventilation 51/1207 (42) 30/608 (49) 21/599 (35) 072 (041, 126) 0258 074 (042, 131) 0313
* Pregnancy outcomes were adjusted for maternal age, ethnicity, total years of full time education, household income, gravidity, intake of alcohol and recreational drugs, smok-
ing, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Per-
ceived Stress Scale (PSS-10), physical activity, infertility treatment, asthma and estimated season of delivery Birth outcomes were additionally adjusted for infant's sex.
y Poisson regression model was used because the log binomial model failed to converge.
z For congenital anomalies analysis, the exposure time window comprised the first trimester and women vaccinated after first trimester were classified as unvaccinated.
x Reasons for admission: Preterm, Respiratory distress Infection, Feeding problem, Hypoglycaemia, Drug withdrawal, SGA, Birth asphyxia, congenital abnormality, Phototherapy
and Cyanosis.
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findings, a secondary analysis of the RCT in Nepal [24], which was the
only trial powered to detect difference in birth weight has found that
maternal influenza vaccination significantly increased mean birth-
weight by 42 g. Birth weight is an important indicator of an infant's
vulnerability to the risk of childhood illness and chances of survival
and the health burden of babies born SGA or LBW is very high in low
income countries [25]. Reduction of these adverse birth outcomes fol-
lowing maternal influenza vaccination would be an important
achievement, particularly in tropical regions, where influenza circu-
lates year-round.
Consistent with previous studies, [26, 27] we demonstrated that
newborns whose mothers were vaccinated for influenza in preg-
nancy were not more likely to experience any adverse outcomes,
including admission to the neonatal care unit, respiratory distress,
low Apgar scores nor need for mechanical ventilation at birth com-
pared with neonates born to unvaccinated women. A protective
effect of maternal influenza vaccination on preventing either influ-
enza or influenza-related complications in infants up to 6 months old
[28, 29] provides important additional evidence that women should
be offered influenza vaccination during pregnancy, irrespective of
time of year.
Our study has a number of strengths and some potential limita-
tions. The major strength is the prospective cohort design that
recruited a large number of nulliparous women with singleton preg-
nancies at low risk for obstetric complications at two major maternity
hospitals, reducing potential confounding by indication. Such bias
could have occurred if women with known comorbidities and/or
high-risk factors were more likely to receive the influenza vaccine
during pregnancy and have a higher baseline risk of adverse preg-
nancy outcomes than healthy women leading to an underestimation
of vaccine safety. The opposite effect (i.e. an overestimate of the size
of the protective effect of maternal vaccination) due to a ‘healthy vac-
cinee bias’ could also have occurred. Vaccinated women in our study
were more likely to engage in healthy lifestyles i.e. pregnancy micro-
nutrient supplementation, exercise regularly and were less likely to
smoke or use illicit drugs in pregnancy than unvaccinated women.
The analysis framework used herein adjusted for putative risk factors,
including psychosocial factors, to mitigate the impact of any ‘healthy
vaccinee bias’ on our findings.
Our use of Cox proportional-hazards models accounting for time-
varying vaccine exposure within pregnancy, minimized the introduc-
tion of immortal time bias in our data [30]. The potential for this bias
arises because the opportunity for vaccination increases the longer a
woman remains pregnant and free of adverse foetal outcomes. The
fact that the pregnancies were not followed from the beginning (i.e.
first day of the last menstrual period), causes downward bias in esti-
mation of spontaneous abortion. Such data are said to be left trun-
cated. Additionally, including follow-up time during which
pregnancies are no longer at risk of some adverse outcomes (e.g. ges-
tation after 37 weeks’ considered for preterm birth outcomes) can
lead to overestimation of any true benefits of maternal vaccination
but our analysis strategy minimized the risk of these biases occurring.
One potential limitation that we could not take into account is that
vaccine administered in non-traditional settings (i.e. pharmacist or
community or workplace-administered vaccination) might not be
recorded in women’s Pregnancy-Hand-Held-Records. Thus, uptake of
vaccination during pregnancy may have been underestimated. How-
ever, this is unlikely as women were interviewed by a research mid-
wife at several time points including post-delivery to confirm final
vaccination status. Another limitation in our study is the inability to
distinguish pre-delivery hospital admission due to laboratory-con-
firmed influenza infections from influenza-like illness. However,
these limitations are likely to have negligible effects on our study
findings.
Evidence from previous influenza pandemics, and seasonal influ-
enza demonstrates that pregnant women and their infants are at
high risk of severe influenza-related complications [1, 2]. Our robust
study analysis demonstrated that maternal influenza vaccination
reduced pregnant women's risk of pre-delivery hospitalisation with
influenza like illness. Furthermore, our study provides a unique pro-
spective assessment of the safety of an inactivated influenza vaccine
amongst pregnant women providing reassurance for health pro-
viders and pregnant women. Importantly, although numerous factors
may contribute, we show positive impacts on key birth outcomes
that inordinately occur in low-middle income countries with long
term consequences for offspring health and impacts on low capacity
health systems.
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a b s t r a c t
Objective: To evaluate the safety of maternal pertussis vaccination on pregnancy and birth outcomes.
Methods: The study population comprised 1272 healthy nulliparous pregnant women who participated
in Screening Tests to identify poor Outcomes in Pregnancy (STOP) study at two obstetric hospitals in
South Australia between 2015 and 2018. Participants were followed prospectively, with vaccination (con-
firmed by medical records), extensive amounts of pregnancy and birth outcome data collected by
research midwives. Adjusted relative risks (aRRs) and hazard ratios (aHRs) were estimated accounting
for time-varying vaccine exposure and the temporal nature of each outcome.
Results: Of the 1272 women included in this study, 80.1% (n = 1019) received maternal pertussis vacci-
nation. Vaccinated women had an average 0.22 weeks (95% CI 0.001, 0.44) longer gestation at delivery
compared to unvaccinated women. Maternal pertussis vaccination was not associated with chorioam-
nionitis (aRR 0.71, 95% CI 0.27,1.82), gestational hypertension (aHR 1.24, 95% CI, 0.66, 2.30), preeclampsia
(aHR 0.75, 95% CI 0.47, 1.18) nor preterm birth (aHR 0.99, 95% CI 0.47, 2.07). Neither risk of low birth
weight (aHR 0.72, 95% CI 0.41, 1.27) nor small for gestational age infants (aHR 0.67,95% CI 0.29, 1.55)
were increased following maternal pertussis vaccination. No associations between pertussis vaccination
during pregnancy and adverse birth outcomes including admission to the neonatal care unit, low Apgar
scores, and mechanical ventilation were observed. Results were not materially changed after adjustment
for maternal influenza vaccination.
Conclusion: Our study provides reassuring evidence of the safety of maternal pertussis vaccination with
no increased risk of adverse pregnancy and birth outcomes. These findings support recommendations for
pertussis vaccination during pregnancy to prevent morbidity and mortality associated with early-infant
pertussis disease.
 2020 Elsevier Ltd. All rights reserved.
1. Introduction
There has been a global resurgence in pertussis in recent years,
with the highest rates of hospitalization and death in infants too
young to be fully protected by routine childhood vaccination series
[1–3]. Infection of young infants occurs primarily through house-
hold contacts, with new mothers identified as the most common
sources of transmission [4]. Pertussis vaccination during pregnancy
protects the mother from pertussis infection but more importantly
offers passive immunity to her newborn via transplacental trans-
port of maternal antibodies and is currently considered the most
successful and effective intervention to prevent early infant dis-
ease [5]. Maternal pertussis vaccination at least seven days before
delivery has been shown to protect against pertussis in up to 91%
of infants in the first two months of life [6,7]. Following the imple-
mentation of government funded maternal pertussis vaccination
https://doi.org/10.1016/j.vaccine.2020.11.052
0264-410X/ 2020 Elsevier Ltd. All rights reserved.
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programs for pregnant women in different countries there has
been an increasing general pertussis vaccine uptake in pregnancy
[8]. However, uptake varies across and within countries in preg-
nant women and is suboptimal [8]. One of the reasons for low per-
tussis vaccination uptake is healthcare providers’ and/or women’s
concerns about the safety of the vaccine during pregnancy [9,10].
Several systematic reviews [11–14] have demonstrated that
maternal pertussis vaccination during pregnancy does not
adversely affect obstetric or neonatal outcomes, although the qual-
ity of the evidence in underlying studies is low. Many previous
studies have investigated the safety of pertussis vaccination during
pregnancy retrospectively, due to the relatively cheaper cost, fewer
ethical concerns, and difficulty in recruiting pregnant women to
randomized controlled trials. Three retrospective cohort studies
[15–17] reported a small but statistically significant increased rel-
ative risk of chorioamnionitis in women who had received pertus-
sis vaccination during pregnancy. This unreplicated finding merits
further investigation since chorioamnionitis is associated with sev-
ere short-term and long-term neonatal complications [18]. Most
observational studies have been unable to account for the time-
dependent nature of exposure to pertussis vaccination during
pregnancy. To accurately determine any risk of maternal pertussis
vaccination for pregnant women and their infants, prospectively
designed studies incorporating statistical approaches suitable for
analyzing time-dependent associations between maternal pertus-
sis vaccine exposure on pregnancy and birth outcomes are war-
ranted. The primary aim was to prospectively assess pregnancy
and birth outcomes following pertussis vaccination during preg-
nancy considering time-dependent vaccine exposure and using
the most comprehensive set of potential confounding variables
considered to date.
2. Materials and methods
2.1. Study design and participants
The current study draws on data collected as part of a prospec-
tive cohort study (STOP), which aims to develop screening tests to
identify adverse pregnancy outcomes. Healthy nulliparous preg-
nant women were recruited at two major maternity hospitals,
the Lyell McEwin Hospital, the tertiary hospital serving a lower
socio-economic community in Adelaide’s Northern suburbs and
the Women’s and Children’s Hospital, the primary tertiary mater-
nity hospital for complex care in metropolitan Adelaide, South Aus-
tralia. Between March 2015 and December 2017, nulliparous
women with a singleton pregnancy attending their first antenatal
clinic between 9+0 and 16+0 weeks’ gestation were enrolled as part
of the prospective cohort study described elsewhere [19–21].
Women were excluded if they were considered already at high risk
of pregnancy complications at screening (i.e. experienced three or
more previous miscarriages or with pre-existing hypertension or
diabetes). Participants were followed prospectively, with vaccina-
tion, pregnancy, and birth outcome data collected by research mid-
wives. As pertussis vaccination was recommended to be
administered between 28 and 32 weeks’ gestation, we restricted
the analyses to data from women whose pregnancies reached at
least 32 weeks’ gestation to allow all women to have had the
opportunity to receive the pertussis vaccine.
2.2. Exposure
The exposure of interest was pertussis-containing vaccine
(tetanus-diphtheria-acellular pertussis: dTpa). A research midwife
interviewed and collected maternal vaccination status of the
women during their study visit interview at 32–36 weeks’
gestation. Maternal vaccination date and gestation at administra-
tion were recorded. Following delivery, a research midwife verified
final vaccination status by reviewing Pregnancy-Hand-Held-
Records and interviewing women. Pregnancy-Hand-Held-Records
are the primary medical record of pregnancy care in South
Australia.
2.3. Outcomes
Pregnancy outcomes assessed were gestational hypertension
(GH), preeclampsia (PE), chorioamnionitis and/or funisitis, pre-
delivery hospitalisation due to acute respiratory infections or
influenza-like illness, premature rupture of membranes (PPROM),
placental abruption, spontaneous preterm birth (sPTB) and pre-
term birth (PTB). Birth outcomes included small for gestational
age (SGA), low birthweight (<2500 g) (LBW), LBW at term
(37 weeks’ gestation), Apgar scores at 1 and 5 min, neonatal care
unit admissions, respiratory distress and mechanical ventilation.
Pregnancy and birth complications were diagnosed using the
Brighton Collaboration consensus list of terms [22] and the Global
Alignment of Immunization Safety Assessment in Pregnancy
(GAIA) project [23]. GH was defined as hypertension [systolic BP
(SBP)  140 mmHg or diastolic BP (DBP)  90 mmHg] after
20 weeks of gestation in previously normotensive women. PE
was defined as GH with proteinuria (24 h urinary
protein  300 mg or spot urine protein: creatinine
ratio  30 mg/mmol creatinine or urine dipstick protein  2 + )
or any multi-organ complication of PE, including SGA age infant.
Suspected Chorioamnionitis was considered to be present only
with a physician’s diagnosis, which was dependent on maternal
fever  38 C, with at least two of the following: maternal tachy-
cardia, fetal tachycardia, uterine tenderness, foul odour of amniotic
fluid, or maternal leucocytosis or increased CRP. Funisitis is a
histopathologic diagnosis, and it is the extension of infection or
inflammation to the umbilical cord. Preterm birth (PTB) was
defined as any birth after 20+0 and before 37+0 weeks of gestation.
SGA was defined as neonates with a birthweight < 10th percentile
customized for maternal factors including maternal height, book-
ing weight, ethnicity and gestational age at delivery. The estimated
date of delivery was calculated from a certain last menstrual period
(LMP) date and was only adjusted if either (1) a scan performed
at < 16 weeks of gestation found a difference of  7 days between
the scan gestation and that calculated by the LMP or (2) on 20-
week scan a difference of  10 days was found between the scan
gestation and that calculated from the LMP. If the LMP date was
uncertain, then scan dates were used to calculate the estimated
date of delivery.
2.4. Covariates
During the first study visit at 9–16 weeks’ gestation, informa-
tion was obtained regarding baseline socio-demographic, lifestyle
and clinical characteristics including age, ethnicity, level of educa-
tion, household income, employment, exercise, smoking, supple-
ment use, intake of alcohol and recreational drugs, medical and
obstetric history, and complications during the current pregnancy.
Participants also completed questionnaires assessing stress levels
in the past month (Perceived Stress Scale (PSS-10)) [24], current
anxiety symptoms (short form of the Spielberger State–Trait Anx-
iety Inventory (STAI)) [25] and depressive symptoms during preg-
nancy (Edinburgh Postnatal Depression Scale (EPDS)) [26].
2.5. Statistical analysis
Demographic, lifestyle and clinical characteristics of partici-
pants were summarized descriptively by pertussis vaccination
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exposure during pregnancy. Continuous variables were summa-
rized as mean with standard deviation (SD) or median with
interquartile range (IQR), as appropriate, while counts and percent-
ages were used to summarize categorical variables. To assess if
there was an association between maternal pertussis vaccination
status and each of the outcome variables, we initially conducted
independent samples t-tests and Mann-Whitney U tests, as appro-
priate, for continuous variables and chi-square tests of association
for binary and categorical variables.
The timing for vaccination exposures and time-at-risk windows
were calculated for each time-sensitive pregnancy and birth out-
come, accounting for the temporal nature of each outcome of inter-
est. For instance, women were at risk for PTB from 20+0 until 36+6
weeks of gestation but had to attain at least 32 weeks’ gestation for
inclusion in the analysis data set. Cox proportional-hazards models
with gestational age in weeks as the underlying time metric were
used to derive hazard ratios (HRs) that compared the hazard rates
between vaccinated and unvaccinated women for time-sensitive
outcomes. Vaccination status was treated as a time-varying expo-
sure in these models, in that each vaccinated woman’s pregnancy
was divided into unvaccinated and vaccinated exposure periods.
Thus, a woman who did not receive the vaccine during pregnancy
was classified into the unvaccinated group in any risk set, whereas
a woman who received the vaccine at some point during her preg-
nancy was initially classified as unvaccinated and then classified as
vaccinated from the time at vaccination onwards.
We used log-binomial models to estimate risk ratios (RR) and
adjusted risk ratios (aRR) comparing the risk of late onset or early
postpartum adverse pregnancy outcomes and time-independent
birth outcomes between vaccinated and unvaccinated mothers. A
multivariable linear regression model was applied to compare
the difference in mean gestational age at delivery and mean birth-
weight by maternal pertussis vaccination status. For all multivari-
able models, age, level of education, ethnicity, gravidity, annual
household income, alcohol intake, recreational drug use, smoking,
pre-pregnancy body mass index (BMI), use of micronutrient sup-
plements, asthma, assisted reproductive treatment and current
psychological states were amongst the variables selected as poten-
tial confounders based on evidence in the literature [11–14] guided
by directed acyclic graphs. Sensitivity analyses were conducted in
all multivariable models to evaluate whether the effects of mater-
nal pertussis vaccination on pregnancy and birth outcomes were
maintained after adjustment for receipt of maternal influenza vac-
cination. The overall missing covariate data at baseline was < 5%
and therefore all available data were used in the analyses of all
pre-specified outcomes. For all analyses, p values < 0.05 were con-
sidered statistically significant. We did not correct for multiple
comparisons to minimize the risk of Type II errors. Data were
recorded in a REDCap [27,28] online database and all statistical
analyses were conducted using Stata version 15. Written informed
consent was obtained from all women. Personal identifying infor-
mation in the study database was eliminated to ensure that confi-
Fig.1. Participants flow diagram.
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Table 1
Maternal characteristics of vaccinated and unvaccinated pregnant women who delivered at two obstetric hospitals in South Australia, 2015 to 2018 (N = 1272).
Variable Vaccinated
women
N = 1019, n (%)
Unvaccinated
women










































 Secondary school qualification
Diploma/certificate










Total years of formal education, mean (SD) 13.4 ± 2.4 13.0 ± 2.6
Moderate exercise during 1st trimester/pre-pregnancy












Gravidity > 1 296 (29.0) 57(22.5)
Asthma 146 (14.3) 31 (12.5)














Pre-pregnancy BMI (kg/m2), mean (SD) 28.2 ± 7.1 26.7 ± 6.7













Illicit drug use during 1st trimester/pre-pregnancy 51 (5.0) 26 (10.2)
Multivitamin and mineral supplements use












Psychological measures at 9–16 weeks’ gestation
Edinburgh Perinatal Depression Scale (EPDS) scores, mean (SD)
State and trait anxiety (STAI) scores, mean (SD)










Gestational week of vaccine administration, mean (SD) 30.3 ± 2.8 NA
Gestational week of vaccine administration, median (IQR) 30 (26–34) NA
Received influenza vaccination during pregnancy 555 (54.4) 42 (16.6)
Data are mean (SD) or n (%)
SD = standard deviations IQR = interquartile range AUD = Australian dollars. BMI = body-mass-index.
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dentiality of all patients’ records was maintained. The STOP study
protocol was approved by the Human Research Committee of the
Women’s and Children’s Hospital Adelaide, Australia (HREC/14/
WCHN/90) [19].
3. Results
Of 1364 pregnant women enrolled, 12 withdrew access to their
medical records, six were lost to follow up, and 14 delivered else-
where; all 32 women were excluded from our final analyses. After
excluding 60 pregnancies that ended before 32 weeks’ gestation,
our final cohort consisted of 1272 women (Fig. 1). At enrolment,
the mean (SD) maternal age of nulliparous women was 25.9 (4.9)
years (range: 15–45 years). A total of 1040 (81.7%) women
attended their first antenatal visit in first trimester at a mean ges-
tational age of 11.4 (1.7) weeks.
The uptake of pertussis vaccination was 80.1%. Of the 1019
women who received maternal pertussis vaccination, 77.8%
(n = 790) received the pertussis vaccine within the recommended
timeframe of 28–32 weeks, 2.7% (n = 28) before 28 weeks (range
12–27 weeks) and 19.4% after 32 weeks’ gestation. The mean ges-
tational age at vaccination was 30.3 (2.8) weeks. Both pertussis and
influenza vaccinations were administered in 555 of 1272 (43.6%)
pregnancies. Those women who did not receive maternal pertussis
vaccination were more likely to have no previous history of termi-
nation and/or miscarriage, be younger, in the healthy weight range,
smoke cigarettes, use illicit drugs, physically inactive, in the lowest
household income group, have lower educational attainment and
were less likely to take micronutrient supplements pre-
conception or during pregnancy compared with vaccinated preg-
nant women. Women who received pertussis vaccination were
more likely to receive influenza vaccine (Table 1).
Of the 1272 women, 82 had a PTB (6.4%). The mean gestational
age at delivery was 39.4 (1.5) weeks. After adjusting for covariates,
women who had received pertussis vaccination during pregnancy
had on average 0.22 weeks (95% CI 0.001, 0.44) longer gestation
at delivery than unvaccinated women (Table 2). The time-
dependent Cox proportional hazards regression model shows that
receiving pertussis vaccination during pregnancy did not increase
the risk of PTB (aHR 0.99, 95% CI 0.47, 2.07), sPTB (aHR 0.99, 95%
CI 0.57, 1.70) or PPROM (aHR 1.01, 95% CI 0.52, 1.97) (Table 2).
Our time dependent analyses also indicated that there was no
increased risk for maternal hypertensive disorders (i.e. GH, PE),
Table 2
Crude and adjusted hazard ratios for time-based pregnancy and birth outcomes by maternal pertussis vaccination status at two obstetric hospitals in South Australia 2015–2018.









Gestational hypertension d 86/1267 (6.7) 10/249 (4.0) 76/1018 (7.4) 1.45 (0.79, 2.66) 0.228 1.24 (0.66, 2.30) 0.497
Preeclampsia d 116/1268 (9.1) 26/250 (10.4) 90/1018 (8.8) 0.77 (0.49, 1.19) 0.246 0.75 (0.47, 1.18) 0.220
Pre-delivery hospitalization due to
influenza like illness e
94/1272 (7.3) 24/253 (9.4) 70/1019 (6.8) 0.75 (0.47, 1.21) 0.245 0.84 (0.51, 1.36) 0.488
Preterm premature rupture of
the membranes f
42/1272 (3.3) 12/263(4.7) 30/1019 (2.9) 0.83 (0.41, 1.69) 0.616 0.99 (0.47, 2.07) 0.987
Preterm birth f 82/1272 (6.4) 21/253 (8.3) 61/1019 (5.9) 0.95 (0.56, 1.60) 0.852 0.99 (0.57, 1.70) 0.984
Spontaneous preterm birth f 51/1272 (4.0) 14/253 (5.5) 37/1019 (3.6) 0.87 (0.46, 1.67) 0.693 1.01 (0.52, 1.97) 0.961
Birth outcomes
LBW (<2500 g) 71/1268 (5.6) 21/250 (8.4) 50/1018 (4.9) 0.69 (0. 40, 1.19) 0.189 0.72 (0.41, 1.27) 0.261
LBW at term (<2500 g) g 31/1186 (2.6) 8/229 (3.4) 23/957 (2.4) 0.64 (0.28, 1.46) 0.299 0.67 (0.29, 1.55) 0.361
SGA 150/1266 (11.8) 36/249(14.4) 114/1017 (11.2) 0.77 (0.52, 1.15) 0.211 0.80 (0.53, 1.20) 0.295
Difference in means
(vaccinated - unvaccinated)
Difference in adjusted means
(vaccinated -unvaccinated)
Mean birth weight, grams
(95% CI)
3368.0 ± 496.2 3313 ± 565.3 3381.2 ± 477.5 68.0 (-3.0, 139.1) 0.061 44.6 (-26.0, 115.3) 0.216
Mean gestational age at delivery,
weeks (95% CI)
39.4 ± 1.5 39.2 ± 1.7 39.4 ± 1.4 0.23 (0.01, 0.44) 0.038 0.22 (0.001, 0.44) 0.048
CI, confidence interval; HR, hazard ratios; LBW, low birthweight; SGA, small for gestational age
a: Denominators differ due to missing data.
b: HR results compared outcome variable in vaccinated group to reference (unvaccinated).
c: Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, smoking, pre-pregnancy body
mass index (continuous), use of multivitamin supplements, estimated season of delivery, Edinburgh Postnatal. Depression Scale (EPDS), The State-Trait Anxiety Inventory
(STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment, and asthma. Birth outcomes were additionally adjusted for infant’s sex.
d: For hypertensive disorders analysis, women who were vaccinated at or after the gestational age at diagnosis were censored
e: Women admitted to hospital with respiratory tract infection/influenza-like illness were censored at their admission date
f: Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of preterm birth.
g: Low birthweight at term (<2500 g and  37 completed weeks’ gestation at birth).
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or hospitalisation with acute respiratory/influenza-like illness
among vaccinated women compared with unvaccinated women
(Table 2). In log-binomial models, maternal pertussis vaccination
was not associated with chorioamnionitis, placental abruption, or
postpartum hemorrhage (Table 3).
Of all 1272 births included in this study, 1269 (99.7%) were live
births and three (0.2%) were stillbirths at term. The majority of
infants (93.5%, n = 1190) were born at term. The mean birthweight
of the infants was 3368 g. In the multivariable linear regression
model, infants born to vaccinated mothers were on average
44.6 g heavier than infants born to unvaccinated mothers but the
confidence intervals were wide (95% CI 26.0 g, 115.3 g) (Table 2).
All birth outcomes had an adjusted relative risk of less than one,
although all confidence intervals were wide (Table 2 & 3).
The time-dependent Cox proportional hazards regression mod-
els demonstrate that receiving pertussis vaccination during preg-
nancy was not associated with increased risk of delivering LBW
infants (aHR 0.72, 95% CI 0.41, 1.27), LBW at term infants (aHR
0.67, 95% CI 0.29, 1.55) or SGA infants (aHR 0.80, 95% CI 0.53,
1.20) (Table 2). Our log-binomial models also suggest there was
no increased risk of other adverse perinatal outcomes including
Apgar scores < 7 at one and five minutes, admission to the neonatal
care unit, mechanical ventilation, and respiratory distress syn-
drome following pertussis vaccination during pregnancy (Table 3).
Adjustment for influenza vaccination did not appreciably change
any of the findings (Table S1 & S2).
4. Discussion
This study provided a unique prospective assessment of accu-
rate pregnancy and infant data with confirmed maternal vaccina-
tion status. The analytical framework treated pertussis
vaccination as a time-varying exposure and computed time at risk
windows for each of the time sensitive outcomes of interest and
adjusted for a comprehensive set of confounding factors to reaffirm
that maternal pertussis vaccination is safe for both the mothers
and their newborn infants.
Our Cox proportional hazards models accounting for the time-
dependent nature of exposure to vaccination during pregnancy,
thereby avoiding the introduction of immortal time bias to our
analyses, found no association between maternal pertussis vacci-
nation and PTB, sPTB, nor PPROM, reaffirming the conclusion from
previous systematic reviews [11–14].
In keeping with previous studies [11,12], our findings demon-
strated no association between maternal pertussis vaccination
and gestational hypertensive disorders. The new Australian guide-
lines recommend pregnant women to receive a pertussis vaccine
from 20 weeks of gestation rather than 28 weeks’ to maximize
the opportunity for vaccination to protect all infants, including pre-
term infants [29]. Administration of maternal pertussis vaccination
from 20 weeks’ can align with other key routine antenatal visits
such as morphology scanning and gestational diabetes testing,
potentially improving the uptake of pertussis vaccination among
pregnant women. However, there is a need for continued surveil-
lance and monitoring to confirm that a broader window for pertus-
sis vaccination during pregnancy is safe for the pregnant mother
and the newborn.
Our study demonstrates that maternal pertussis vaccination
was not associated with chorioamnionitis. In contrast, three large
retrospective studies [15–17] conducted in the USA showed receipt
of pertussis vaccination during pregnancy was associated with a
small but significant increase in risk of developing chorioamnioni-
tis. These studies [15–17] used commercial health data and ICD
codes for identifying chorioamnionitis from electronic medical
records with no clinical case definition. Coding for commercial rea-
sons, such as insurance claims, is potentially subject to favoring
more severe diagnoses and might be prone to poor external valid-
ity, selection bias, confounding and misclassification bias [30]. Fur-
thermore, these studies did not find an association with an
increased risk of PTB, which is an expected major clinical sequel
of chorioamnionitis and most women with chorioamnionitis had
at least one pre-existing risk factor for this complication. This sug-
gests the observed relation between receipt of pertussis vaccina-
tion during pregnancy and chorioamnionitis was unlikely to be
casual, and is probably more reflective of residual confounding
affecting the results in these studies.
In our study, we found an association between maternal pertus-
sis vaccination during pregnancy and longer gestation. There are
no known biologically plausible direct effects of pertussis vaccina-
tion on pregnancy duration but women who remained pregnant
longer have more opportunity to have received pertussis vaccine
in the late third trimester of pregnancy. This may have created a
spurious relationship between pregnancy duration and time-
varying pertussis vaccine exposure during pregnancy because lin-
ear regression analysis is not suited to include both the event
and time aspects in the model.
Our study provides further assurance that pertussis vaccina-
tion during pregnancy is not associated with any adverse birth
outcomes including LBW or SGA births, consistent with previous
findings [11–14]. Receipt of pertussis vaccination during preg-
nancy was not associated with increased risk of perinatal out-
comes including admission to the neonatal care unit, respiratory
distress, Apgar scores < 7 nor need for mechanical ventilation at
Table 3
Pregnancy and birth outcomes following pertussis vaccination during pregnancy at two obstetric hospitals in South Australia 2015–2018.









Chorioamnionitis and/or funisitis 23/1272 (1.8) 7/253 (2.7) 16/1019 (1.5) 0.52 (0.21, 1.26) 0.149 0.71 (0.27, 1.82) 0.481
Placental abruption 32/1266 (3.3) 7/250 (2.8) 25/1016 (2.4) 0.90 (0.37, 2.20) 0.833 1.04 (0.41, 2.62) 0.923
Postpartum haemorrhage 115/1269 (9.0) 26/251 (10.3) 89/1018 (8.7) 0.85 (0.55, 1.31) 0.475 0.81 (0.52, 1.26) 0.357
Birth outcomes
Apgar at 1 min < 7 149/1263 (11.8) 30/247 (12.1) 119/1016 (11.7) 0.91 (0.62, 1.34) 0.646 0.87 (0.59, 1.29) 0.496
Apgar at 5- min < 7 26/1265 (2.0) 6/248 (2.4) 20/1017 (1.9) 0.84 (0.31, 2.25) 0.738 0.75 (0.27, 2.06) 0.582
Admitted to Neonatal unit c 285/1272 (22.4) 65/253 (25.6) 220/1019 (21.5) 0.81 (0.64, 1.04) 0.115 0.84 (0.66, 1.07) 0.177
Respiratory distress syndrome 10/1272 (0.7) 3/253 (1.1) 7/1019 (0.6) 0.56 (0.14, 2.16) 0.406 0.61 (0.20, 1.82) 0.384
Mechanical ventilation 42/1272 (3.3) 9/253 (3.5) 33/1019 (3.2) 0.78 (0.38, 1.63) 0.526 0.71 (0.34, 1.50) 0.381
a: Denominators differ due to missing data.
b: Pregnancy outcomes were adjusted for maternal age, ethnicity, total years of full-time education, household income, gravidity, intake of alcohol and recreational drugs,
smoking, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal Depression Scale (EPDS), The State-Trait Anxiety Inventory
(STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment and asthma. Birth outcomes were additionally adjusted for infant’s sex.
c: Reasons for admission: preterm, respiratory distress infection, feeding problem, hypoglycaemia, drug withdrawal, SGA, birth asphyxia, congenital abnormality, pho-
totherapy and cyanosis.
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birth compared with infants born to unvaccinated women [11–
14].
The major strength of this study is the prospective cohort
design that recruited a large number of nulliparous women with
singleton pregnancies at low risk for obstetric complications at
two major maternity hospitals. Vaccinated women in our study
were more likely to engage in healthy lifestyles i.e. pregnancy
micronutrient supplementation, regular exercise, non-smoking
than unvaccinated women. The analysis framework used herein
adjusted for putative risk factors, including psychosocial factors,
to mitigate the impact of any ‘healthy vaccinee bias’ on our find-
ings. However, we cannot rule out the possibility of residual con-
founding. Our use of Cox proportional-hazards models
accounting for time-varying vaccine exposure during pregnancy
minimized the introduction of immortal time bias in our data.
The potential for this bias arises because the opportunity for vacci-
nation increases the longer a woman remains pregnant [31]. Fur-
thermore, many studies use the earliest recommended maternal
pertussis vaccination time (i.e. 28 weeks’ gestation in this case)
as a cut-off point to restrict their data but pregnancies must sur-
vive within the recommended timeframe (i.e. 28–32 weeks’ gesta-
tion) to be eligible to receive the vaccines. Hence, immortal time
bias may also be present in studies of maternal pertussis vaccina-
tion evaluating adverse pregnancy outcomes that develop in mid-
to-late pregnancy, including PE and GH, where the bias may atten-
uate the true relative risk. Our analytic approach used 32 instead of
28 weeks’ gestation as the cut-off point in order to allow all
women to have had the chance to receive the recommended per-
tussis vaccination in that optimal 4-week window. This may have
reduced the introduction of immortal time bias in our analyses.
Additionally, including follow-up time during which pregnancies
are no longer at risk of some adverse outcomes (e.g. gestation after
37 weeks considered for PTB outcomes) can lead to incorrect esti-
mation of the effect of maternal vaccination on the outcome of
interest but our time-to-event analytic approach minimized the
risk of these biases occurring. Another major strength of our study
is confirmed maternal vaccination status. As this study was a sec-
ondary analysis, we did not conduct an a priori power analysis to
show sample size adequacy. A post-hoc power analysis was not
conducted as there is a rich literature, in both medical and statis-
tical journals, warning against post-hoc power calculations
[32,33]. However, the cohort was originally powered on the basis
of 25% of women affected by pregnancy complications (PE, SGA
and sPTB) [19]. The recruitment of only healthy nulliparous
women limits the generalizability of the study findings to women
with high-risk pregnancies or multiparous women.
5. Conclusions
The present study offers a unique prospective and robust
assessment of the safety of pertussis vaccination during pregnancy
and provides reaffirming evidence of the safety of maternal pertus-
sis vaccination for both mothers and their infants. Evidence pre-
sented in our study provide further reassurance to expecting
women and healthcare providers about the safety of pertussis vac-
cination during pregnancy and supports recommendations for per-
tussis vaccination during pregnancy to prevent morbidity and
mortality associated with early-infant pertussis disease. The study
findings also aid evidence-based decision making for clinicians and
policy makers in countries considering implementation of univer-
sal maternal pertussis immunization programs.
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Chapter 8: Discussion, Future directions and Conclusion 
 
The overall aims of this thesis were to provide i) evidence on the safety and protective effects 
of seasonal influenza and pertussis during pregnancy ii) to determine psychosocial factors 
influencing uptake of maternal vaccination and iii) to identify strategies that were effective in 
improving uptake of pertussis vaccines during pregnancy. In this final chapter, the main 
findings of the thesis are summarised, and originality and significance of the thesis findings 
are discussed. The strengths and limitations of the thesis are outlined and implications of the 
findings are described. Finally, potential areas for future research directions are suggested and 
a concluding remark is provided. 
8.1  Summary of Key Findings of the Thesis 
 
Interventions to improve uptake of maternal pertussis vaccination  
The systematic review (Chapter 4) collected and summarised the available evidence on the 
effectiveness of interventions used to increase maternal pertussis vaccination among pregnant 
women. Implementation of automated electronic reminders for healthcare providers to 
vaccinate pregnant women at the point of antenatal care and a standing order, allow midwives 
to administer maternal vaccination without the need for a prescription from a medical doctor 
at the place of antenatal service. These were found to be effective strategies in increasing 
pertussis vaccine uptake among pregnant women.  Educational interventions targeting pregnant 
women alone were not an effective strategy for increasing uptake of maternal pertussis 
vaccination. However, the review highlighted the need for well-designed educational 
interventions for pregnant women that are used alongside other interventions emphasising the 
role of maternal pertussis vaccination in mitigating the burden of pertussis infections in young 





relation to maternal vaccine uptake could aid in designing robust maternal immunisation 
programs. 
Psychosocial determinants of pertussis and influenza vaccine uptake in pregnant women 
This study (Chapter 5) extends our understanding of the role of psychosocial factors in 
influencing vaccine decision making during pregnancy. Using a prospective cohort study of 
nulliparous women at two obstetric hospitals in South Australia, we found overall, 48% and 
79% of the women received seasonal influenza and pertussis vaccines respectively. Irrespective 
of psychosocial status, most women were willing to receive the recommended vaccinations 
during pregnancy. Conversely, the actual receipt of pertussis and influenza vaccines among 
pregnant women was influenced by psychosocial factors. Interestingly, a history of severe 
depression that required antidepressant medication was the strongest independent predictor of 
pertussis and influenza vaccine uptake during pregnancy. Moreover, screening positive for 
antenatal depression was associated with receipt of pertussis vaccine during pregnancy.  
Based on The Edinburgh Postnatal Depression Scale (EPDS) score, pregnant women with 
elevated depressive scores at their first antenatal visit were referred to a GP for further 
assessment and interventions. Frequent encounters with a GP or mental health midwife services 
might have provided better opportunities for women with depressive symptoms to receive the 
recommended vaccinations during pregnancy. In contrast, women with high-perceived stress 
in the antenatal period were significantly less likely to receive maternal pertussis vaccination. 
This finding aligned with the research hypothesis that non-adherence to maternal healthy 
behaviours such as vaccine refusal during pregnancy is influenced by high level of stress during 
pregnancy. However, unlike the EPDS, the Perceived Stress Scale (PSS) as a tool to measure 
perception of stress during pregnancy does not have clinical cut-off values for appropriate 





healthcare provider interaction is an important determinant of uptake of the recommended 
vaccines during pregnancy. Addressing healthcare provider–patient barriers and examining the 
influence of antenatal psychological stressors on maternal vaccine decision making is crucial 
in improving vaccine uptake among pregnant women. 
In the context of engaging in risky maternal health behaviours, uptake of pertussis and 
influenza vaccines during pregnancy were lower for smokers and illicit drug users; the 
differences were not statistically significant in the final adjusted model, but the disparity needs 
to be further studied, as they are a high-risk group for severe respiratory diseases. Furthermore, 
women who never exercise or who did not take multivitamins or supplements in the 
preconception or antenatal period were less likely to receive pertussis or influenza vaccination 
during pregnancy. Less engagement in periconceptional health-promoting behaviours or 
unplanned pregnancies were correlated with suboptimal uptake of the vaccines during 
pregnancy. Maternal vaccination information should be provided to women presenting in pre-
pregnancy counselling to improve the uptake of the recommended vaccines during pregnancy. 
Receipt of maternal pertussis vaccine was lower among Indigenous women and those born 
overseas, although the difference was not statistically significant. More research is needed to 
understand and reduce this disparity. Educational materials on maternal vaccinations should be 
easily readable and accessible to culturally and linguistically diverse women in different 
languages. There is a need to deliver culturally appropriate interventions to Indigenous women 
within Aboriginal health services. Other sociodemographic determinants such as younger 
maternal age and unemployment status were significantly associated with low pertussis and 
influenza vaccination uptake during pregnancy. Understanding the role of psychosocial factors 
in relation to vaccination receipt during pregnancy is crucial in designing effective 





Safety and benefits of seasonal influenza vaccination during pregnancy 
The findings of our cohort study provided evidence of the safety and benefits of seasonal 
influenza vaccination during pregnancy in healthy nulliparous women. In robust nuanced 
analyses that accounted for time-varying maternal vaccine exposure and time at risk windows 
for each of the time sensitive pregnancy and birth outcomes, maternal influenza vaccination 
was demonstrated to be safe for both mothers and their newborn infants. The study findings 
reaffirm the evidence of no increased risk of spontaneous abortion, congenital anomalies, 
gestational diabetes, gestational hypertensive disorders, and preterm birth following seasonal 
influenza vaccination during pregnancy.  
Newborns whose mothers received seasonal influenza vaccine in pregnancy were not more 
likely to experience any adverse perinatal outcomes. Most importantly, maternal seasonal 
influenza vaccination reduced the risk of hospitalisation for respiratory diseases during 
pregnancy by 39%. Furthermore, women who received seasonal influenza vaccines during 
pregnancy had a reduced risk of delivering low birthweight and small for gestational age infants 
during periods of widespread influenza activity. 
Safety of pertussis vaccination during pregnancy 
Additionally, in the prospective cohort of healthy pregnant women with confirmed vaccination 
status and accurate pregnancy and infant outcome data, we demonstrated maternal pertussis 
vaccination is safe for both the mother and newborn infant (Chapter 7). The study provided 
further reassurance that pertussis vaccination during pregnancy is not associated with increased 
risk of chorioamnionitis, gestational hypertensive disorders or preterm birth. Further, no 
increased risk was observed for adverse neonatal health outcomes including, small for 
gestational birth, low birth weight, admission to the neonatal care unit, respiratory distress, low 





8.2  Originality and Significance of the Thesis 
 
This thesis has many original contributions and significance. The systematic review was the 
first peer-reviewed protocol registered in the international prospective register of systematic 
reviews in February 2017 (PROSPERO, ID CRD42017058178) to summarise the evidence for 
effectiveness of interventions used to improve maternal pertussis vaccination coverage. The 
review solely focused on strategies to improve uptake of maternal pertussis vaccination to make 
recommendations in a global context considering the increasing implementation of antenatal 
pertussis vaccine programs around the world. Currently more than 40 countries including 
middle-income countries recommended pertussis vaccination for pregnant women (340).  
Furthermore, the recommendations in the review considered the diversity of maternity care 
settings and antenatal vaccination service models available in different countries. For instance, 
the suggestion of incorporating a reminder in medical records to prompt healthcare providers 
to offer maternal vaccination could be either electronic alerts or paper medical records/case 
note reminders depending on the type and variability of maternity services nationally and 
internationally. Moreover, the recommendation of standing orders for midwives discussing and 
offering pertussis vaccination to pregnant women at the place of antenatal service could be 
applicable but not limited to countries where maternity settings have well-functioning 
midwifery programs. Midwife delivered immunisation programs for pregnant women could be 
feasible in low resource setting countries as there are on-going mechanisms to improve quality 
of midwifery care and to reduce maternal and neonatal mortality (341). The review is also 
unique in strengthening the generalisability and practicality of the findings by classifying 
interventions into three distinct groups: provider-focused interventions, pregnant women 
focused interventions and interventions to enhance access to maternal vaccination. Moreover, 
the absolute benefit increase (ABI) was computed to describe the standardised effect sizes of 





This thesis was the first to explore a range of psychosocial factors including psychological, 
social, individual health-related behaviours, cognitive and emotional or mental wellbeing status 
in the perinatal period, in relation to willingness and uptake of pertussis and influenza vaccine 
among pregnant women. The thesis showed the decisions to receive the recommended pertussis 
and influenza vaccinations are complex, and influenced by many clinical and psychosocial 
factors. Importantly, this thesis is original in addressing whether experiencing psychological 
distress such as depression, anxiety, and/or perceived stress during pregnancy influence 
acceptance and uptake of maternal vaccinations. These psychosocial factors provide a number 
of targets for improving maternal immunisation programs and should be considered in the 
design of effective strategies or interventions in improving uptake of pertussis and influenza 
vaccines during pregnancy. Existing or new theoretical models should consider these 
psychosocial factors to better address inconsistencies in uptake of maternal vaccinations.  
Additionally, the psychosocial factors explored in this thesis can help determine the focus and 
content of patient centered educational materials on maternal vaccination and can be utilized 
to explain how interventions work to facilitate decision-making processes around maternal 
vaccination uptake. This thesis is unique in not only examining a wide range of psychosocial 
factors in relation to uptake of vaccines during pregnancy but also including extensive antenatal 
psychological stressors as potential cofounders in evaluating the effects of maternal influenza 
and pertussis vaccination. Previous studies have demonstrated that the presence of 
psychosocial morbidity, particularly high levels of anxiety, depression and stress in pregnancy 
can adversely impact fetal development and lead to increased risk of intra-uterine growth 
restriction, preterm birth and delivering low birth weight infants (342, 343). Thus, the thesis 
employed the most comprehensive and accurate set of potential confounding factors to date, 





This thesis provided a unique prospective evaluation of the safety and protective effects of 
seasonal influenza and pertussis vaccination during pregnancy among healthy nulliparous 
women, with confirmed vaccination status and accurate pregnancy and infant outcome data 
using robust nuanced time-to-event analyses. This thesis is also original in presenting nuanced 
evidence that seasonal influenza vaccination is effective in reducing the risk of maternal 
hospitalisations with influenza-like illness by stratifying influenza activity according to the 
local laboratory confirmed influenza rate in South Australia during the study period as opposed 
to stratifying by typical influenza seasons in Australia (April/May through September). This 
analytical approach was extended to demonstrate the protective effects of maternal seasonal 
influenza vaccination on birth outcomes such as low birth weight and small for gestational age 
birth during peak influenza activity after controlling for the most comprehensive set of potential 
confounding factors and concurrent or sequential pertussis vaccine exposure during pregnancy 
as an effect modifier time varying covariate. Furthermore, this thesis investigated the protective 
effects of seasonal influenza vaccine on key birth outcomes by trimester of vaccine 
administration.  
The work in this thesis was the first prospective cohort in the Southern Hemisphere to 
demonstrate that influenza vaccination is strongly associated with reduced risk of admission to 
hospital with influenza-like illness among pregnant women using a robust nuanced time to 
event analytical approach with confirmed maternal vaccination status. Although no clear trend 
of association by trimester of influenza vaccination administration on birth outcomes was 
observed, a protective effect of influenza vaccination on small for gestational age births was 
most pronounced in the third trimester. A subsequent analysis of the RCT in Nepal (344) 
demonstrated the protective effect of maternal influenza vaccination on birth weight, and small 
for gestational age birth was the strongest among pregnant women who were exposed to 





identify an ideal time for maternal influenza vaccination in improving birth outcomes, it has 
highlighted the importance of accounting for level of influenza activity in relation to the stage 
of pregnancy.  
The findings of this thesis are also distinctive in affirming safety of pertussis vaccination using 
a prospective cohort study with a large volume of accurate pregnancy and birth data, confirmed 
maternal vaccination exposure and analysed using a rigorous time dependent analysis. 
Moreover, the research is original in computing time at risk windows for each of the time 
sensitive outcomes of interest and adjusting for a comprehensive set of confounding factors to 
each outcome. 
8.3  Strengths and Limitations of the Thesis 
 
Strengths 
This thesis has a number of strengths. Systematic reviews are a robust methodology for 
assessing interventions. The systematic review emphasised the role of patient-provider 
interactions in improving maternal vaccination uptake, and highlighted the knowledge gap in 
psychological and social factors influencing women’s decisions to receive vaccines during 
pregnancy. These findings provided important conceptual understanding and aided the 
interpretation of psychosocial factors in predicting the uptake of maternal pertussis and 
influenza vaccines in the context of patient-provider interaction. Psychosocial determinants of 
maternal vaccination uptake were then used as potential confounding factors in evaluating the 
effect of maternal influenza and pertussis vaccines on pregnancy and birth outcomes. The 
analysis framework used in this thesis, herein adjusted for putative risk factors, including social 
and antenatal psychological risk factors, such as stress, anxiety and depression to reduce the 





The data presented in Chapters 5, 6 and 7 were sourced from the Screening Tests to predict 
poor Outcomes of Pregnancy (STOP) study. The STOP study aimed to validate algorithms to 
predict the risk of pregnancy complications as early as at the 12th week of gestation. Given the 
nature of predictive research, this comprehensive set of fine-grained prospectively routinely 
collected variables in the cohort was its distinctive strength. The prospective character of this 
multi-center observational cohort study and the collection of comprehensive baseline 
information made it the ideal cohort to conduct a high-quality prospective study on the safety 
and predictors of uptake the recommended vaccines during pregnancy. Other major strengths 
of the cohort approach included i) early pregnancy recruitment of a well-defined population of 
healthy nulliparous women with singleton pregnancies at low risk for obstetric complications, 
ii) first trimester screening tests to assess the health of the pregnant women and their fetus, iii) 
monitoring of the women throughout their pregnancy iv) strict diagnostic criteria for key 
pregnancy and birth complications and v) confirmed maternal vaccination. This enabled the 
thesis to provide a high level of evidence internationally on the safety and impact of influenza 
and pertussis vaccines for mothers and their newborn infants. 
Additionally, the high quality of ultrasound measurement in determination of an accurate 
gestational age and expected date of delivery enabled this body of work to conduct robust 
nuanced time-to-event analyses in evaluating the effect of maternal influenza and pertussis 
vaccines, thereby avoiding critical time related biases. Furthermore, almost 8 out 10 women in 
the study cohort were recruited in the first trimester of pregnancy, which allowed assessment 
of the effect of first trimester influenza vaccination on early pregnancy outcomes such as 
spontaneous abortion and congenital anomaly. This was important considering the lack of 
robust evidence from prospective studies on safety of maternal influenza vaccine in early 
pregnancy and reluctance of pregnant women receiving the influenza vaccine in first trimester 





(live or fetal death) reducing selection bias as most observational studies into maternal vaccine 
uptake and safety only include those women who delivered a live infant, which excludes 
women who had either a stillbirth, miscarriage, or late spontaneous abortion.  
Another strength of the research presented in this thesis is the robust analytical framework 
applied in determining psychosocial predictors of maternal vaccination receipt in Chapter 5. 
The natural logarithm of the total time of a pregnancy in gestational weeks was included in the 
final adjusted model as an offset term to account for the shorter window of opportunity some 
women (i.e. women who had miscarriages or terminations) had to receive the vaccine. 
Moreover, the study cohort contains details of antenatal visits as well as information on pre-
conception/early pregnancy lifestyle, psychological status and intention to receive maternal 
vaccines. This aided the study in Chapter 5 in identifying psychosocial predictors of maternal 
vaccination uptake as well as willingness to receive the recommended vaccines during 
pregnancy. Furthermore, the study was able to examine whether willingness to receive the 
recommended maternal vaccine is a good predictor of actual vaccination receipt during 
pregnancy.  
Limitations 
Although the limitations of each study are detailed in the respective chapters, some of the 
overall major limitations are summarised below. The use of secondary data sources for the 
three quantitative studies (Chapters 5, 6 and 7) meant the analysis was reliant on the variables 
collected through the cohort. Whilst the cohort included rich accurate data on pregnancy and 
birth outcomes, other factors that may be important for examining psychosocial predictors of 
maternal vaccination uptake might have been omitted. Information regarding the level of 
English proficiency, primary language, migration status (recent migrants, settled migrants) and 





have been important variables in assessing factors related to maternal vaccine uptake among 
culturally and linguistically diverse (CALD) women. There was also limited information 
collected in the study cohort regarding mothers' perceptions of pertussis and influenza as 
vaccine-preventable diseases in terms of perceived susceptibility, severity, benefits and 
knowledge of maternal vaccines. Furthermore, willingness to receive the recommended 
vaccines was not asked separately for pertussis and influenza vaccine. Previous research 
indicated that most women perceive influenza as a disease affecting the mother, whereas they 
perceive pertussis as a threat to the new born infant and thus relatively more risky (265). This 
has been suggested as one of the reasons for the relatively higher maternal pertussis vaccine 
rate compared to that for influenza.   
Another potential limitation of studies in Chapters 6 and 7 is the prospective cohort study was 
not designed or powered to specifically evaluate the safety of maternal vaccination. The 
secondary data analysis of study cohort with a modest size (n=1364), yielded power to compare 
common adverse pregnancy and birth outcomes in vaccinated and unvaccinated pregnancies. 
This study was originally powered on the basis of 25% of women likely affected by pregnancy 
complications (preeclampsia, small for gestational age birth, spontaneous preterm birth and 
gestational diabetes mellitus). However, the studies in Chapters 6 and 7 are possibly 
underpowered to investigate the effect of maternal seasonal influenza and pertussis vaccination 
on rare outcomes such congenital anomalies. Post-hoc power calculation was not presented as 
there is a rich literature, in both medical and statistical journals, warning against post-hoc 
power calculations (338, 339).  
In the study cohort, the gestational age at enrollment ranged from 6 to 16 weeks and the median 
gestational age at enrollment was 11 weeks. The fact that the pregnancies were not followed 
from the beginning (i.e., gestational age zero, first day of the last menstrual period), causes 





truncated data). The studies in Chapters 6 and 7 used Cox proportional-hazards models to 
properly estimate the event rates by including a woman in the risk sets at the time points after 
she enrolled in the study. Another potential limitation that we could not take into account is 
that maternal vaccine administered in non-traditional settings (i.e. pharmacist or community 
health clinics or workplace-administered vaccination) might not be recorded in the South 
Australian Pregnancy Record (SAPR). Although it is possible that some women were 
misclassified as unvaccinated if they failed to report being vaccinated, the direct method of 
interviewing the mother about their maternal vaccination status (including gestational timing 
of vaccination) by a research midwife at several time points including after delivery suggests 
this would be unlikely to occur. Additionally, maternal immunisations were confirmed in the 
majority of cases. 
Although seasonal influenza activity and vaccine effectiveness can differ from year to year, the 
study in Chapter 6 was unable to perform sub analyses of season-by-season estimates for all 
pregnancy and birth endpoints due to the modest sample size. However, the findings are 
generalizable, as the study and analyses were not restricted to one influenza season which could 
have introduced bias. Given the variation in antigenic match between the circulating viruses 
and the strains included in the annual seasonal vaccine (166), further studies with larger 
datasets are warranted to evaluate the effect of seasonal maternal influenza vaccine annually.  
Another limitation of the thesis is inability to measure pre-delivery hospitalisations with 
laboratory confirmed influenza as an outcome and the unavailability of data on influenza illness 
or hospitalisations among newborns. Further studies with larger numbers of women and infants 
are needed to confirm effectiveness of influenza vaccination during pregnancy in reducing 
laboratory confirmed influenza infections or related hospitalisation in both the mother and her 
newborn infant. However, one of the challenges with conducting large population-based 





routinely monitoring and recording antenatal vaccination coverage (52, 53, 345). Pregnancy 
status is not collected to the Australian Immunisation Register (AIR), making it challenging to 
ascertain maternal immunisation status using AIR alone (346). Western Australia, Queensland 
and the Northern Territory have introduced routine collection of maternal vaccination records 
via either state-based immunisation registers or through perinatal data collections. A large, 
population based, multi-jurisdictional cohort of mother-infant pairs is established to measure 
the uptake, safety and effectiveness of maternal influenza and pertussis vaccines in these three 
Australian states (346). 
8.4  Research Implications 
 
The findings of the studies in this thesis have a number of implications for public health practice 
and maternal vaccination programs. The results from the systematic review have reinforced the 
important role that healthcare providers play in driving vaccination uptake among pregnant 
women. In countries where routine maternal vaccination is implemented, policy makers and 
program managers for vaccination and antenatal care programs should consider strategies for 
alerting healthcare providers to target unvaccinated pregnant women and offering them the 
recommended vaccination during pregnancy. Incorporating an automated reminder within 
electronic medical records or medical case note reminders in an antenatal care setting may 
encourage healthcare provider–patient discussions on the safety, effectiveness and importance 
of the routinely recommended vaccines during pregnancy.  
Furthermore, the use of provider reminders or an alert system would facilitate antenatal care 
providers to administer the vaccine at a moment when the pregnant women can act immediately 
with a minimum of additional time, effort or cost. Provider reminder or alert system to prompt 
healthcare providers could be implemented on the GP, obstetrics and antenatal shared care 





Systemic changes are required to incorporate alerts or reminders in medical records in 
combined settings for successful maternal vaccination programs.  
The review findings also suggest that provision of maternal vaccination by midwives at the 
place of antenatal service is another effective strategy that can be considered by regional, 
national and international antenatal health policy makers for improving the success of maternal 
vaccination programs. The midwife vaccine delivery program is a relatively low-cost 
intervention and can also be feasible in low resource settings where well-functioning midwifery 
programs are incorporated. Training and equipping midwives with knowledge and skills to 
engage with pregnant women on the topic of the recommended maternal vaccinations and 
allowing them to administer the routinely recommended vaccinations to pregnant women using 
a standing medication order, without the requirement for a prescription from a medical doctor 
should be considered. Importantly, maternal vaccination programs should incorporate the 
recommended vaccines during pregnancy, as part of standard antenatal care.  
The findings of this thesis can be utilized in developing a toolkit to assist healthcare providers 
with managing rollout and implementation of maternal vaccination program. The SKAI 
(Sharing Knowledge About Immunising) is a communication tool developed to improve 
communication during primary health care consultations about routine childhood vaccinations 
(347). The SKAI communication tool involves assessing parental attitudes and beliefs about 
vaccines and selecting information and communication strategies tailored to address parents' 
vaccine questions and concerns (347). A similar communication tools could be designed to 
address pregnant women’s concerns about vaccine safety during pregnancy. Additionally, there 
is a need for high-quality educational interventions targeting pregnant women and highlighting 
the safety and benefits of pertussis as well as influenza vaccination during pregnancy. High 
quality educational materials should be provided in a range of formats including posters, 





be tailored to different vulnerable high-risk groups, particularly to Indigenous. Interventions 
designed to enhance maternal vaccination uptake among Indigenous women should be 
inclusive of Aboriginal healthcare workers as the primary healthcare providers in delivering 
information and offering the recommended maternal vaccines. 
Findings described in this thesis demonstrated that most expectant mothers are willing to 
receive the recommended vaccination regardless of their antenatal psychosocial profile. 
However, psychosocial factors influenced the uptake of maternal vaccines highlighting the 
need to address healthcare provider–patient barriers and emphasising the role of provider 
cognisance of psychosocial factors in improving maternal vaccination rates. Mental health 
midwives or nurses are well positioned to recommend vaccines to pregnant women while 
undertaking psychosocial assessment. Additionally, the findings of this thesis could aid the 
implementation of maternal vaccination programs and development of tailored interventions 
for women with psychological stressors in the antenatal period. Providing education to 
pregnant women is not enough, a combination of approaches is required. 
Evidence presented in the thesis provides further reassurance to expecting mothers and 
healthcare providers about the safety of pertussis vaccination during pregnancy and supports 
recommendations for pertussis vaccination during pregnancy to prevent morbidity and 
mortality associated with early-infant pertussis disease. The thesis findings also aid evidence-
based decision making for national immunisation program managers and policy-makers in 
countries considering implementation of universal maternal pertussis programs.  
Other important public health implications of the thesis findings are further evidence for the 
safety and benefits of maternal seasonal influenza vaccination that can be used to communicate 
to pregnant women, antenatal care providers, and community members. In addition to 





influenza vaccination during pregnancy, the thesis findings reaffirmed the vaccine 
effectiveness in reducing pre-delivery hospitalisations with influenza like illness. As protecting 
vulnerable newborn infants against infection is the driving factor for mothers to receive a 
vaccine during pregnancy, evidence from this thesis on the potential protective effects of 
maternal influenza vaccination in reducing small for gestational age and low birth weight 
infants could be used in educational materials for pregnant women. In countries where maternal 
influenza vaccination is recommended, the potential benefits in improving birth outcomes 
presented in this thesis can be used to encourage healthcare providers to deliver evidence-based 
information to pregnant women. Furthermore, these findings may aid policy makers and 
governing bodies in instilling and improving public confidence in maternal influenza 
vaccination. Importantly, the potential benefits of receiving influenza vaccine during 
pregnancy in improving neonatal health outcomes can be important for countries weighing up 
the additional benefits of incorporating maternal influenza vaccination programs. This may be 
particularly important for low-and middle-income countries where the rates of low birthweight 
and small for gestational age births occur inordinately, resulting in long term consequences for 
offspring health and health systems have poor capacity to mitigate short and long-term effects.  
8.5  Future Directions 
 
Additional research should focus toward developing effective interventions that target 
healthcare providers as well as pregnant women to improve maternal pertussis and seasonal 
influenza uptake. With the potential for more vaccines to be incorporated to the antenatal 
vaccination programs, it is important to determine factors associated with vaccine decision 
making during pregnancy and design effective interventions to improve maternal vaccine 





Respiratory syncytial virus (RSV) (348) and Group B streptococcus (GBS) (349) vaccines are 
new vaccines in development or currently in clinical trials for pregnant women. A recent large-
scale efficacy trial demonstrated that maternal RSV vaccine decreased the risk of 
hospitalisation with RSV during pregnancy by around 44% and reduced hospitalisation for 
infants with severe RSV disease by almost 50% (348). However, vaccine efficacy against RSV-
associated medically significant lower respiratory tract infection in the first 3 months of life 
was 39% and did not meet prespecified criteria for vaccine efficacy, warranting further research 
(348).  
The current global coronavirus disease 2019 (COVID-19) pandemic calls for a revisiting of 
frameworks for the inclusion of pregnant women in the development and deployment of 
COVID-19 vaccines (350). Pregnant women are not placed among the highest priority groups 
when COVID-19 vaccines are approved for use. However, mounting evidence suggest 
pregnant women are at increased risk of respiratory failure with the need for admission to 
intensive care and mechanical ventilation following confirmed COVID-19 infection compared 
with non-pregnant women of similar age (351, 352). Additionally, a growing body of evidence 
suggests women with confirmed COVID‐19 in early pregnancy are at increased risk of preterm 
birth (353) and stillbirth (354). COVID-19 vaccines in pregnancy will be an important 
consideration for antenatal vaccination programs. The methods established as part of this thesis 
to provide reassuring evidence on safety and identifying predictors of maternal vaccine uptake 
could be adopted in future research of potential COVID-19 and other new maternal vaccines. 
The new Australian guidelines recommend pregnant women to receive a pertussis vaccine in 
each pregnancy (including pregnancies that are closely spaced) from 20 weeks of gestation 
rather than 28 weeks to maximise the opportunity for vaccination to protect all infants, 
including preterm infants (44). Healthcare providers could use the routine morphology scan at 





prompt to offer pertussis vaccine or schedule a vaccination visit. A wider opportunity for 
maternal pertussis vaccination could also potentially increase concomitant administration of 
influenza vaccine. There is a need for continued surveillance and monitoring to confirm 
whether a broader window for pertussis vaccination during pregnancy and concomitant 
administration with influenza vaccination is safe for the mother and the newborn. Additionally, 
the safety of closely spaced doses in successive pregnancies should be explored. The time-to-
event analytic approach used in this thesis could be utilised when conducting future studies on 
the safety of administrating pertussis vaccine from 20 weeks gestation with seasonal maternal 
influenza vaccination exposure as a time-dependent covariate.  
Currently, seasonal influenza vaccine in Australia is available almost all year round for 
pregnant women due to the variability of peak influenza activity between years (355). The 
updated recommendation for pregnant women who received an influenza vaccine in the 
preceding year is to revaccinate if the influenza vaccine becomes available in the current year 
before the end of pregnancy (355). Moreover, the current recommendation for women who 
receive pre-conception influenza vaccine is to revaccinate during pregnancy to protect the 
unborn infant (355). Ongoing changes to recommendations require monitoring of vaccine 
safety and effectiveness particularly for receipt of two doses of inactivated influenza vaccine 
during the same pregnancy, and receipt of influenza vaccination during the preconception 
period and during pregnancy. 
 
8.6  Concluding Remarks 
 
The body of work provides reassuring evidence on the safety of maternal pertussis and seasonal 
influenza vaccination for both mothers and their newborn infants. Maternal seasonal influenza 





influenza-like illness. Additionally, this thesis demonstrated potential protective effects of 
maternal influenza vaccination in improving neonatal health outcomes by modestly reducing 
the risk of delivering small for gestational age and low birth weight infants during periods of 
high influenza activity. Results from this thesis have identified a range of psychosocial factors 
influencing uptake of pertussis and influenza vaccination that can be used in designing and 
targeting effective interventions. Furthermore, the thesis findings provided evidence-based 
information for optimising effective communication between healthcare providers and 
expectant mothers about maternal vaccines. Healthcare provider prompts, incorporation of 
maternal vaccinations as part of standard antenatal care, and implementation of midwife 
delivered maternal vaccination programs are the most effective strategies to maximise uptake 
of pertussis vaccine among pregnant women to mitigate pertussis associated morbidity and 
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What are the most effective interventions used to improve pertussis vaccination uptake in pregnant women?
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Society for Pediatric Infectious Diseases (WSPID).
 
Types of study to be included
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Intervention(s), exposure(s)
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Data extraction (selection and coding)
Titles of studies retrieved using the search strategy and those from additional sources will be screened
independently by two review authors to identify studies that potentially meet the inclusion criteria outlined
above. The full texts of these potentially eligible studies will then be retrieved and independently assessed
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criteria take into account the consistency, directness, and precision of the results.
 
Strategy for data synthesis
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Section/topic  # Checklist item  
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on page #  
TITLE:  A systematic review of interventions used to improve uptake of pertussis vaccination in pregnancy  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
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METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
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Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4(see 
Table 1) 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
see S2 
Table 




Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
5,6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
5,6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
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Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  5,6  
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
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RESULTS   
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7, Fig 1 
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provide the citations.  
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Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  8,9 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
10 (table 
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Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-13 
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Table 3) 




Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  n/a 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
13-16 
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Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
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Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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(Pregnant women [MH] OR Pregnan*[ALL] OR Maternal* [ALL]) AND (Pertussis vaccine 
[MH] OR Pertussis vaccin*[ALL] OR Whooping cough vaccin*[ALL] OR Diphtheria-
Tetanus-acellular Pertussis Vaccin* [ALL] OR DTaP Vaccin* [ALL] OR Diphtheria-
Tetanus-Pertussis Vaccin*[ALL) NOT (ANIMALS[MH] NOT Humans[MH]) 
1 AND 2  
Hits= 578 
Filter= Pub dates 10 years  
Hits= 350 
PMC 
(Pregnant women [majr] OR Pregnant[ALL] OR Pregnancy[ALL] OR  Maternal [ALL]) 
AND (Pertussis vaccine [majr] OR Pertussis vaccin*[ALL] OR Whooping cough 
vaccin*[ALL] OR Diphtheria-Tetanus-acellular Pertussis Vaccin* [ALL] OR DTaP Vaccin* 
[ALL] OR Diphtheria-Tetanus-Pertussis Vaccin*[ALL) NOT (ANIMALS[MH] NOT 
Humans[MH]) 
Hits =1631 
Filter= Pub dates 10 years   
Hits= 865 
Medline- Ovid 
1. exp *Pregnant women/ 
2. Pregnan$.MP. 
3. Maternal$ .MP. 
4. 1 or 2 or 3 AND  
5. exp *Pertussis vaccine/ 
1. Pertussis vaccine 
 
Pertussis vaccine [majr] OR 




Pertussis Vaccin* [ALL] OR 
DTaP Vaccin* [ALL] OR 
Diphtheria-Tetanus-Pertussis 
Vaccin*[ALL]  
2. Pregnant women 
 
Pregnant women [majr] OR 
Pregnan*[ALL] OR 




6. Pertussis vaccin$.MP.  
7. Whooping cough vaccin$.MP.  
8. Diphtheria-Tetanus-acellular Pertussis Vaccin$ .MP.  
9. DTaP Vaccin$ .MP.  
10. Diphtheria-Tetanus-Pertussis Vaccin$.MP. 
11 5 or 6 or 7 or 8 or 9 or 10 
12.   4 and 11 
13 limit 12 to yr= "2006 -Current" 
14. Humans/ 
15. exp animals/ 
16.15 NOT 14 
17. 13 NOT 16 
Hits= 1946 
CINAHL 
#  Query  
S13  S9 AND S12  
S12  (MM "Pertussis Vaccine") OR TX "Pertussis vaccin*" OR TX "Whooping cough 
vaccin*" OR TX "DTap vaccin*"  
S11  (MM "Pertussis Vaccine")  
S10  (MH "Pertussis Vaccine+")  
S9  (MM "Expectant Mothers") OR TX Pregnan* OR TX Maternal*  
S8  (MM "Expectant Mothers")  
S7  S2 AND S5  
S6  S2 AND S5  
S5  (MM "Pertussis Vaccine") OR TX "Pertussis vaccin*" OR TX "Whooping cough 
vaccin*" OR TX "DTap vaccin*"  
S4  (MM "Pertussis Vaccine")  
S3  (MH "Pertussis Vaccine+")  
S2  (MM "Expectant Mothers") OR TX Pregnan* OR TX Maternal*  




Combined hits after removing duplicated articles on Endnotes= 1935 
 
Other Sources 
I. European Society for Paediatric Infectious Diseases (ESPID) 
Abstracts from 2011- 2016 
Hits = 0 
II. World Society for Paediatric Infectious Diseases (WSPID) 
WSPID 2015 and WSPID 2013 and WSPID 2011   
Hits= 0 
III. International Congress on Infectious Diseases (ICID)= 0 












S3 Table. Quality assessment of the reviewed randomized controlled trials 
 
 


















































High risk of bias 
15% of the control group and 
10% in intervention groups 




High risk of bias 
The study did not 
validate vaccination 
from vaccination 
records as described 




High risk of bias 
Quote: “limited to 
African American 














Insufficient number of 






assigned by a coin 




















High risk of bias.   
 
Quote”16 (3%) did not 
complete the survey due to 
technical problems with the 
electronic device” 
 
Comments: The proportion of 
missing outcomes compared 
with observed event risk was 
not enough to induce relevant 
bias in intervention effect 
estimates. 
Judgement 
Low risk of bias 
Quote “intention to 
receive the vaccine; 
and to determine 
associations between 
health perceptions 








Quote “the majority 
of patients were of 
low socioeconomic 
level and had 
limited health 















Sufficient number of 
participants in both 
arms  
 
A sample of 250 was 



















using a coin toss 
by blinded 
statistician on 
paired practices.  
 
Judgement 






assignment.   
 
Judgement 





High risk of bias 
Quote “Of the 48 women who 
did not complete the follow-up 
questionnaire, equal 
proportions were from the 
intervention (n = 24) and 
control (n = 24) groups”  
 
Comments: 
The proportion of missing 
outcomes compared with 
observed event risk was not 
enough to induce relevant bias 
in intervention effect estimates. 








Low risk of bias 
Self-report was the 
primary method 
used to judge if a 














“since the study was 
designed to detect 
differences in 
antenatal vaccine 
receipt, we likely 
lacked the sample size 
necessary to detect 






detect a difference on 
outcome 
Moderate 
S4 Table. Quality assessment of the reviewed observational studies  
 
           Quality assessment Morgan (25) 
 
Healy (32) Mohammed (34) 
 
 Yes No Unclear Yes No Unclear Yes No Unclear 
1. Is it clear in the study what is the cause’ and what is the ‘effect’ (i.e. 
there is no confusion about which variable comes first)? 
Y   Y   Y   
2. Were the participants included in any comparisons similar?    U   U   U 
3. Were the participants included in any comparisons receiving similar 
treatment/care, other than the exposure or intervention of interest? 
  U  N  Y   
4. Was there a control group? Y   Y   Y   
5. Were there multiple measurements of the outcome both pre and post 
the intervention/exposure? 
 N   N   N  
6. Was follow-up complete, and if not, was follow-up adequately 
reported and strategies to deal with loss to follow-up employed? 
  U   U Y   
7. Were the outcomes of participants included in any comparisons 
measured in the same way?  
Y   Y   Y   
8. Were outcomes measured in a reliable way? Y   Y    N  
9. Was appropriate statistical analysis used? Y    N  Y   
S5 Table. Characteristics of the excluded studies  
 
Study ( year) Reasons for exclusion 
Donaldson (2015) No standard care group was available for 
comparison 
Barber (2017) No intervention component ( Adequate 
prenatal care is not an intervention) 
Manzoni  ( 2016) Ineligible participants: study was not directed 
to pregnant women only 
Celikel ( 2013) Pertussis vaccination uptake was not included 
Goldfarb (2014) No standard care or comparator group 
Mazzoni ( 2016) Ineligible participants: study was not directed 
to pregnant women only 
Bonville ( 2015) No intervention component 
Maertens (2016) No intervention component 
Kharbanda ( 2011) study was directed to postpartum 







Appendix B – Supplementary materials for Chapter 6  
 
 STROBE (Strengthening The Reporting of Observational Studies in Epidemiology) 
Checklist 
 Supplementary Table 1. Comparison of women included and excluded from the study 
(for whom data are available) in terms of key variables of interest 
 Supplementary Table 2. Time-based pregnancy and birth outcomes by maternal 
influenza vaccination status after controlling for the receipt of a pertussis vaccine in 
pregnancy at two obstetric hospitals in South Australia 2015-2018 
 Supplementary Table 3. Crude and adjusted hazard ratios for pre-delivery 
hospitalisation due to influenza like illness and key adverse birth outcomes stratified by 
trimester of influenza vaccination and influenza activity after controlling for the receipt 
of maternal pertussis vaccination. 
 Supplementary Table 4. Pregnancy and birth outcomes following influenza vaccination 
in pregnancy after controlling for the receipt of a pertussis vaccine in pregnancy at two 













STROBE (Strengthening The Reporting of OBservational Studies in Epidemiology) Checklist  
 
A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript 
where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript 
accordingly before submitting or note N/A. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published 
examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web 
sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology 
at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
 





Title and Abstract  1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract  
 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found   
 
Introduction  
Background/Rationale 2 Explain the scientific background and rationale for the investigation being 
reported   
 
Objectives 3 State specific objectives, including any prespecified hypotheses   
Methods  
Study Design 4 Present key elements of study design early in the paper   
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection  
 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up  
Case-control study—Give the eligibility criteria, and the sources and methods of 
case ascertainment and control selection. Give the rationale for the choice of 
cases and controls  
Cross-sectional study—Give the eligibility criteria, and the sources and methods of 
selection of participants 
 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed  
Case-control study—For matched studies, give matching criteria and the number 
of controls per case   
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable  
 







8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group   
 
Bias 9 Describe any efforts to address potential sources of bias    
Study Size 10 Explain how the study size was arrived at    
Quantitative Variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why  
 
Statistical Methods 12 (a) Describe all statistical methods, including those used to control for 
confounding   
 
(b) Describe any methods used to examine subgroups and interactions    
(c) Explain how missing data were addressed   
(d) Cohort study—If applicable, explain how loss to follow-up was addressed  
Case-control study—If applicable, explain how matching of cases and controls was 
addressed   
Cross-sectional study—If applicable, describe analytical methods taking account of 
sampling strategy   
 
(e) Describe any sensitivity analyses   
Results     
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
 
  (b) Give reasons for non-participation at each stage    
  (c) Consider use of a flow diagram    
Descriptive Data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders    
 
  (b) Indicate number of participants with missing data for each variable of interest    
  (c) Cohort study—Summarise follow-up time (eg, average and total amount)     
Outcome Data 15* Cohort study—Report numbers of outcome events or summary measures over 
time   
 
  Case-control study—Report numbers in each exposure category, or summary 
measures of exposure   
 
  Cross-sectional study—Report numbers of outcome events or summary measures    





Main Results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence interval). Make clear which confounders 
were adjusted for and why they were included   
 
  (b) Report category boundaries when continuous variables were categorized    
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period   
 
Other Analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses   
 
Discussion    
Key Results 18 Summarise key results with reference to study objectives    
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias   
 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence   
 
Generalisability 21 Discuss the generalisability (external validity) of the study results    
Other Information    
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based   
 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in 
cohort and cross-sectional studies. 
 
Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this 




Title: Safety and protective effects of maternal influenza vaccination on pregnancy and birth outcomes: A 
prospective cohort study 
Authors:  Hassen Mohammed, BHSc-Hons,1,2,3  Claire T Roberts, PhD 2,3,4, Luke E Grzeskowiak, PhD,2,3,5 
Lynne Giles, PhD,2,3,6 Gustaaf A Dekker, MD,2,3,7 Helen S Marshall, MD,1,2,3,6 
Supplementary Material: 
 
Supplementary Table 1: Comparison of women included and excluded from the study (for whom data are 
available) in terms of key variables of interest  





















Pre-delivery hospitalisation due to influenza like illness 5/93 (5.3) 95/1253 (7.5) 
Spontaneous abortion 5/93 (5.3) 34/1253 (2.7) 
Gestational hypertension 5/76 (6.5) 81/1205 (6.7) 
Pre-eclampsia 10/77 (12.9) 111 /1205 (9.2) 
Preterm birth 7/79 (8.8) 89/1207 (7.3) 
LBW 5/77 (6.4) 80/1205 (6.6) 
LBW at term 2/70 (2.8) 29 /1116 (2.6) 
SGA 11/76 (14.4) 142/1203 (11.8) 
2 
 
Supplementary Table 2: Time-based pregnancy and birth outcomes by maternal influenza vaccination status 
after controlling for the receipt of a pertussis vaccine in pregnancy at two obstetric hospitals in South Australia 
2015-2018 
CI=confidence interval. HR=hazard ratios. LBW=low birthweight. SGA=small for gestational age.  
* HR results compared outcome variable in vaccinated group to reference (unvaccinated).  
† Adjustments were made for pertussis vaccine in pregnancy, maternal age, race/ethnicity, education, household income, gravidity, intake of 
alcohol and recreational drugs, smoking, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal· 
Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment, 
asthma and estimated season of delivery. 
‡ Women admitted to hospital with influenza/ acute respiratory tract infection were censored at their admission date. 
§ For hypertensive disorders analysis, women who were vaccinated at or after the gestational age at diagnosis (≥ 20 weeks' gestation) and 
pregnancies ending prior to 20 weeks of gestation were censored.  
|| Women who were vaccinated at or after the gestational age at diagnosis of gestational diabetes mellitus (median gestational age at screening 
was 27·8 (IQR, 26·5-29) weeks) were censored.  
¶ Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of preterm birth. 
** Additionally adjusted for infant's sex. 



























aHR (95% CI) 
p-value 
Pre-delivery hospitalisation due to 
influenza like illness ‡ 
 
Accounting the 2-weeks period 






















  0·60 (0·37, 0·98) 
 




  0·044 
 
Gestational hypertension § 81/1205 (6·7) 41/606 (6·7) 
 
40/599 (6·6) 0·80 (0·49, 1·31) 0·391 0·72 (0·43, 1·21) 0·299 
Pre-eclampsia § 111/1205 (9·2) 58/606 (9·5) 53/599 (8·8) 0·85 (0·58, 1·26) 0·445 0·89 (0·57, 1·38) 0·622 
Severe pre-eclampsia § 28/1204 (2·3) 14/606 (2·3) 14 /598 (2·3) 0·86 (0·37, 1·96) 0·725 0·68 (0·25, 1·81) 0·450 
Gestational diabetes || 190/1207 (15·7) 85/608 (13·9) 105/599 (17·5) 1·33 (0·95, 1·84) 0·088 1·10 (0·75, 1·60) 0·611 
Preterm premature rupture of the 
membranes ¶  
47/1207 (3·8) 27/608 (4·4) 20/599 (3·3) 0·82 (0·43, 1·56) 0·561 0·90 (0·44, 1·82) 0·722 




89/1207 (7·3) 49/608 (8·0) 40/599 (6·6) 
 












 Spontaneous preterm birth 
¶ 
 




0·71 (0·38, 1·32) 0·287 
 
LBW (<2500 g) ** 
 
 























 SGA **  
 
 




0·91 (0·62, 1·34) 0·710 
 
    Difference in means                                                                                                                   
(vaccinated-unvaccinated) 
 
Difference in adjusted means
(vaccinated - unvaccinated) 
 
Mean birth weight h, g    
(95% CI) 
3360·3± 505 3343·7 ± 526 
 
 













 Mean gestational age at delivery, 

























Supplementary Table 3: Crude and adjusted hazard ratios for pre-delivery hospitalisation due to influenza like 
illness and key adverse birth outcomes stratified by trimester of influenza vaccination and influenza activity after 






HR * (95% CI) 
p-
value 
Adjusted †, ‡ 




Pre-delivery hospitalisation due to 






Low influenza activity 
High influenza activity 
 
 
60/650 (9·2) 35/603 (5·8) 0·58 (0·37, 0·91) 
 
 
0·43 (0·18, 0·99) 
0·09 (0·01, 0·68) 
0·70 (0·43, 1·13) 
 
0·58 (0·33, 0·99) 











0·60 (0·37, 0·97) 
 
 
0·45 (0·19, 1·08) 
0·09 (0·01, 0·71) 
0·71 (0·41, 1·22) 
 
0·59 (0·33, 1·04) 




















Low influenza activity 
High influenza activity 
 
49/608 (8·0) 40/599 (6·6) 
 
0·94 (0·60, 1·47)  
 
0·46 (0·18, 1·16) 
0·91 (0·43, 1·93) 
0·79 (0·47, 1·33) 
 
0·61 (0·33, 1·12) 













1·01 (0·61 1·66)  
 
0·51 (0·19, 1·32) 
0·93 (0·42, 2·03) 
0·77 (0·44, 1·37) 
 
0·62 (0·34, 1·17) 















Low influenza activity 
High influenza activity 
 
36/608(5·9) 23/599 (3·8) 0·71 (0·40, 1·26)  
 
0·37 (0·11, 1·22) 
0·61 (0·21, 1·73) 
0·61 (0·31, 1·18) 
 
0·53 (0·25, 1·11) 









0·71 (0·38, 1·32) 
 
0·39 (0·11, 1·32) 
0·57 (0·20, 1·69) 
0·59 (0·29, 1·21) 
 
0·52 (0·24, 1·13) 















Low influenza activity  
High influenza activity 
 
 
49/606 (8·0) 31/599 (5·1) 0·70 (0·42, 1·14)  
 
0·56 (0·24, 1·35) 
0·47 (0·16, 1·30) 
0·57 (0·32, 1·03) 
 
0·66 (0·37, 1·19) 









0·81 (0·47, 1·39) 
 
0·58 (0·24, 1·41) 
0·44 (0·15, 1·28) 
0·66 (0·35, 1·22) 
 
0·67 (0·36, 1·24) 









LBW at term  
(<2500 g) ||, ¶  , ** 
 
Low influenza activity  




20/557 (3·5) 9 /559 (1·6) 0·43 (0·18,1·09) 
 
 
0·61 (0·24, 1·54) 






0·38 (0·15, 0·94)  
 
 
0·47 (0·17, 1·26) 













Low influenza activity  




83 /608 (13·6) 61/599 (10·1) 0·77 (0·55, 1·09) 
 
1·15 (0·71, 1·86) 
0·79 (0·42, 1·49) 
0·57 (0·36, 0·89) 
 
0·88 (0·59, 1·32) 









0·91 (0·62, 1·34) 
 
1·27 (0·77, 2·11) 
0·84 (0·43, 1·61) 
0·66 (0·40, 1·08) 
 
0·98 (0·64, 1·50) 









CI=confidence interval. HR=hazard ratios. LBW=low birthweight. SGA=small for gestational age.  
* HR results compared outcome variable in vaccinated group to reference (unvaccinated).  
† Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, 
smoking, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal· Depression Scale (EPDS), 
The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment, asthma and estimated 
season of delivery. 
‡ Additionally adjusted for receipt of pertussis vaccine during pregnancy. 
§  Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of having a preterm birth.  
||  Additionally adjusted for infant's sex. 
¶ Low birthweight at term (<2500 g and ≥ 37 completed weeks’ gestation at birth). 
** Analysis by trimester of influenza vaccination was not performed because a small number of mothers who delivered LBW at term babies 






Supplementary Table 4: Pregnancy and birth outcomes following influenza vaccination in pregnancy after 




* Pregnancy outcomes were adjusted for maternal age, ethnicity, total years of full time education, household income, gravidity , intake of 
alcohol and recreational drugs, smoking, pre-pregnancy body mass index (continuous) , use of multivitamin supplements, Edinburgh Postnatal· 
Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment, 
asthma and estimated season of delivery. Birth outcomes were additionally adjusted for infant's sex.  
† Additionally adjusted for receipt of pertussis vaccine during pregnancy. 
‡ Poisson regression model was used because the log binomial model failed to converge for the adjusted model. 
§ Reasons for admission:  Preterm, Respiratory distress Infection, Feeding problem, Hypoglycaemia, Drug withdrawal, SGA, Birth asphyxia, 

























Risk Ratios  














haemorrhage   
113/1205 (9·3) 62/606 (10·2) 51/599 (8·5) 0·79 (0·55, 1·14) 0·215 0·73 (0·49, 1·09) 0·129 
Caesarean delivery 
(Vs Vaginal) ‡ 
349/1205 (28·9) 176/606 (29·0) 173/599 (28·8) 1·01 (0·93, 1·08) 0·758 0·91 (0·79, 1·05) 0·239 
Birth outcomes          
Low Apgar at 1 min 
(<7) 
151/1201 (12·5) 72/603 (11·9) 79/598 (13·2) 1·13 (0·83, 1·53) 0·433 1·26 (0·90, 1·77) 0·160 
Low Apgar at 5-min 
(<7) 
31/1203 (2·5) 16/604 (2·6) 15/599 (2·5) 0·93 (0·44, 1·97) 0·874 1·05 (0·46, 2·39) 0·902 
Admitted to Neonatal 
unit § 
282/1207 (23·3) 140/608 (23·0) 142/599 (23·7) 0·98 (0·80, 1·22) 0·780 1·12 (0·89, 1·40) 0·309 
Respiratory distress 
syndrome 
14/1207 (1·1) 10/608 (1·6) 4/599 (0·6) 0·40 (0·12, 1·26) 0·120 0·78 (0·20, 2·95) 0·722 
Mechanical 
ventilation 





Appendix C – Supplementary materials for Chapter 7   
 
 Table S1. Crude and adjusted hazard ratios sensitivity analysis for time-based 
pregnancy and birth outcomes by maternal pertussis vaccination status adjusted for 
maternal influenza vaccination at two obstetric hospitals in South Australia 2015-
2018. 
 Table S2. Pregnancy and birth outcomes following pertussis vaccination during 
pregnancy adjusted for maternal influenza vaccination at two obstetric hospitals in 






















Table S1. Crude and adjusted hazard ratios sensitivity analysis for time-based pregnancy and birth 
outcomes by maternal pertussis vaccination status adjusted for maternal influenza vaccination at two 
obstetric hospitals in South Australia 2015-2018.  
 
CI, confidence interval; HR, hazard ratios; LBW, low birthweight; SGA, small for gestational age 
a: Denominators differ due to missing data. 
b: Adjusted aHR results compared outcome variable in vaccinated group to reference (unvaccinated).  
c: Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, 
smoking, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal Depression Scale (EPDS), The 
State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment, and asthma. Birth outcomes 
were additionally adjusted for infant's sex. 
d: Additional adjustments were made for influenza vaccination during pregnancy 
e: For hypertensive disorders analysis, women who were vaccinated at or after the gestational age at diagnosis were censored. 
f: Women admitted to hospital with respiratory tract infection/influenza like illness were censored at their admission date 
g: Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of preterm birth.  
























Adjusted b, c  
aHR (95% CI) 
p-
value 
Adjusted  c, d 
aHR (95% CI) 
p-
value 
Gestational hypertension e 86/1267 (6.7) 10/249 (4.0) 
 
76/1018 (7.4) 1.24 (0.66, 2.30) 0.497 1.33 (0.70, 2.53) 0.368 
Preeclampsiae 116/1268 (9.1) 26/250 (10.4) 90/1018 (8.8) 0.75 (0.47, 1.18) 0.220 0.74 (0.46, 1.20) 0.226 
Pre-delivery hospitalization due 






















Preterm premature rupture of the 
membranes g 
42/1272 (3.3) 12/263(4.7) 30/1019 (2.9) 0.99 (0.47, 2.07) 0.987 1.06 (0.48, 2.31) 0.878 




82/1272 (6.4) 21/253 (8.3) 61/1019 (5.9) 
 












Spontaneous preterm birth g 
 








Birth outcomes        
LBW (<2500 g) 
 
 




0.80 (0.44, 1.45) 
 
0.472 
























0.83 (0.55, 1.28) 
 
0.418 








Mean birth weight, grams    
(95% CI) 
3368.0 ± 496.2 3313 ± 565.3 
 
 














Mean gestational age at delivery, 




















Table S2. Pregnancy and birth outcomes following pertussis vaccination during pregnancy adjusted for 
maternal influenza vaccination at two obstetric hospitals in South Australia 2015-2018  
 
a: Denominators differ due to missing data. 
b: Pregnancy outcome were adjusted for maternal age, ethnicity, total years of full-time education, household income, gravidity, intake of 
alcohol and recreational drugs, smoking, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal. 
Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), physical activity, infertility treatment, 
and asthma. Birth outcomes were additionally adjusted for infant's sex.  
c: Additionally adjusted for receipt of influenza vaccine during pregnancy. 
d: Reasons for admission:  preterm, respiratory distress infection, feeding problem, hypoglycaemia, drug withdrawal, SGA, birth asphyxia, 












Adjusted b  
aRR (95% CI) 
p-
value 
Adjusted b, c 





23/1272 (1.8) 7/253 (2.7) 16/1019 (1.5) 0.71 (0.27, 1.82) 0.481 0.60 (0.21, 1.70) 0.399 
Placental abruption 32/1266 (3.3) 7/250 (2.8) 25/1016 (2.4) 1.04 (0.41, 2.62) 0.923 0.98 (0.35, 2.75) 0.978 
Postpartum 
haemorrhage 
115/1269 (9.0) 26/251 (10.3) 89/1018 (8.7) 0.81 (0.52, 1.26) 0.357 0.89 (0.56, 1.42) 0.923 
Birth outcomes          
Apgar at 1 min <7 149/1263 (11.8) 30/247 (12.1) 119/1016 (11.7) 0.87 (0.59, 1.29) 0.496 0.76 (0.50, 1.16) 0.213 
Apgar at 5- min <7 26/1265 (2.0) 6/248 (2.4) 20/1017 (1.9) 0.75 (0.27, 2.06) 0.582 0.71 (0.24, 2.01) 0.521 
Admitted to Neonatal 
unit d 
285/1272 (22.4) 65/253 (25.6) 220/1019 (21.5) 0.84 (0.66, 1.07) 0.177 0.82 (0.63, 1.06) 0.136 
Respiratory distress 
syndrome  
10/1272 (0.7) 3/253 (1.1) 7/1019 (0.6) 0.61 (0.20, 1.82) 0.384 0.64 (0.18, 2.24) 0.495 
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 During the period of candidature, the candidate led the publication of the following 
article which was included in the systematic review and relate to the body of work 
described in this thesis. 
 Findings of this study has been used by the Commonwealth Government to develop 
key messages for pregnant women and their partners about the importance of maternal 
immunisation.   
 Cited 38 times 
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Maternal immunization is an effective strategy to protect pregnant women and their infants
from vaccine-preventable diseases. Despite the recommendation of maternal influenza and
more recently pertussis immunization in Australia, uptake of these vaccines has been sub-
optimal. A midwife delivered immunization program for pregnant women at the Women’s
and Children’s Hospital in South Australia commenced in April 2015. Monitoring the uptake
of the current funded vaccine programs for pregnant women is limited. The study aimed to
estimate maternal vaccine uptake and assess factors associated with influenza and pertus-
sis vaccine uptake among pregnant women.
Methods
This prospective study was undertaken between November 2014 and July 2016 at the
Women’s and Children’s Hospital. Following consent, demographic details and vaccination
history for South Australian pregnant women who attended the antenatal clinic were col-
lected. A standardised self-reported survey was completed during pregnancy with a follow
up telephone interview at 8–10 weeks post-delivery.
Results
205 women consented and completed the self-reported survey. Of the 180 pregnant women
who completed the study, 76% and 81% received maternal influenza and pertussis vaccines
respectively. The adjusted odds of women receiving maternal vaccines during pregnancy
were significantly higher for women delivering after the implementation of the midwife deliv-
ered program compared with women who delivered babies prior to the program for both per-
tussis vaccination (AOR 21.17, 95% CI 6.14–72.95; p<0.001) and influenza vaccination
(AOR 5.95, 95% CI 2.13–16.61, p<0.001). Women receiving a recommendation from a
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health care provider and first time mothers were significantly more likely to receive influenza
vaccination during pregnancy.
Conclusions
High uptake of influenza and pertussis vaccines during pregnancy can be attained with
health care provider recommendation and inclusion of maternal immunization as part of
standard antenatal care. A midwife delivered maternal immunization program is a promising
approach to improve maternal vaccine uptake by pregnant women.
Introduction
Pregnant women are at increased risk of morbidity and death from influenza infection during
seasonal and pandemic influenza outbreaks [1–3]. This was particularly evident during the
2009 ‘H1N1’ influenza pandemic outbreak in Australia, in which the admission rate of preg-
nant women to an intensive care unit following infection with influenza was significantly
higher compared to non-pregnant adults [4, 5]. Infants born to women affected by influenza
during pregnancy are at increased risk of adverse birth outcomes such as preterm birth and
low birthweight [6]. Similarily, Bordetella pertussis infections can also pose high risk to infants
prior to their receipt of a complete primary course of pertussis immunization [7,8].
Immunization of pregnant women with influenza and pertussis has now been shown to be
effective in not only protecting the mother but also the fetus /newborn via transfer of transpla-
cental antibodies [9, 10] and through breastfeeding [11]. Maternal pertussis vaccination at
least 7 days before delivery can prevent up to 91% of pertussis disease in infants under 3
months of age [12]. Similarly, influenza vaccination during pregnancy can prevent up to 91%
of influenza related hospital admissions in infants under 6 months of age [13] and has been
shown to reduce influenza infections in pregnant women [14]. The safety of maternal influ-
enza and pertussis immunization is well established, with no reports of serious adverse compli-
cations to the unborn infant and pregnant women [15, 16]. Concomitant influenza and
pertussis vaccination will occur in pregnancies that overlap with the influenza season, with the
potential for different responses compared to separate adminsation of the vaccines in pregnant
women [17]. However, a study evaluating the safety of co-administering pertussis-containing
vaccine (Tdap) and influenza vaccines in pregnant women has not found an increased risk of
adverse events [18].
The Australian Immunisation Handbook was updated in March 2015 to recommend per-
tussis-containing vaccine (Tdap) for all pregnant women during the third trimester of each
pregnancy [19]. State government funded pertussis vaccination programs for pregnant women
were introduced progressively between August 2014 and June 2015 in all Australian states and
territories [20]. All Australian states provide pertussis vaccine for pregnant women via general
practitioners and hospital antenatal clinics, local councils, community health care centres, and
obstetricians. In South Australia, the funded vaccine was introduced from April 2015 and
accompanied with a large state-wide promotional campaign targeting health professionals and
pregnant women [20]. Influenza immunization for pregnant women has been supplied free of
charge and recommended at any time during pregnancy in Australia through the National
Immunization Program since 2010 [19]. Additionally, a midwife delivered maternal immuni-
zation program for influenza and pertussis vaccine was introduced in the antenatal clinic at
the Women’s and Children’s Hospital in South Australia (WCH) from April 2015. This
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program enables registered midwives to administer maternal influenza and pertussis vaccina-
tion using a standing medication order, without the need for a prescription from a medical
doctor [19].
Despite the recommendation of maternal influenza and more recently pertussis vaccina-
tions in Australia, uptake of the recommended vaccines has historically been poor. Maternal
influenza vaccine uptake in Australia has been estimated to range from about 7% to 40% [21–
26]. However, these estimates are usually derived from relatively small sample studies. There
are no published data on national maternal pertussis vaccine coverage in Australia. It is impor-
tant to monitor and evaluate the impact of government funded pertussis vaccination programs
for pregnant women and determine strategies to maximize uptake of vaccination for this pop-
ulation group. The primary objective of this study was to identify factors associated with the
uptake of pertussis and influenza vaccines during pregnancy and to determine the uptake of
influenza and pertussis vaccines among pregnant women in South Australia.
Materials and methods
Study population and design
This observational prospective study was undertaken between Nov-2014 and Jun-2016 at the
WCH (a major tertiary maternity hospital in South Australia with an annual birth cohort of
approximately 5000). Participation involved answering 26 questions about vaccination for pro-
tection against influenza and pertussis. A total of 300 pregnant women were approached and
invited to participate in this research study. Participation in the survey was voluntary. A
research nurse/medical officer discussed the study with the participants prior to obtaining
written informed consent
Eligibility criteria
Pregnant women were eligible to participate if they were aged 18 years or over at the time of
enrolment and had sufficient understanding of the English language. Pregnant women were
eligible to partake in this study regardless of their gestational stage or expected delivery date.
Data collection instrument
A standardised self-report questionnaire was designed to collect socio-demographic details
and information on awareness and uptake of the recommended maternal influenza and per-
tussis immunizations among pregnant women. A follow up telephone interview were con-
ducted 8–10 weeks post-delivery. Participants were classified as ‘lost to follow- up’ and
omitted from the analysis, if incorrect contact details were provided, if they refused further
participation, or did not answer six phone call attempts at different times and on different
days. The follow up telephone interview included questions to confirm whether they received
influenza and/or pertussis vaccination during their pregnancy, a date and location, and if not
during pregnancy, whether they had received influenza or pertussis vaccine post birth of their
baby (See supplement). Delivery date of the woman was used to compare maternal influenza
and pertussis immunization coverage prior to and following the implementation of the mid-
wife delivered maternal immunization program. The midwife vaccine delivery program
equipped midwives with knowledge and skills to engage with pregnant women on the topic of
maternal immunizations and administer pertussis and influenza immunizations to pregnant
women [27].
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Statistical analysis
The sample size was calculated assuming 55% of pertussis vaccine uptake during pregnancy
based on a self-reported survey (FluMum cohort study) [28] in 2015 collected over a three
month period at the Women’s and Children’s Hospital in South Australia. For this study, an
expected sample size of 200 participants enabled the uptake of pertussis vaccination amongst
pregnant women to be estimated and to determine predictors of maternal influenza and per-
tussis vaccination uptake with a ±5% precision at a 95% confidence level.
Survey data were analysed using STATA Version 14. Descriptive analysis such as propor-
tions for categorical variables and mean (median) for continuous variables were calculated.
Chi squared tests (χ2) were used to determine any crude association between categorical vari-
ables. Results were considered to indicate statistical significance, if a two-tailed p-value was
less than 0.05. Univariate and multivariable logistic regression models were used to estimate
unadjusted (ORs) and adjusted odds ratios (AORs) to identify variables related to the uptake
of maternal influenza and pertussis vaccines.
Human research ethics approval
The study protocol was approved by the Women’s and Children’s Health Network Human
Research Ethics Committee (HREC/14/WCHN/3).
Results
Participant’s characteristics
Of 300 pregnant women approached at the WCH, 205 women consented and completed the
antenatal survey questionnaire. Of the 205 participants, 24 were lost to follow up for the post-
natal interview and one participant was excluded from the study because of fetal death during
the pregnancy. Overall, 180 (88%) of the enrolled participants completed both the antenatal
survey and the postnatal follow-up telephone call questionnaire (Fig 1). Data analysis was per-
formed based on the 180 participants who completed both portions of the study.
The median age of participants was 31.1 years (range 21–43 years old), similar to the
median age (30.6 years) of South Australian pregnant women reported by Australian Bureau
of Statistics (ABS) in 2014 [29]. The majority of the pregnant women who participated in this
study were born in Australia (74%) (Table 1). These sample characteristics are similar to South
Australian for pregnant women according to the 2013 Pregnancy outcome SA report [30]. No
indigenous women particpated in this study. A total of 82 (46%) of the women were first time
mothers, while 54% of the participants were multiparous (Table 1).
Uptake of the recommended maternal vaccines
Pertussis. Almost all the participants (167/180, 93%) had heard of ‘pertussis’, regardless of
their immunization status. Of the 180 participants, 66% (n = 119) were aware of the recom-
mendation of pertussis vaccination during the 3rd trimester and 46% (n = 83) were aware that
they could receive a pertussis vaccination shortly after delivery if the vaccine was not given
during pregnancy. Overall, 82% (148/180) of the participants received pertussis vaccination;
81% (n = 145/180) during pregnancy and 2% (n = 3/180) post-delivery of their baby. Overall,
63% (92/145) of the women reported receiving the vaccine during pregnancy from a midwife
during their antenatal visit at WCH, 32% (47/145) from a general practitioner (GP), 3% (4/
145) from an occupational immunization provider and 1% from a community health center.
Women who had heard of the availability of maternal pertussis vaccination prior to study par-
ticipation had almost 8 times higher odds of receiving the vaccine during pregnancy (OR 7.8,
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CI 3.3–18.3; p<0.001) (Table 2). Almost all infants 97% (175/180) were vaccinated with the
routine diphtheria, tetanus and acellular pertussis (DTaP) vaccines (scheduled at 6–8 weeks of
age).
Fig 1. Recruitment flowchart.
https://doi.org/10.1371/journal.pone.0197867.g001
Table 1. Baseline characteristics of the study population.
Study population (n = 180)
Characteristics Level Total number Percentage
Maternal Age 18–31 96 53
32–41 84 47
Born in Australia Yes 116 74
No 42 26
Parity Primiparous 82 46
Multiparous 98 54
Pregnancy trimester (at the time of enrolment) 1st 17 9
2nd 62 34
3rd 101 56
NB: Country of birth missing data, n = 22.
https://doi.org/10.1371/journal.pone.0197867.t001
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Influenza. Overall, 80% (144/180) of the women who participated in this study received
influenza vaccination; 76% (n = 136) of the participants received influenza vaccination during
pregnancy and 5% (n = 8) received the vaccine post-delivery. Overall, 38% of the women
reported receiving the vaccine during pregnancy from a general practitioner (GP), 37% from a
midwife at WCH, 8% from occupational immunization provider, 1% from a community
health center and 16% of the women failed to report where they have received the vaccine. Of
the 180 study participants, 82% of them were aware that influenza vaccine is recommended
during pregnancy, 67% were aware that they could receive influenza vaccine at any stage of
their pregnancy and 65% of the women had discussed maternal influenza vaccination with
their health care providers (HCPs). Pregnant women who had received a recommendation
from their HCP had 3 times greater odds of receiving maternal influenza vaccination than
women who had not received a recommendation (Table 3). Of the 130 women who received
influenza vaccination during pregnancy (6 participants did not report their dates of vaccina-
tion), the majority (62%, 81/130) received the influenza vaccine in April (n = 47) or May
(n = 34). A further 45 women (35%) received the vaccine during the influenza season which is
typically between May to October in South Australia, with very few women (3%) being vacci-
nated between January and March. It should also be noted that influenza vaccine has generally
not been available between January and March prior to release of the new seasonal vaccine.
Among the most common reasons women cited for not receiving the vaccine during preg-
nancy were lack of recommendations from their HCPs (28%, n = 14) (Table 4).
Maternal vaccine uptakes pre-post introduction of a midwife delivered
immunization program at WCH in SA
Pertussis. The proportion of women who received pertussis vaccine during pregnancy
following the introduction of the midwife delivered vaccination program for pregnant women
was significantly higher (140/155, 90%) compared with women who delivered prior to the
introduction of the program (5/25, 20%; p<0.001) (Fig 2). The univariate odds of women













Maternal age category 21–31 85/96 (89%) 1.00 1.00
32–43 60/82 (73%) 0.35 0.18–0.78 0.010 0.39 0.130–
1.11
0.078
Country of birth Australia 102/116(88%) 1.00
Other 32/42(76%) 0.30 0.28–2.14 0.124
Parity Primiparous 70/82 (85%) 1.00
Multiparous 75/98 (77%) 0.53 0.24–1.18 0.116
Awareness of maternal pertussis
recommendation
No 37/64 (63%) 1.00 1.00
Yes 108/117(82%) 7.78 3.31–18.2 <0.001 4.43 1.61–
12.23
0.009
A midwife delivered maternal
immunization program








aAdjusted odds ratio comparing odds of receiving pertussis vaccine during pregnancy if offered, controlling for other variables.
bOnly univariate associations with p value <0.1 were included in the multivariable logistic regression.
https://doi.org/10.1371/journal.pone.0197867.t002
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receiving maternal pertussis vaccine following the implementation of the government funded
pertussis program and midwife delivered maternal immunization program in the antenatal
clinic of the WCH was almost 32 times higher than women who delivered babies prior to the
program (OR 31.73, CI 10.24–98.27; p<0.001) (Table 2).
Influenza. Women who had received pertussis vaccine during pregnancy were also more
likely to have both been recommended the influenza vaccine during their pregnancy (90% vs
66%; p<0.001) and been immunized against influenza during pregnancy (92% vs 49%,
p<0.001) compared to pregnant women who had not received pertussis vaccine. The univari-
ate odds of women receiving influenza vaccine following the implementation of the midwife
program was 8 times higher than women who have given birth prior to the program (OR 8.0,
CI 3.06–20.9; p<0.001) (Table 3).
Table 4. Reasons cited for not receiving maternal influenza vaccination.
Reasons cited for NOT receiving the influenza vaccination during pregnancy Number (n) Percentage %
It was not suggested/recommended to me 14 28%
Prior experience of an adverse reaction after being vaccinated 8 16%
I did not know that pregnant women should be vaccinated 8 16%
I was unsure of the benefits or effectiveness of the vaccine 5 10%
Never had time to receive the vaccine 3 6%
Received the vaccine earlier this year 3 6%
I was not pregnant during the flu season 3 6%
Prefer natural immunity 2 4%
Flu vaccine exacerbates my Asthma 2 4%
Prefer to receive the vaccine after the baby is born 2 4%
NB. Women were allowed to report >1 reason.
https://doi.org/10.1371/journal.pone.0197867.t004
Table 3. Factors potentially associated with influenza vaccine uptake during pregnancy.
Univariate binomial regression Multivariable binomial regression











Maternal age category 21–31 81/96 (84%) 1.00 1.00





Country of birth Australia 91/116 (78%) 1.00
Other 32/42 (76%) 0.50 0.16–
1.57
0.763
Parity Primiparous 69/82 (84%) 1.00





Provider recommendation received No 40/64 (63%) 1.00 1.00





A midwife delivered maternal
immunization program








a Adjusted odds ratio comparing odds of receiving influenza vaccine during pregnancy if offered, controlling for other variables.
b Only univariate associations with p value <0.1 were included in the multivariable logistic regression
https://doi.org/10.1371/journal.pone.0197867.t003
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Association between socio-demographic factors and maternal vaccination
rates
Maternal age. The median age of participating women was 31 years. Maternal age older
than 31 years was associated with lower uptake of maternal influenza and pertussis immuniza-
tions. The odds of older women (32–43 years) receiving maternal influenza vaccine was less
than half that of younger women (OR 0.36; CI 0.17–0.74; p = 0.005). In multivariable logistic
regression analysis, maternal age remained a strong predictor for the uptake of influenza vac-
cine during pregnancy (AOR 0.40; CI 0.17–0.92 p = 0.031) (Table 3). Similarly, the odds of
older women receiving maternal pertussis vaccine was less than half that of younger women
(OR 0.35; CI 0.18–0.78; p = 0.010). However, after adjusting for all independent variables, the
association between maternal age and pertussis vaccine uptake during pregnancy was no lon-
ger statistically significant (AOR 0.39 CI 0.130–1.11; p = 0.078) (Table 2).
Country of birth. The proportion of women vaccinated against influenza and pertussis
during pregnancy was not statistically significantly different between women who were born
Fig 2. Maternal receipt of pertussis and influenza vaccine pre-and post-implementation of a midwife delivered maternal immunization program at the WCH in
South Australia.
https://doi.org/10.1371/journal.pone.0197867.g002
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in Australia and women born overseas (78% vs 76%; p = 0.763) (88% vs 76%; p = 0.124)
(Tables 2 and 3).
Parity. In the univariate analysis, the odds of multiparous women having received mater-
nal influenza vaccine was less than half that of first time mothers (OR 0.42 CI 0.20–0.87;
p = 0.022). In multivariate analysis, the odds of mothers with previous children receiving
maternal influenza vaccine remained less than half that of women with no previous children
(AOR 0.43; 95% CI 0.19–0.99 p = 0.048) (Table 3). However, for pertussis vaccine uptake,
whilst the odds of multiparous women receiving the vaccine was lower compared to first time
mothers in a univariate analysis, this was not statistically significant (OR 0.53 CI 0.24–1.18;
p = 0.116) (Table 2).
Discussion
Our results showed high uptake of pertussis (81%) and influenza (76%) vaccines during preg-
nancy. The higher uptake of pertussis vaccine during pregnancy compared to influenza vac-
cine in our study could be because most women perceive influenza as a disease affecting the
mother, whereas they see pertussis as a threat to the infant and thus relatively more risky [31].
Uptake of maternal pertussis vaccine by women who delivered at the WCH prior to the gov-
ernment funded immunization programs was 20%, which significantly improved to 90% fol-
lowing the introduction of a midwife delivered and government funded pertussis program.
Similarly, the uptake of influenza vaccine during pregnancy has improved from 32% to 83%
following the implementation of a midwife delivered immunization program. National cover-
age for maternal pertussis vaccination programs in other countries is limited to local surveys
of vaccine coverage, for example an estimated coverage of over 60% was reported in the UK in
2016 [32], and 51% of women delivering during March 2014 in Wisconsin [33] while uptake
of 51–67% was reported in Argentina in 2014 [34].
The rise in vaccination rates could also be attributed to introduction of free pertussis vac-
cine for all pregnant women in South Australia in March 2015 [15]. The higher uptake of per-
tussis compared to influenza vaccine suggests pertussis vaccine uptake is driving influenza
vaccine uptake in pregnant women as the vaccines are co administered. Our results demon-
strate that the provision of maternal pertussis and influenza vaccination by midwives at the
place of antenatal service was an independent strong predictor of vaccination uptake during
pregnancy. It is a relatively low cost intervention, which has produced a significant increase on
vaccine uptake. Pregnant women view midwives as a trusted source of health information
[35]. A previous study suggested that administering maternal immunizations into standard
antenatal care through midwives could improve immunization uptake among pregnant
women [36].
Our study demonstrated that receiving a recommendation from a HCP was a strong predic-
tor for receipt of maternal influenza vaccine. Women who had not received influenza vaccine
during their pregnancy were less likely to have been offered influenza vaccines. About one-
quarter of the women who had not received the vaccines reported they had not received a rec-
ommendation to have influenza vaccine during pregnancy. This suggest there is room for
improvement for HCPs in discussing maternal vaccinations with pregnant women. Several
other studies suggested that a recommendation from a HCP is the most significant factor in
improving vaccination uptake during pregnancy [27, 37, 38].
Previously identified factors associated with poor uptake of vaccines in pregnancy include
lack of perceived benefit by pregnant women [22], concern about the safety of maternal vacci-
nation [39], lack of awareness of vaccine recommendation during pregnancy [40, 41] and
expectant mother’s attitudes toward immunization during pregnancy [42, 43]. In this study,
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maternal age and parity were associated with uptake of influenza vaccines during pregnancy.
Multiparous women were less likely to be vaccinated against the influenza during pregnancy
compared to first time mothers. A similar finding has been reported from a previous study in
South Australia [44]. Multiparous women are more likely to attend fewer antenatal visits than
first time mothers [45]. They also tend to have lower emotional attachment to their unborn
baby [46] and have been found to think less about the health of their fetus than first time moth-
ers [47]. This may describe why women who had been pregnant before were less likely to be
immunized against influenza vaccine during pregnancy. However, our findings have shown
that there is no influence of parity on pertussis vaccine uptake during pregnancy
Our study also demonstrated that older women were less likely to be vaccinated against
influenza during pregnancy. A previous study also suggested that older women are less likely
to seek antenatal health care [48]. This could explain why older women were less likely to be
vaccinated against influenza during pregnancy. Our study findings indicate the need for tai-
lored and targeted interventions for older multiparous women in maternal influenza vaccina-
tion campaigns. However, a study conducted in the Netherlands has found that influenza
vaccine uptake during pregnancy was higher among older and multiparous pregnant women
which is in contrast to our study findings [49]. Our study also indicates that there is no influ-
ence of age on pertussis vaccination coverage, which is in contradiction with previous studies
[44, 50]. Hence, further research is needed to explore if older multiparous women are more or
less likely to receive maternal influenza or pertussis vaccine compared with young first time
mothers.
The primary strength of our study sample is the inclusion of pregnant women prior to and
following the implementation of a midwife delivered pertussis immunization programs for
pregnant women. This enabled us to compare the antenatal vaccination uptake rates prior to
and following the introduction of midwife delivered maternal immunization program. This
study has also examined the intention of pregnant women to receive the recommended vac-
cines during or post pregnancy and uptake of these vaccines was verified by follow up tele-
phone interview with the mothers after delivery.
This study was subject to some limitations. The participants in this study were recruited
through a public hospital antenatal clinic. Thus, the study findings may not be a representative
of the overall population of pregnant women in South Australia. Our relatively small sample
size could also be a limitation to this study. Results from the vaccination coverage before the
government funded immunization programs are based on a very small sample size and this
could be a potential limitation of the study. The study sample also excluded non-English-
speaking women and no indigenous women participated in the study therefore our findings
may not be representative of culturally and linguistically diverse (CALD) and Aboriginal and
Torres Strait Islander women. Vaccine uptake among women who reported they had received
influenza and pertussis vaccination during their pregnancy was not verified through audit of
medical records. Our study has also a potential selection bias, as women who are more accept-
ing of vaccination may have been more likely to agree to participate in the survey. Another
limitation of the study is that the questionnaire did not capture primary language, ethnicity,
household income, educational level, working situation and marital status, which may also be
important variables in assessing factors related to vaccine uptake during pregnancy.
Conclusions
High uptake of influenza and pertussis vaccines during pregnancy can be attained with health
care provider recommendation and inclusion of maternal immunization as part of standard
antenatal care. A midwife delivered maternal immunization program is a promising approach
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to improve maternal vaccine uptakes by pregnant women. Additional studies are needed to
monitor and evaluate the impact of government funded pertussis programs for pregnant
women to ensure optimum protection for pregnant women and their infants.
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